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Animal research has contributed immensely to medical and scientific advances over 
the last century, and continues to play important roles in enhancing our understanding 
of infectious and non-communicable disease development, and the search for 
treatments. The mouse, for example, shares ~95% of human genes and is the most 
widespread vertebrate model in use. Since the late 1980s, there has been several UK 
and EU directives (e.g., 2010/63/EU) to improve the welfare of animals considered 
essential for experimentation, and to link directly with the principle of the 3Rs, to 
Replace, Reduce and Refine animal use. Additionally, animal maintenance, 
husbandry, compliance with legislation and licencing, and staff training are costly and 
time-consuming. Hence, there is much to gain from developing alternative in vivo 
models and complementary in vitro, in chemico and in silico tools. 
Larvae of the wax moth Galleria mellonella represent one such surrogate to rodents, 
and have been used successfully to study microbial isolates for virulence traits, 
putative antibiotic therapies, and more recently, toxicological assessment. There is an 
abundance of practical and biological advantages to selecting G. mellonella over 
rodents and traditional non-mammalian fruit flies and nematodes (which are described 
in Chapter 1), but one area lacking in knowledge is their applicability for studies of 
gut pathobiology. Therefore, the aim of this thesis was to evaluate the usefulness 
and accuracy of G. mellonella larvae as a model for gut specific toxins and 
pathogens when administered through an oral route (gavage). 
A series of whole-organism (phenotype), cellular, biochemical, microbiological and 
microscopy methods were used to interrogate the gastrointestinal tract of G. mellonella 
in the absence and presence of chemicals and microbes known to cause gastropathy in 
rodents and humans. First, the transferability of the indomethacin restraint/ulcer assay 
was established in G. mellonella, with levels of tissue deterioration and enhanced 
leakiness reminiscent of rodents (Chapter 2). Second, the rearing of insects on 
nutraceuticals Cordyceps sinensis and bovine colostrum alleviated gut damage caused 
by indomethacin, and improved survival outcomes when challenged with the enteric 
pathogen Campylobacter jejuni (Chapter 3). Third, oral administration of shellfish 
poisoning toxins (okadaic acid and azaspiracids 1-3) to G. mellonella, interfered with 
tissue integrity and microbial stability of the gastrointestinal tract, and produced 
comparable LD50 levels to their rodent counterparts (Chapter 4).   
The results presented here go beyond establishing synonymous damage phenomena 
between G. mellonella larvae and vertebrates (Chapter 5), but adds new knowledge 
to the structure and function of the lepidopteran alimentary canal, the cytopathology 
of emerging marine toxins, and how diet invariably influences a host’s capacity to 
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1.1 Thesis overview   
In 2019, some 3.4 million procedures were carried out on living animals in Great Britain alone 
with rats, mice and fish representing 93% of all test subjects (Home Office, Annual Statistics 
of Scientific Procedures on Living Animals 2019). Over half (1.73 million) were for 
experimental procedures, which includes 437,000 for regulatory purposes (33% of these were 
classified as toxicity and safety testing for medicine, dentistry and veterinary). Partially due to 
the efforts of the National Centre for Replacement, Refinement and Reduction of Animals in 
Research (NC3Rs; https://www.nc3rs.org.uk/) and the Fund for the Replacement of Animals 
in Medical Experimentation (FRAME; https://frame.org.uk/), the numbers of living animals 
used has decreased annually, for example, 4.14 million were approved for use in 2015. 
Although it is unlikely that all (vertebrate) animal experimentation will be eliminated, there are 
alternative non-vertebrate models available as well as emerging in vitro and in silico 
approaches. For example, the fruit fly Drosophila melanogaster and the nematode worm 
Caenorhabditis elegans have fulfilled the role of alternative models to mammals for almost a 
century. Another insect, namely the wax moth (Galleria mellonella), has been in use as an 
infection model for at least 40 years (Ratcliffe and Gagen, 1976). G.mellonella’s popularity 
has increased dramatically over the last 5 years, in part, due to the availability of molecular 
resources and the genome (Lange et al., 2018a). Now, G. mellonella larvae represent a common 
surrogate model for the investigation of microbial pathogenicity, virulence, and antibiotic 
screening. Relatively low maintenance costs, limited ethical considerations and functional 
similarities to the human innate immune system are some of the key features that attract lab 
users to adopting G. mellonella (Wojda, 2017, Tsai et al., 2016).  
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Wax moths have a relatively short life cycle, which can be split into four stages: (1) eggs that 
incubate for 5 to 8 days; (2) caterpillars/larvae that grow for 6 to 7 weeks (up to ~23 mm long 
over 8  to 10 moults); (3)  pupate (form brownish, hardened cocoons) for 1 to 8 weeks before 
(4) emerging as an adult moth (final stage) (Figure 1.1). The female moths are lighter in colour 
and slightly larger than the males, and females have a bifurcated proboscis. Females lay 
between 10-50 eggs at a time (Jorjão et al., 2018). This closed life cycle can be easily 
maintained in laboratory settings and manipulated for experimental purposes. A further benefit 
of using G. mellonella larvae is their culturing parameters. Larvae naturally encounter 
temperatures between 24 – 32°C (infesting beehives) and survive comfortably at 37°C (Tsai et 
al., 2016, Jorjão et al., 2018), thereby enabling researchers to use wax moth larvae to study 
pathogens at human relevant temperatures.  
  
Figure 1.1 Complete life cycle of the wax moth Galleria mellonella  
 
As an invertebrate, G. mellonella does not possess an adaptive immune system, i.e., appears 
incapable of producing immunoglobulins clonally (Rowley and Powell, 2007), but does share 
broad structural/functional innate immune mechanisms with mammals (Browne et al., 2013). 
For example, pathogen discrimination from self, intracellularisation, and subsequent 
destruction by NADHP-dependent oxidative burst is highly conserved among insect 






(final instar larva) 
(early instar larva) 
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defences, lepidopteran insects appear to have tissue organisation and structural features 
reminiscent of the human gastrointestinal (GI) tract, such as the epithelial layer and mucosa 
akin to the intestines, and an organ called the fat body that acts as the liver (Vallet-Gely et al., 
2008). With that said, comparatively little is known regarding the gut physiology in G. 
mellonella and its putative suitability as a model for the human GI tract disorders, specifically, 
enteric pathogens or toxins encountered orally. Inoculation of G. mellonella with test 
compounds/microbes is predominantly carried out through intrahaemocoelic injection, with 
precious few studies attempting gavage (force-feeding). Research within this thesis endeavours 
to address these shortfalls, and in doing so, provide a more in-depth account of G. mellonella's 
alimentary canal, as well as the optimisation of techniques for investigating tissue damage, 
permeability, and restitution that mimic most closely those methods developed in rodents. 
The overall aim of this thesis was to evaluate the usefulness and accuracy of Galleria 
mellonella larvae as a substitute in vivo model for gut-related pathobiology. To achieve the 
overall aim, the presented thesis is constructed around three primary objectives: 
1. To test whether the established indomethacin gastric damage (ulcer) assay of rodents 
can be recapitulated in an insect (Chapter 2) 
2. To determine if dietary intervention with nutraceuticals, Cordyceps sinensis and 
colostrum, can alleviate gastric damage caused by chemicals and/or microbes (Chapter 
3) 
3. To screen emerging marine toxins (associated with food poisoning) for signs of 
gastropathy and dysbiosis, assessing how generalisable the model is for future 
applications.  
 
1.2 Innate immunity of Galleria mellonella  
G. mellonella's immune system has similarities to that of humans with haemolymph being the 
functional equivalent of blood. Insect haemocytes found within the haemolymph can carry out 
phagocytosis and produce antimicrobial peptides (AMPs). The larval innate immune system is 
comprised of two broad lines of defence known as the humoral and cellular responses, however 
they lack the acquired immune system of humans. The humoral response incorporates AMPs, 
enzyme cascades and reactive oxygen and nitrogen species, instigating haemolymph clotting 
and melanisation (Browne et al., 2014). The cellular response is mediated by a heterogeneous 
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population of haemocytes and involves various processes such as phagocytosis, nodulation and 
encapsulation – with evidence of chromatin trap release (Browne et al., 2013, Nathan, 2014). 
1.2.1 Cellular immune response in Galleria mellonella 
The cellular immune response of insects is complex relying on several distinct classes of 
haemocytes – including plasmatocytes, granular haemocytes, oenocytoids, spherule cells and 
prohaemocytes. However, some researchers argue that there are other classes of haemocytes 
called coagulocytes and adipoheamocytes (Ribeiro et al., 2016, Arteaga Blanco et al., 2017). 
The cellular response bares resemblance to that in humans whereby the immune cells are 
capable of phagocytosis, degranulation and produce superoxide to destroy pathogens akin to 
mammalian neutrophils and monocytes (Browne et al., 2014). Haemocytes also express 
encapsulating proteins that have been found to have high homology to human calreticulin, 
which is involved in protein folding and immunomodulation (Choi et al., 2002, de Bruyn et al., 
2015). Haemocytes are found freely circulating in the haemolymph and/or adhered (sessile) to 
organs. Levels of haemocytes fluctuate throughout the lifespan of the insect and circulating 
levels drop during infection (Marmaras and Lampropoulou, 2009, Choi et al., 2002, Browne 
and Kavanagh, 2013). There are up to 8 different types of haemocytes characterised among 
insects, however it is unusual that all 8 are found within a single species.   
Plasmatocytes are the most commonly found haemocyte and along with granular cells are 
involved in phagocytosis to remove pathogens in a similar way to mammalian macrophages 
and neutrophils (Lamprou et al., 2007). Mammalian neutrophils are involved in the formation 
of NADPH required for oxidative burst to kill internalised pathogens. Homology of neutrophil 
proteins p47phox and p67phox has been identified in G. mellonella haemocytes 67-kDa and 47-
kDa proteins which contained peptides matching those of p67phox and p47phox and are thought 
to be involved with the production of an oxidative burst (Bergin et al., 2005).  
Encapsulation in G. mellonella occurs when larger foreign bodies are identified such as 
parasites and protozoa. During this process granular cells bind to, and lyse, the parasite and 
release plasmatocyte spreading protein, driving further recruitment and attachment of 
plasmatocytes (Butt et al., 2016). Multiple layers of bound plasmatocytes release cytoplasmic 
adhesion molecules onto their surface, forming a capsule around the parasite. Granular cells 
then adhere to the capsule and undergo apoptosis to form an inert outer layer. The production 
of reactive oxygen or nitrogen species then assist in killing the intruder (Nappi and Ottaviani, 
2000, Butt et al., 2016).  
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Nodulation is a process unlike any in the human body and occurs when clusters of bacteria are 
bound by multiple haemocytes, forming a shell and immobilising them inside. Once contained, 
the process can be completed by the oenocytoids undergoing cell lysis to release 
prophenoloxidase (proPO) into the haemolymph for melanin biosynthesis. The activation of 
proPO is regulated by proteases (serpins) and initiated by haemocyte bound pattern recognition 
receptors (PRRs) interacting with pathogen associated molecular patterns (PAMPS) (Sideri et 
al., 2008, Browne et al., 2013, Hoffmann, 1995, Kim et al., 2018, Butt et al., 2016, Whitten 
and Coates, 2017). Inactive proteolytic enzyme precursors, known as zymogens are activated 
leading to the cell to burst and release activated PO and the production of melanin, killing the 
pathogen (Sideri et al., 2008, Browne et al., 2013, Hoffmann, 1995, Kim et al., 2018, Butt et 
al., 2016).  
The immune response in G. mellonella predominantly involves AMPs, proPO cascade and 
opsonins (Tsai et al., 2016). Toll and Immune deficiency (IMD) signalling pathways mediate 
responses from PRRs detecting PAMPs such as peptidoglycans within the pathogens cell wall. 
When host PRR detect peptidoglycan recognition protein (PGRP) or Gram-negative binding 
protein (GNBP) a signal cascade is activated within the fat body through toll receptor pathway 
leading to the expression of AMPs. AMPs are then synthesised within the haemocytes, epithelia 
and fat body and secreted into the haemolymph (Wojda et al., 2009, Mak et al., 2010, Nehme 
et al., 2007). Toll pathway relays signals intracellularly when presented with Gram-positive 
bacteria and fungi, whereas the IMD pathway is active against Gram-negative bacteria. This 
separation gives a level of specificity in the insect immune response, resulting in the production 
of specific AMPs (Wang and Ligoxygakis, 2006).  
Melanisation is a vital part of G. mellonella's clotting and immune response. Once a pathogen 
is detected by PRRs, the proPO cascade is initiated. Serine protease inhibitors such as serpin 
regulate the proPO cascade, proPO is proteolytically cleaved during the response to infection 
to form the active phenoloxidase (PO) (Kanost and Gorman, 2008, Sheehan et al., 2018, Butt 
et al., 2016). PO then enables the oxidation and hydroxylation of phenols to create quinones, 
which are further processed a series of enzymatic and spontaneous reactions to form melanotic 
polymers (Sheehan et al., 2018, Butt et al., 2016). Melanin is deposited on pathogen surfaces 
and recruits' haemocytes to encapsulate or engulf the pathogen. This process also produces 
toxic reactive oxygen species (ROS) intermediates that further damage bacterial cell walls 
(Tsai et al., 2016). 
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1.2.2 Galleria mellonella humoral immune response 
G. mellonella have a wide range of humoral responses to infection, these include the production 
of ROS, PO and AMPs. There have been at least 18 AMPs identified in G. mellonella such as 
cecropin, gallerimycin and galiomicin are (Wojda et al., 2009, Moghaddam et al., 2016). AMPs 
are found the haemolymph and in the midgut of pre-pupae and are vital in the immune defence. 
Interestingly the AMP lysozyme found in G. mellonella is structurally similar to lysozymes 
identified in chicken and is active against gram-positive bacteria through the hydrolysis of 
peptidoglycan, lysozyme is also somewhat effective against gram-negative bacteria and fungi 
(Jiang et al., 2010). Gallerimycin and galiomicin are cysteine-rich defensin AMPs, which are 
homologous to human cysteine-rich peptides hBD1, 2, 3 and 4. Gallerimycin and galiomicin 
are the most effective AMP against fungal infection, studies infecting G. mellonella with 
Candida found an upregulation of both defensins within the first hour of inoculation and a 
maximum regulation 24 hours post-inoculation (Lee et al., 2004). This suggests that 
gallerimycin and galiomicin are involved with the initial antimicrobial response. 
Another branch of the humoral immune response is the production of ROS and reactive 
nitrogen species (RNS) which are essential antimicrobial and signalling molecules (Butt et al., 
2016). ROS such as superoxide (O2−) and hydrogen peroxide (H2O2) are produced in 
haemocytes and released into the haemolymph within the first 30 minutes of a foreign body 
entering the hemocoel and during the encapsulation and melanisation process (Dubovskii et 
al., 2010). The haemocyte production of ROS is thought to be mediated by an NADPH oxidase 
complex, and there is evidence to suggest that O2− is involved in the activation of cationic 
granule enzymes that kill the pathogens (Bergin et al., 2005, Reeves et al., 2002). ROS can be 
harmful to the host and pathogen, damaging DNA, causing protein degradation and lipid 
peroxidation therefor the host also produces an array of antioxidants such as superoxide 
dismutase (SOD), catalase and glutathione-S-transferase (GST) (Dubovskii et al., 2010).  
1.3 Galleria mellonella gastrointestinal morphology 
Generally, the insect gastrointestinal tract can be divided into three sections; foregut, midgut, 
and the hindgut. The larval gut has several similarities to that in mammals, including microvilli, 
natural flora and epithelial cells (Table 1.1). G. mellonella larvae are of interest due to its 
tolerance of temperatures up to 37°C and its large size, making them more suitable for accurate 
injection of microbes into the gut, compared to other insect models such as Drosophila 
melanogaster (Vogel et al., 2011, Fedhila et al., 2010, Tsai et al., 2016).  
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The gut of insect larvae also contains smooth septate junctions between epithelial cells which 
act similarly to tight junctions found in mammals, whereby they control the movement of 
molecules in and out of the gut (Green et al., 1980). Additionally, within the midgut of G. 
mellonella larvae there is the peritrophic matrix, which lines the digestive tract acting similarly 
to the mucus layer, protecting the epithelial cell layer from pathogens and aiding food 
digestion. The peritrophic matrix is formed of proteins, glycoproteins and chitin, making a thin 
and semi-permeable barrier (Campbell et al., 2008). The midgut is where the majority of 
digestion and absorption of nutrients occurs and contains specialised cells such as goblet and 
columnar cells for the secretion of enzymes and ion transport (Tanigawa et al., 2016). 
Interestingly, the midgut also contains intestinal stem cells (ISCs) which are vital for repair and 
replacement of damaged tissue, and during larval moulting. The differentiation of ISCs is 
controlled by the secretion of hormones from endocrine cells within the epithelial layer of the 
midgut (Franzetti et al., 2016). The foregut of larvae contains sclerotized microspines to assist 
digestion, little to no absorption of nutrients occurs here but serves to start the physical 
degradation of the food and passage of the bolus into the midgut (Wang et al., 2018).  
Recent research shows melanisation occurring within the gut as a mode of protection against 
ingested pathogens (Whitten and Coates, 2017). However, there is debate as to whether the 
proPO is produced in the haemolymph then transported into the gut before becoming activated 
by gut trypsin acting as serine protease (Joseph, 2014). Further research indicates that in 
silkworms proPO is expressed in the hindgut where PO melanises faeces (Whitten and Coates, 
2017). Interestingly, there is evidence the gut of G. mellonella larvae can differentiate between 
symbiotic and pathogenic bacteria through microbe-associated molecular patterns (MAMPs) 
and elicit different intensities of immune response – similar to both mice and humans (Lange 
et al., 2018b). 
Other than ultrastructural diagrams of the G. mellonella gut, there is little information of the 
cellular/molecular arrangements, and much of what is indicated is based on other insect models 
and assumptions. To improve the data on the structure and morphology of the G. mellonella 
gut, a computer-assisted 3D render would be helpful. The natural microbiota of G. mellonella 
larva consists of some bacterial species found routinely in human guts such as Proteobacteria, 
Bacteroidetes and Firmicutes, all of which are associated with syndromes such as Crohn's 




Table 1.1 Comparison of gastric features in humans, rats and Galleria mellonella larvae  
Feature Human Rat G. mellonella 
larvae 
Supporting evidence 
Peristalsis  ✓ ✓ ✓ (Sláma and Lukáš, 
2011, Grider et al., 
1998) 
Mucosal layer ✓ ✓ Peritrophic 
membrane 
(Campbell et al., 2008, 
DeSesso and Jacobson, 
2001) 
Tight Junctions ✓ ✓ Septate 
junctions 
(Green et al., 1980) 
Villi ✓ ✓ ✓ (Wang et al., 2018) 
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Gastric pH is an important factor for digestion and the metabolic processing of toxins and 
pharmaceuticals, therefore it must be considered when modelling the human gut. The pH of 
the stomach in both rats and humans are very acidic (Table 1.1) and the pH of the intestine is 
9 
 
close to neutral (Nugent et al., 2001, McConnell et al., 2008). However, the gut of G. mellonella 
larvae is very alkaline with a pH range of 8-11 (Coddington and Chamberlin, 1999). This 
indicates a physiological limitation of G. mellonella’s ability to act as a model for the human 
gut, as it could result in the production of different metabolites and changes to 
pharmacokinetics during the digestion of toxins and pharmaceuticals (Hughes et al., 1989). It 
is understood that stomach pH can alter the absorption and bioavailability of drugs. For 
example, when tyrosine-kinase inhibitors are co-administered with proton-pump inhibitors, the 
stomach acid pH increases, causing tyrosine-kinase inhibitors to become the non-ionised form, 
which is less soluble and reduces the bioavailability (van Leeuwen et al., 2014). 
Pharmaceuticals are designed with a drug delivery method, many of which include pH due to 
difference of pH within tissues eg., slightly acidic tumours and areas of the GI tract (Cao et al., 
2019).  
Similar to rodents and humans, G. mellonella larvae utilise digestive enzymes to break down 
large, complex macromolecules. Serine proteases, β-glucosidases and α-amylase are some of 
the digestive enzymes identified in both G. mellonella larvae and humans (Bulushova et al., 
2011b, Kara et al., 2014, Bulushova et al., 2011a). Serine proteases are a large group of 
enzymes that make up one third of all proteases that break peptide bonds of proteins. Of these 
serine proteases, chymotrypsin, trypsin and pancreatic elastase are categorised as digestive 
enzymes (Hedstrom, 2002). Interestingly, several serine proteases including three anionic and 
two cationic forms of trypsin, one anionic and one cationic form of chymotrypsin and one 
elastase-like protease have been identified in midgut of G. mellonella larvae. Although they 
are analogues to the mammalian equivalent, their optimum pH is between 9.5-11 (Bulushova 
et al., 2011a).  
β-glucosidases are enzymes that hydrolyse glycosidic linkages present in disaccharides, 
oligosaccharides and glucosides (Yeoman et al., 2010). Most β-glucosidases, including human 
analogues have an optimum pH between 4-7.5, whereas those present in the midgut of G. 
mellonella larvae are active under alkaline conditions (Ketudat Cairns and Esen, 2010, Kara et 
al., 2014). β-glucosidases are adapted to the diet of the species, therefore it is unsurprising that 
those present in G. mellonella larvae differ to those in rats and humans. The natural diet of G. 
mellonella is limited to bees wax, honey, pollen and pupal skins, therefore most of the midgut 
β-glucosidases target β-glucosides (Kara et al., 2014, Jorjão et al., 2018). A potential limitation 
of using G. mellonella larvae as a model for the human gut is differences in gastric enzymes. 
Although β-glucosidases are present in midgut of G. mellonella, they may lack some key 
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analogues. Currently, there has not been a study comparing gastric enzymes between G. 
mellonella and mammalian models, this would be beneficial to further develop G. mellonella 
larvae as a gastric model.  
A potential limitation of G. mellonella larvae as a model is the comparison between hepatic 
metabolism and the functional equivalent, which is insect the fat body. The larval fat body is 
an important energy store and produces AMPs similarly as in humas, however the fat body’s 
metabolism of drugs compared to the liver is likely to differ. Research shows that the fat body 
contains a number of enzymes involved in drug detoxification, including several cytochrome 
P450s and sulfo-, glutathione- or glucose-conjugation enzymes  (Maguire et al., 2017). A recent 
study determined that force feeding G. mellonella larvae caffeine produced similar metabolites 
theobromine and theophylline to those usually detected in humans. Additionally, the same 
study found the larvae to have reduced movement and development (Maguire et al., 2017). 
Although there are differences in the specific enzymatic profiles, there are analogues active at 
a high pH resulting in similar metabolites and metabolic pathways, therefore G. mellonella 
larvae may be a broad model for the human gut but could be limited in the assessment of 
pharmaceuticals that rely on a specific pH range for their mode(s) of action. Therefore, 
although there are differences between G. mellonella’s and humans digestive enzymes and pH, 
there are enough functional similarities to utilise G. mellonella as a model in this manner  
1.4 Methods of infecting Galleria mellonella 
There are several methods to administer bacteria or compounds to G. mellonella larvae, directly 
injecting into the body cavity (haemocoel) through a pro-leg, topical application, submersion 
in particulate suspensions, and feeding (Kavanagh and Reeves, 2004, Salamitou et al., 2000, 
Grizanova et al., 2014, Maguire et al., 2016, Coates et al., 2019). Most studies inject the 
compound directly through the last proleg, however, Fedhila et al. (2010) argue that this 
method bypasses the usual oral route and therefore force-feeding the larvae could give a more 
accurate response to the pharmaceutical or microbe administered. Further research found that 
delivering saline solution alone via gavage did not result in mortality and delivered comparable 
results to direct injection (Coates et al., 2019). Maguire et al. (2017) provided some evidence 
that caffeine is similarly metabolised in G. mellonella as in humans (Maguire et al., 2017). 
Considering pathogens and toxins that lead to gastropathy are delivered through an oral route, 
then studies directly injecting such compounds into insects or mice (intraperitoneal injection) 
may not accurately characterise the effects or targets of these factors.  
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1.5 Existing evidence for Galleria mellonella as a candidate model for gut 
pathology 
Although some similarities between the gut of G. mellonella and the human are documented, 
there is a knowledge deficit regarding the specific physiology and importance of microbiota 
that colonise it, and there are significant gaps as to whether they are a good model for gut 
properties such as leakiness, inflammation, apoptosis and restitution. G. mellonella larvae have 
shown to be useful models for studying the pathogenicity of food poisoning associated bacteria, 
e.g., Bacillus cereus upon oral administration (Jensen et al., 2003, Salamitou et al., 2000), 
Campylobacter jejuni, Clostridium perfringens, Vibrio spp., via subcutaneous injection (Senior 
et al., 2011, Wagley et al., 2018, Bokhari et al., 2017, Kay et al., 2019). Interestingly, some 
probiotic bacteria such as Lactobacillus rhamnosus GG were screened in G. mellonella for 
their potential protective properties against gut-damaging microbes (e.g., Salmonella enterica), 
but these were not studied through an oral route (Scalfaro et al., 2017). 
 
1.6 Gut specific challenges  
1.6.1 Marine biotoxins  
To test how generalisable G. mellonella larvae is as a model for gut specific damage and 
disease, using a gastrointestinal-specific marine biotoxins such as okadaic acid and azaspiracid 
is an additional proof of concept approach. Okadaic acid has previously been used in G. 
mellonella to study toxicological end point (LD50), therefore its usefulness can be extended to  
marine toxins that are poorly understood and have not yet been screen in a non-mammalian 
model eg., azaspiracids (Coates et al., 2019).  
1.6.1.1 Okadaic acid  
Okadaic acid (OA) is a lipophilic phycotoxin (Figure 1.2) found in shellfish and causes 
diarrheic shellfish poisoning (DSP) upon human consumption of contaminated tissue and is 
produced by dinoflagellates of the genera Dinophysis and Prorocentrum (Dietrich et al., 2019). 
The consumption of < 50 μg per kg of OA contaminated tissue can result in DSP causing 
stomach cramps, diarrhoea and vomiting which begin within 4 hours of ingestion and can last 
several days (Dominguez et al., 2010). OA is an inhibitor of protein phosphatases that play 
various roles in cellular metabolism, which not only affects the GI tract but also contributes to 
neuronal toxicity and tumour promotion. These combined make OA highly toxic, and therefore, 
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current upper regulatory limits with the UK/EU are set at  160 µg OA equivalents per kg of 
shellfish (Munday, 2013). 
OA causes damage to the villi and the epithelial layer, increasing permeability of the intestine 
and erosion of the mucosal layer in mice (Ito and Terao, 1994). The increased permeability 
could be caused by OA increasing paracellular permeability through the disruption of tight 
junctions (TJ) and adherens junctions (AJ). TJ and AJ are regulated through protein 
phosphatases 1 and 2A (PP1 and PP2A) and protein kinases in rats and humans. The exact 
mode of OA’s increased permeability remains unclear, it has been suggested to involve 
inhibiting PPA2 and PP1 (Bialojan and Takai, 1988) or through disrupting F-actin cytoskeleton 
with is involved in TJ control (Fiorentini et al., 1996, Dietrich et al., 2019).  
OA is known to increase tumour necrosis factor α (TNFα) release from host cells which then 
increased paracellular permeability of epithelial cells in culture (Munday, 2013). OA's increase 
in permeability could be a result of cellular damage rather than a targeted effect (Turner, 2006, 
Ito and Terao, 1994, Berven et al., 2001). The microbiome of rats that were administered with 
a low oral dose of OA (80 µg/kg tissue) daily for 30 days was assessed. This study found that 
although the rats appeared healthy with no weight change, or no changes to microbiome 
richness or diversity,  however there was a significant change in individual abundance in the 
gastric microbiota, with an increase in Clostridiales (Liu et al., 2020). Interestingly, 
Clostridiales include many pathogenic bacteria such as Clostridium difficile, which is 
associated with inflammation and tissue damage (Smits et al., 2016).  
 




Azaspiracids (AZAs) are also lipophilic polyether toxins – first detected in 1995 from a 
contaminated batch of mussels on the West coast of Ireland. AZAs represent one of the most 
potent marine toxins, which induce similar gastrointestinal distress as observed in OA (Román 
et al., 2002). Since their discovery in 1995 there has been over 30 analogues identified globally 
(Krock et al., 2019). Currently, there are four known producers of AZAs; Azadinium spinosum, 
Azadinium dexteroporum, Azadinium poporum and Amphidomataceae languida all of which 
are dinoflagellates (Krock et al., 2014, Rossi et al., 2017, Tillmann et al., 2017, Kilcoyne et al., 
2014). Studies in mice demonstrated that AZA not only affects the GI tract but also targetsthe 
liver, lung, pancreas, thymus and spleen (Furey et al., 2010). Additionally, AZAs induce 
breathing difficulties and paralysis of limbs in mice, which show clear indications of 
neurotoxicity and separates AZA poisoning from other diarrheic shellfish poisoning (DSP) 
(Román et al., 2002).  
 
Figure 1.3 Chemical structures of AZA toxins 1, 2 and 3 (Twiner et al., 2012a) 
 
AZA consumption results in increased permeability of the intestine, leading to fluid 
accumulation in the small intestine and diarrhoea. The mode of action of AZA is unclear, 
studies conducted on Caco-2 cells that model the human intestine found that exposure to AZA-
1 interfered with the protein occludin, and leading to disruption in paracellular permeability 
(Abal et al., 2017). A further observation of AZA-1 exposure to Caco-2 cells was a 
disorganisation of actin cytoskeleton and a decrease in adherence, this could be a factor 
involved in increased intestinal permeability (Vilariño et al., 2006, Vilariño, 2008). AZA-1 
exposure also results in an increase in caspase activity. For example, in T lymphocytes an 
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increase in caspase-2 was observed, which may go on to induce caspase -3 via the release of 
cytochrome c in mitochondria through the caspase -9 independent pathway leading to apoptosis 
(Twiner et al., 2012b).  
Neurotoxicity tests conducted on cell cultures, found that AZA-1 neurotoxic effect appears to 
require very low dosages of the nanomolar range to cause toxic effects. In neocortical neurons, 
AZA-1 had a concentration and time dependent effect causing maximum toxicity 48 hours after 
a dosage of EC50 value 31.7nM. It is thought that AZA inhibits the spontaneous Ca
2+ 
oscillations in neocortical neurons which could alter the synaptic signalling between neurons 
and found that AZA-3 was more neurotoxic than AZA-1 and AZA-2 in neocortical neurons 
(Cao et al., 2010). A study using PC12 cells which are derived from rat pheochromocytoma 
cells in the adrenal medulla assessed the effects of AZA-1 (Hjørnevik et al., 2015). This study 
found that exposure to AZA-1 resulted in a down-regulation of the intermediate filament 
protein peripherin and an increase in differentiated phenotype of PC12 cells which had 
protrusions similar to neurites (Hjørnevik et al., 2015).  
A change in the regulation of peripherin has been linked to amyotrophic lateral sclerosis (ALS), 
a neurodegenerative disease and is important for neuronal repair after injury (McLean et al., 
2010, Robertson  et al., 2003) these findings could elude to some of the neurotoxicity properties 
of AZA. The full mechanisms of AZA are unclear however AZA-1 is thought to induced 
changes in cell morphology by acting on F-actin resulting in cytoskeleton destruction in 
neuroblastomas and T cells also causing an increase in Ca2+ in cells and causing villi erosion 
(Ito et al., 2006). A study in epithelial colorectal adenocarcinoma cells known as Caco-2 cell 
line show AZA-1 caused increased permeability in a concentration dependent manor. This 
study found that there was a decrease in trans-epithelial electric resistance which indicates a 
reduction in barrier stability which could be linked to an increase in permeability (Abal et al., 
2017). 
 
1.6.2 Campylobacter jejuni 
Campylobacter jejuni is a gram-negative bacteria and is one of the most significant bacterial 
causes of diarrheal illness in humans, and is most commonly transmitted through the 
consumption of chicken (Harris et al., 1986, Taylor et al., 2017). Estimated to cause more than 
2 million cases of gastrointestinal illness annually in America and can have complications such 
as reactive arthritis and Guillain-Barre' syndrome (a type of acute peripheral neuropathy), 
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making it an important pathogen to model (Kelly et al., 2003). Most infections result in 
diarrhoea, stomach cramps and fever which can persist for a week, however some patients can 
continue for several weeks (Acheson and Allos, 2001). In three quarters of patients, red blood 
cells are found in infected patients' faeces and the colon becomes inflamed with is similar to 
the initial stages of IBD and occasionally leads to a miss diagnosis (Blaser et al., 1979, Lawson 
et al., 1999). Due to C. jejuni’s gut specific pathogenicity it is a suitable candidate to assess G. 
mellonella’s ability to model a microbes, toxins and pharmaceuticals. 
The molecular pathogenesis of C. jejuni in the GI is unclear, as C. jejuni does not secrete typical 
virulence factors, rather it is hypothesised that the mechanism includes outer membrane 
vesicles (OMVs) to deliver virulence factors to the host. It has been found that they produce 
OMVs between 10 – 250nm diameter and are of different density suggesting differences in 
their contents (Elmi et al., 2012). It is understood that C. jejuni produce three different OMVs 
containing different virulence factors including serine proteases, these are HtrA, Cj0511, and 
Cj1365c. These serine proteases are involved with cleaving epithelial cells in the intestine and 
binds to the junction proteins occludin thus promoting further invasion of epithelial cells (Elmi 
et al., 2018). C. jejuni uses invasive antigens to infect cells, and produce cytolethal distending 
toxins (CdtA, B, C). Cytolethal distending toxins are the only toxins produce by this bacterium 
and it appears to be involved in the stimulation of host cell apoptosis which is a main factor of 
C. jejuni pathogenicity (Dasti et al., 2010). Other developments in understanding C. jejuni 
pathogenesis have identified the type VI secretion system (T6SS) to be involved in virulence 
and could be associated with more severe infections. It is postulated that T6SS is involved in a 
contact dependent secretion of effector proteins into host cell (Bleumink-Pluym et al., 2013).  
Lipopolysaccharides (LPS) are important in maintaining outer membrane stability and 
protecting the bacterium against host defences. Studies have found that LPS present on the C. 
jejuni cell surface are pivotal in immunopathogenesis of the infection, resulting in increased 
inflammation and is linked to the development of Guillain-Barre' syndrome, IBS and  reactive 
arthritis as a result of prolonged C. jejuni infection (Naito et al., 2010, Zarantonelli et al., 2006, 
Mortensen et al., 2009, Godschalk et al., 2007). LPS binds to TLR-4 receptors on host cell 
surface, this stimulates an intracellular signalling cascade via the Toll-interleukin receptor 
(TIR) containing interferon-β (TRIF) and TRIF- related adaptor molecule (TRAM), this is 
known as the TRIF-TRAM pathway which upregulates type one interferons and triggers 
tumour necrosis factor (TNF)-α production and secretion. The other signalling cascade known 
as the TIRAP-MyD88-pathway which involves the TIR-domain containing adaptor protein 
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(TIRAP) and myeloid differentiation primary response 88 (MyD88), resulting in the activation 
of NF-KB cells and upregulation of inflammatory cytokines such as IL-12 (Mousavi et al., 
2020). Interestingly, one of the difficulties in understanding C. jejuni infection is due to the 
murine model's intrinsic resistance to C. jejuni infection. This is partly due to rats having 
10,000-fold increase in resistance to LPS than in humans (Mousavi et al., 2020). Other animal 
models such as G. mellonella and ferrets have been used to study C. jejuni infection but are 
limited (Senior et al., 2011, Nemelka et al., 2009), therefore an insect can help  to improve the 
understanding of C. jejuni infection.  
 
1.7 Gastric targeting Nutraceuticals  
To study G. mellonella’s ability to act as a model for gastric protection and assess the 
therapeutic potential of selected nutraceuticals. Suitable nutraceuticals to study gastric 
protection against pharmaceutical, toxin and microbial induced damage are those that have 
anti-inflammatory, anti-apoptotic and antioxidant properties, i.e., Cordyceps sinensis extract 
and colostrum.   
1.7.1 Cordyceps sinensis  
Cordyceps sinensis is an entomopathogenic fungus, for which its uses in traditional medicine 
can be dated back to the late 1400's in Tibet. Spores from the fungus penetrate through the 
cuticle layer of insect larvae, e.g., Hepialus armoricanus, which then infect and grow within 
the host, progressively taking control of the insect before eventually resulting in its death and 
the fruiting body protruding from the cadaver (Chen et al., 2013). 
1.7.1.1 C. sinensis in gut repair and protection 
There has been increasing interest towards C. sinensis due to the discovery of numerous 
therapeutic effects in cancer treatment, cardiovascular disease, diabetes among others (Li et al., 
2006). It has been shown to have both protective and reparative properties against gastric 
damage, therefore it is important to investigate the specific effects C. sinensis has on the human 
gut and its potential applications as a functional food (Marchbank et al., 2011).  
1.7.1.2 Human gut physiology 
The human GI tract is a continuous layer of cells from the lower oesophageal sphincter to the 
anus with the purpose of delivering nutrients and removing waste from the body. Controlled 
absorption and secretion whilst maintaining a barrier against large molecules, pathogenic 
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material and microorganisms are essential functions of the gut. The complexity of both cellular 
and molecular physiology supports these essential functions. The GI epithelial layer is 
comprised of paneth cells, enterocytes, goblet cells, dendritic cells, apoptotic enterocytes, tight 
junctions and mucosal layer; in addition microvilli on the cell surface increase surface area of 
the cell to improve absorption. Within the Mucus contains secreted defensins, bacteria and IgA, 
all of which perform a vital role in GI tract function (Michielan et al., 2015).  
The mucus layer that is secreted by goblet cells acts as a protective barrier against 
microorganisms, reducing the opportunity for pathogens to cause to enter the blood steam via 
the epithelial layer and cause infection. The gut generally has a wide range of microbial flora 
with one study finding 395 different bacterial phylotypes present which act as competition to 
pathogenic microbes and aid in the digestion of some material (Eckburg et al., 2005). However, 
if the gut becomes damaged some of the commensal bacteria can become pathogenic and cause 
illness and disease. It has been demonstrated that natural population variation reduces through 
antibiotics use and the gut can become prone to infection due to reduced competition for 
resources (Hooper and Gordon, 2001).  
1.7.1.3 Properties for gut restitution 
Gut restitution is typically characterised as a healing process involving cell migration, invasion, 
proliferation and remodelling. This often occurs in response to damage caused by infection, 
intolerances, and disorders such as Crohn's disease (Waller et al., 1988). Although a lot of 
research has focussed on therapeutic properties of C. sinensis, there has been little research into 
its potential in treating gastric issues such as gut restitution.  
Marchbank et al. (2011) investigated C. sinensis reparative properties in rat gastric damage 
induced by the NSAID indomethacin. In that research, rats were randomly given saline or C. 
sinensis extract by oral administration. All rats were then subcutaneously administered 
20mg/kg of indomethacin and placed in restraint cages for 3 hours and then killed. Their 
stomachs were removed, internal pH determined and then filled with neutral buffer formalin 
overnight. Dissecting microscopes were used to determine macroscopic internal injury of the 
stomach, depth of damage was recorded as a scale from 0-4 where 0= no damage, 1 = one small 
erosion, 2=two small or one large erosion area greater than 0.5mm, 3 = two or more large 
erosions and 4=extensive damage where ulceration extends to the muscularis mucosa 
(Marchbank et al., 2011).  
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Marchbank et al. (2011) found that rats administered 20mg protein/ml of C. sinensis extract 2 
had 58% less damage and 20mg protein/mL of C. sinensis extract 3 resulted in 60% less 
damage than those given saline alone (Figure 1.3). The results obtained are promising as a 
significant reduction in gut damage, suggests C. sinensis may have gastric-protective 
properties. However, the authors do not discuss results from C. sinensis extract 1 administered 
group and it is unclear how the extract is acting within the gut to protect from indomethacin 
damage (Marchbank et al., 2011).  
 
Figure 1.4 Effects of C. sinensis on rat gastric indomethacin induced damage. Ground rice and 
potato grown extract (Extract 2) Liquid medium grown extract (Extract 3), Negative control is 
saline. Epidermal growth factor (EGF) is the positive control. (*P<0.05) (P*<0.01) 
(Marchbank et al., 2011). 
 
Marchbank et al. (2011) discovered that hot water extract of both whole and ground rice and 
potato grown C. sinensis had pro-migratory effects in human colonic carcinoma HT29 tissue 
culture post mechanical damage. Although the liquid grown fungi had a pro-migratory effect 
in a similar response, it was at a much lower level of efficacy. (Figure 1.4). This may suggest 
that this liquid culturing method may lack certain qualities required to produce compounds 
involved in initiation cell migration. Additionally, extracts 1 and 2 administered in excess of 
10 mg protein/ml resulted in a reduced level of cell migration compared to a 5 mg protein/mL 
dose. It is unclear why the decrease was observed, it is possible that at this concentration the 
extract has an inhibitory effect, however migration was still increased in comparison to the 
negative control and extract 3 showed an increase in migration at the same concentration. The 
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method of culturing likely impacts the compounds present in the extract, however the mode of 
action is unclear. 
 
Figure 1.5 Effect of C. sinensis extract on cell migration in HT29 cell culture. Whole rice and 
potato grown extract (Extract 1), Ground rice and potato grown extract (Extract 2) Liquid 
medium grown extract, (Extract 3) positive control: 10% Fetal calf serum (FCS), Negative 
control: Dulbecco's modified Eagle's medium (DMEM). (*P<0.05) (**P<0.01) (Marchbank et 
al., 2011). 
 
1.7.1.4 Properties to inhibit apoptosis  
Apoptosis is a natural and necessary process of programmed cell death. It can be separated into 
two paths, the extrinsic whereby death receptors on the cell surface are stimulated, inducing a 
signalling cascade of ligands such as TNF, and caspases. The intrinsic pathway, which is 
initiated by intracellular stimuli such as DNA damage and hypoxia, causes the outer 
mitochondrial membrane to become permeable. Pro-apoptotic proteins such as Bax are 
dimerised on the cell surface and trigger a signalling cascade, resulting in the formation of an 
apoptosome and the stimulation of caspase proteins. Inhibitory proteins are then cleaved, 
allowing caspases to carry out apoptosis (Mukhopadhyay et al., 2014). If it is possible to inhibit 
apoptosis with C. sinensis it could be used therapeutically to help treat ulcerative colitis where 
excessive apoptosis in active disrupts the epithelial cells, thereby exacerbating the disease 
(Hagiwara et al., 2002).  
Several studies have explored C. sinensis anti-apoptotic properties and found that it reduces 
the number of apoptotic cells from various causes of injury; this suggests that C. sinensis may 
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influence signalling pathways, gene regulation and reduction of apoptosis and damage. (Buenz 
et al., 2005).  
Shahed et al. (2001) tested the effect of C. sinensis extracts on rat kidney after ischemia leading 
to reperfusion. The group found that fungal extracts inhibited the expression of apoptotic genes 
Fas and FasL, furthermore, they found that inflammatory gene expression for TNF-α, which is 
involved in extrinsic cell death, had also reduced. Bax and Bcl2 expression in the intrinsic 
pathway were not altered, however caspase 3 activity was lowered with the extract suggesting 
that C. sinensis targets the extrinsic pathway sufficiently to reduce apoptosis (Shahed et al., 
2001).  
Other research groups have investigated C. sinensis ability to inhibit apoptosis via the intrinsic 
pathway. It is considered that C. sinensis compounds may act as reactive oxygen species (ROS) 
scavengers, thus preventing the initiation of apoptosis via oxidative stress. Conversely, there is 
conflicting evidence from Yamaguchi et al. (2000) who investigated C. sinensis extract's 
antioxidant activity by superoxide dismutase (SOD) assays, hydroxyl radical scavenging, free 
cholesterol analysis and macrophage culture and oxidation of low-density lipoprotein. SOD 
assays show that the extracts had some mimetic activity in a concentration dependent inhibition 
of malondialdehyde production. A lower malondialdehyde indicates a reduction in radical 
concentration available to form malondialdehyde.  In addition, macrophage culture tests 
showed that C. sinensis does possess antioxidant properties and inhibited peroxidation of lipid 
and cholesterol ester accumulation in cells in a concentration dependent manner (Yamaguchi 
et al., 2000).  
Although the results discussed suggest that C. sinensis does indeed inhibit apoptosis, research 
carried out by Buenz et al. (2004) indicated this is not that case. In their study, Jurkat T 
lymphocytes were used, and apoptosis was triggered by agonistic anti-Fas antibody or 
hydrogen peroxide. They found that neither water nor ethanol extracted C. sinensis inhibited 
hydrogen peroxide, or agonistic anti-Fas antibody induced apoptosis. This implies that C. 
sinensis extract does not interfere with the Fas signalling pathway, as the Shahed's group 
postulated and that it does not inhibit apoptosis initiation via the reduction the ROS present as 
proposed by the Yamagucghi's group (Buenz et al., 2004, Shahed et al., 2001).  More recently, 
Gu et al., (2015) used rats to investigate preservative effects of C. sinensis extracts on the 
intestinal mucosal barrier in the presence of endotoxin-induced sepsis. This study found that 
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rats treated with C. sinensis extracts had a significantly lower percentage of apoptotic cells  
(Gu et al., 2015) 
1.7.2 Colostrum 
Colostrum is the first milk produced after birth and contains all the vital compounds required 
to support the development of an effective (early) immune system. It is also of high nutritional 
value and also contains AMPs such as lactoferrin (Khan et al., 2002). Colostrum has many 
potential therapeutic properties and has been researched as a treatment for cancer due to its 
lactoferrin contents. It is thought that lactoferrin extracted from colostrum stimulates natural 
killer cells, modulates carcinogen-metabolising enzymes as well has having iron-binding 
properties which would reduce the number of free irons which is a mutagenic promoter. All of 
these have a combined effect of increasing apoptosis and reducing tumour growth (KIM et al., 
2009). Colostrum has also been the subject of research into the protective and reparative 
properties against isoproterenol-induced myocardial infarction in rats due to its contents of 
growth hormones, which could stimulate repair of damaged cardiac muscle and blood vessels. 
Colostrum was found to reduce lipid peroxidation and free radicals that otherwise would go on 
to cause further damage to cardiac tissue (Kaur et al., 2014). These findings make colostrum a 
suitable candidate for studying protective and reparative properties of the gut against 
pharmaceutical and microbial damage in G. mellonella.  
1.7.2.1 Colostrum anti-inflammatory properties  
Colostrum's anti-inflammatory properties have gained interest in recent years with a studies 
conducted in human cell lines and rats focusing on applications against NSAID and 
gastrointestinal diseases such as Crohn's disease (Playford et al., 2001, Chae et al., 2017). A 
study carried out in human Caucasian colon adenocarcinoma cells (Caco-2 and HT-29 cells) 
found that bovine colostrum reduced the production of interleukin-8 (IL-8), which is a pro-
inflammatory mediator after Escherichia coli and tumour necrosis factor α (TNF-α, a cytokine 
which increases IL-8 expression) stimulation. These data suggest that colostrum may prevent 
inflammation by inhibiting TNF-α binding to epithelial cells (Chae et al., 2017, Hechtman et 
al., 1991). 
An experiment conducted in rats found that rats which were administered bovine colostrum 
had lower markers of inflammation (TNF-α, IL-1β, and IL-6) after intestinal ischemia had been 
surgically induced compared to the rats administered saline. This result indicates an anti-
inflammatory property of colostrum, however in the same study the serum anti-inflammatory 
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cytokine interleukin 10 (IL-10) was not significantly different to the saline administered rats 
(Kwon et al., 2010). This supports the idea that colostrum's anti-inflammatory effect is due to 
it inhibiting TNF-α rather than a stimulation of anti-inflammatory cytokines such as IL-10.  
Another study using HT-29 cells found supporting evidence of bovine colostrum to having 
anti-inflammatory effects via the inhibition of IL-1β induced IL-8 (An et al., 2009). Moreover, 
the same study found that bovine colostrum inhibited the nuclear factor κB (NF-κB) signalling 
pathway by inhibiting the phosphorylation of IκB enzyme, which in turn prevents the binding 
of NF-κB DNA, and translocation of NF-κB from its inactive state in the cytoplasm to its active 
state in the nucleus (An et al., 2009, Karin, 1999). A further mode of action of colostrum's anti-
inflammatory effect postulated by An et al. (2009) is the inhibition of COX-2 expression by 
inhibiting IL-1β activity.  
1.7.2.2 Colostrum antioxidant properties  
Human colostrum is known to have antioxidant properties although it is unclear what 
components are responsible for this but are thought to include vitamins A, D and E as well as 
carotenoids and catalase (Hanna et al., 2004). A study conducted in neonatal calves found that 
bovine colostrum contained the antioxidant Cu/Zn-Superoxide dismutase (Cu/Zn-SOD), and 
calves that were fed colostrum had higher serum levels of SOD than calves fed tank milk. 
Additionally, calves reared on colostrum had significantly lower serum concentration of 
malondialdehyde (MDA) which is correlates to damage caused by free radicals which suggests 
calves reared on colostrum have a more established anti-oxidative defence than those reared 
on tank milk and that the higher concentration of SOD may decrease oxidation by reducing 
MDA production (Yang et al., 2015). 
A study inducing toxicity with paracetamol in rats, found that rats administered colostrum 
alone had higher SOD concentration in brain tissue. Those having received paracetamol and 
colostrum had lower kidney MDA concentrations and higher catalase (CAT) concentrations 
than those in receipt of paracetamol only. This indicates that colostrum has anti-oxidative 
properties which may be due to radical scavenging and gives the recipient improved defence 
against toxins (Karabacak et al., 2018). In a subsequent study which induced intestinal ischemia 
in rats found that when rats received colostrum after the ischemic event a reduction in the levels 
of lipid peroxidation and an increase anti-oxidative activity was observed with greater SOD 




1.7.2.3 Colostrum gastric protective and reparative properties  
Due to colostrum's high content of immunoglobulins (such as IgG) and AMPs, it has been 
researched for its protective properties against gastric bacterial induced septic shock in rats. 
Rats that were infected with Escherichia coli and orally administered colostrum, had a 
reduction in endotoxins produced compared to the control (Döhler and Nebermann, 2002). Oral 
delivery of colostrum has also been found to reduce intestinal permeability induced by NSAID 
in rat studies, reduce bacterial translocation and reduce the number of intestinal lesions caused 
by NSAID oral administration in rats (Kim et al., 2005). This indicates that colostrum has 
protective properties to pharmaceutical induced damage and would be a suitable nutraceutical 
test on G. mellonella larvae against NSAIDs. To date, there appears to be no evidence of such 
experiments being replicated in insect larvae. 
Research using hyper-immune bovine colostrum (HBC), which contains higher concentration 
of immunoglobulins, has indicated that it may protect against and treat GI infection of C. 
difficile and enterotoxigenic E. coli. Freedman et al., (1998) found that an oral dose of HBC in 
tablet form prevented diarrhoea in 93% of human subjects orally infected with 106 CFU 
Enterotoxigenic E. coli. They were however unable to identify the molecular basis for the 
observed effects (Freedman et al., 1998). Additional research found defatted colostrum 
protected the intestine against NSAID induced permeability and intestinal erosion in humans 
and rats (Macdonald et al., 1998, Playford et al., 1999). In Playford et al. (1999), that authors 
state the presence of recombinant transforming growth factor β (TGF-β) in colostrum is 
involved in the gastro-protective effect against NSAID induced damage 
1.7.2.4 Colostrum growth factors and hormones 
One of the reasons of interest in colostrum is its bioactive contents such as growth factors and 
hormones. These include insulin-like growth factor 1 (IGF-1), transforming growth factor 
(TGF-β2) and growth hormones (Elfstrand et al., 2002), as well as cortisol, androstenedione, 
testosterone, estradiol, cortisone, progesterone and estrone (Xu et al., 2011). IGF-1 and TGF-
β2 are important factors for cell division, homeostasis, maturation of the gut and wound repair. 
Additionally IGF-1 has been associated with increased weight gain in rats, stimulating muscle 
gain and the burning of fat stores (Uruakpa et al., 2002). This indicates that both growth factors 
could play a vital role in gastric repair and increased larval growth rate. Although TGF-β2 
supports growth and repair, 90% of TGF-β2 present in colostrum is inactive and becomes 
activated through changes in ionic strength, acidification or by enzymes such as cell‐associated 




1.7.2.5 Colostrum impact on gastric microbiome  
It is understood that colostrum is important in the early development of a healthy gastric 
microbiome, calves fed colostrum immediately after birth have higher proportions of 
Bifidobacterium and lower proportion of opportunistic bacteria such as Escherichia and 
Shigella compared to those which did not receive colostrum (Song et al., 2018). There is 
evidence to suggest that the early establishment of a healthy gut microbiome is important in 
the long-term health of an individual, preventing allergies and affecting the metabolites with 
infants fed on formula milk instead of colostrum having a higher concentration of short-chain 
fatty acids and lower concentrations of lactate than infants breast fed (van den Elsen et al., 
2019). A study on mature dogs found that the administration of bovine colostrum led to an 
increase in gut microbial diversity and a more stable population (Satyaraj et al., 2013).  
 
1.8 Summary and Aims 
G. mellonella larvae are useful screening tools for pharmaceutical toxicity and bacterial/fungal 
pathogenicity. Although they do not possess adaptive immune mechanisms, they have a highly 
effective and complex innate immunity with broad functional similarities to humans, e.g., 
production of AMPs, use of PRRs and signalling cascades to stimulate the phagocytosis of 
foreign bodies Wojda, Kowalski and Jakubowicz, 2009, Mak, Zdybicka-Barabas and 
Cytryńska, 2010, Nehme et al., 2007). However, a vital aspect of G. mellonella immunity (as 
well as invertebrates in general) is the melanisation and encapsulation of pathogens using PO, 
which is not used in this manner in humans or rat models (Butt et al., 2016). Although the use 
of PO (i.e., tyrosinase) to kill pathogens in this way is not observed in humans, it remains a 
measurable response to infection when using G. mellonella as a model.  
Similarities in larval GI tissue architecture such as the presence of a protective mucous-like  
layer over the epithelial cells, goblet cells and septate junctions to control permeability 
(Tanigawa et al., 2016) allow the observation of putative pathological changes caused by 
bacterial and pharmacological damages  (Uwo et al., 2002, Endo and Nishitsutsuji-Uwo, 1981, 
Lane et al., 1996). Previous work has promoted the use of G. mellonella larvae to study the 
protective properties of probiotics against enteropathogenic E. coli, through simple 
experimental endpoints such as larval survival and total immune cell (haemocyte) counts 
(Scalfaro et al., 2017). That study, and many others discussed here, suggest it to be a suitable 
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model to study C. jejuni infection and nutraceutical protective properties. Simple cell counts 
and detoxification assays are useful, but to fully establish the potential of G. mellonella as an 
immunotoxicology model, it is essential to also look at tissue-specific changes in the gut (e.g., 
histology), understand the gastric structure /function relationship, as well as observations that 
go beyond survival to look at overall health (development, movement, appearance).  
NSAIDs are one of the most commonly prescribed drugs found to cause GI distress, usually in 
the form of increased permeability, breakdown of the mucosal and epithelial layers, and 
enhanced levels of apoptosis (García-Rayado et al., 2018). Indomethacin and Aspirin are the 
basis of substantial research addressing GI-related damages and their potential modes of action 
(Seo et al., 2012), suggesting they are suitable pharmaceuticals to assess G. mellonella's ability 
as a pathological model. To greater test the applicability and variety of applications that can 
incorporate G. mellonella as a model or oral toxicity, marine biotoxins (OA and AZA) 
represent an exciting opportunity to study toxicity and microbial dysbiosis – to be compared to 
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2.1 Abstract  
 
Indomethacin is a non-steroidal anti-inflammatory drug that causes gastric ulceration and 
increased ‘leakiness’ in rat models and is used routinely as a toxicology assay to screen novel 
compounds for repair and restitution properties. This chapter aims to establish conditions for 
indomethacin-induced gut damage in wax-moth (Galleria mellonella) larvae with a view to 
reducing the need for rodents in such experimentation. Indomethacin (0.5–7.5 µg/larva; 2–
30 mg/kg) was administered to G. mellonella via intrahaemocoelic injection and gavage 
(force-feeding). Larval survival and development, blood cell (haemocyte) numbers, and 
changes in gut permeability were monitored in the absence and presence of this NSAID. 
Increased levels of gut leakiness were observed within the first 4-24 hours by tracking 
fluorescent microspheres in the faeces and haemolymph (blood equivalent). Additionally, 
varying levels of tissue damage were recorded in histological sections of the insect midgut, 
including epithelial sloughing and cell necrosis. Degeneration of the midgut was accompanied 
by significant increases in detoxification-associated activities (superoxide dismutase and 
glutathione-S-transferase) and episodes of dysbiosis. Herein, the reader will find evidence 
that G. mellonella larvae force-fed indomethacin display broad signs of gastric damage similar 




2.2 Introduction  
 
When considering more carefully the use of vertebrates in disease and toxicology 
experimentation, there is constant need to develop alternative model systems in vitro, in vivo 
or in silico. One such in vivo alternative is the larvae of the greater wax-moth, Galleria 
mellonella. These insects are now used widespread as ‘mini-hosts’ for the investigation of 
microbial pathogenicity (Mowlds et al., 2010, Kloezen et al., 2015, Lim et al., 2018, Cools et 
al., 2019) screening of xenobiotics/toxins (Allegra et al., 2018, Coates et al., 2019) and 
functional characterisation of virulence factors (Altincicek et al., 2007, Champion et al., 2016). 
Larvae of G. mellonella are designated a non-animal technology (Allegra et al., 2018), which 
means there are fewer ethical restrictions and regulations compared to vertebrates. 
Additionally, practical advantages include low maintenance costs, thermal tolerance to 37 °C, 
ease of use (accurate dosages) and high turnover results can be obtained within 72 h in contrast 
to vertebrates. Although G. mellonella have been used to study the infectivity of gut pathogens, 
e.g., Campylobacter jejuni (Senior et al., 2011) Listeria monocytogenes (Mukherjee et al., 
2013a), Vibrio spp. (Wagley et al., 2018), Shigella spp. (Barnoy et al., 2017) and Salmonella 
enterica (Card et al., 2016), there remains a distinct lack of information regarding the 
alimentary canal of this insect and its role in pathogenesis. 
From mouth to rectum, the digestive system of lepidopteran larvae (like G. mellonella) consists 
of three distinct regions: the foregut (stomatodaeum), midgut (mesenteron) and hindgut 
(proctodaeum) (Engel and Moran, 2013, Linser and Dinglasan, 2014). The midgut is the 
primary site of digestion and absorption in many insects, and importantly, it lacks the 
exoskeletal/chitin lining seen in the fore- and hind-guts. The basic tissue architecture of the 
midgut is similar to those found in the human intestine, such as epithelial arrangements of 
columnar cells and smooth septate junctions that control permeability—analogous to tight 
junctions (Green et al., 1980). The insect peritrophic matrix is the functional equivalent to the 
mammalian mucus layer, which acts as a barrier for the epithelial cells and impedes pathogen 
movement into the body cavity (i.e., the haemocoel) (Campbell et al., 2008, Kuraishi et al., 
2011). Moreover, some microbial communities characterised in the midgut of G. 
mellonella are similar to those found in crypts of the human intestine (Mukherjee et al., 2013b). 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used extensively to alleviate pain by 
inhibiting the activities of cyclooxygenase isozymes (COX1, COX2), yet known side effects 
29 
 
manifest in gastrointestinal injury (Playford et al., 1999, Brune and Patrignani, 2015). In 
particular, indomethacin causes ulceration by inducing apoptosis, reducing gastric blood flow 
and activating innate immune cells (neutrophils), which all contribute to mucosal secretion, 
maintenance and defence (Marchbank et al., 2011, Matsui et al., 2011). Gastric complications 
arising from indomethacin exposure have been developed into a standard rodent restraint/ulcer 
assay to screen novel compounds and health food supplements for putative therapeutic 
properties—tissue repair and restitution (Aguwa, 1985, Playford et al., 1999, Mahmood et al., 
2007). The adverse effects of indomethacin, notably inflammation, permeability and REDOX 
imbalance, have been studied thoroughly in humans and rodents (Basivireddy et al., 2003, 
Bjarnason and Takeuchi, 2009, Sigthorsson et al., 2000, Perron et al., 2013). Therefore, the 
approach of this chapter was to interrogate the effects of indomethacin on the alimentary canal 
of G. mellonella. First, two inoculation methods (intrahaemocoelic injection and gavage) were 
utilised to assess the relative toxicity of indomethacin in insect larvae across the concentration 
range, 0.5–7.5 μg/larva. Second, histopathology screening, X-ray microtomography - 
microscopy (XRM) and enzyme activities were combined to assess the integrity of the midgut 
tissues in the absence and presence of this NSAID. Indomethacin treatments were established 
by extrapolating from Marchbank et al. (2011), wherein a dose of 20 mg/kg was administered 
to induce gastric damage in rats—the equivalent being 5.0 µg/larva.  
 
2.3 Methods  
2.3.1 Reagents 
Unless stated otherwise, all chemicals and reagents were sourced from Sigma Aldrich (Dorset 
UK) in their purest form listed. Green and blue fluorescent (latex) microspheres ranging from 
0.5 to 6 µm in diameter were purchased from Polysciences, Inc. (Fluoresbite®). Stock solutions 
of indomethacin were prepared in 5% dimethyl sulfoxide (DMSO; v/v) and diluted in filter-
sterilized (0.2 μm) phosphate-buffered saline (PBS) pH 7.4. 
2.3.2 Insects 
Larvae of G. mellonella (final instar) were purchased from Livefoods Direct Ltd (Sheffield 
UK). Upon arrival, each larva was inspected for signs of damage, infection and melanisation. 
Healthy larvae weighing between 0.25 g and 0.35 g were retained and stored at 15 °C in the 
dark for no more than 7 days. 
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2.3.3 Larval survival and pupation studies 
Larvae were assigned randomly to each treatment (n = 10 per replicate) and placed in 90 mm 
petri dishes lined with Whatman filter paper and wood shavings from the commercial supplier. 
Indomethacin was administered by intrahaemocoelic injection (INJ) or force feeding (FF; 
gavage; Figure 2.1) using a sterile 27-gauge hypodermic needle across the concentration range, 
0 to 7.5 µg/larva. The volume of each inoculum was standardised to 10 µL. The negative 
control consisted of PBS pH 7.4 containing 5% dimethyl sulfoxide (DMSO). Post-inoculation, 
larvae were incubated at 30 °C and assessed for mortality (response to prodding) and 
development (cocoon formation) for up to 10 days.  
2.3.4 Haemocyte counts and viability 
Larvae treated with indomethacin, PBS (containing 5% DMSO), or untreated (i.e., no 
inoculation) were assessed for haemocyte numbers within 4- and 72-hours post-inoculation. 
Insects were chilled on ice for ~ 3 min prior to injection of 100 μL anti-coagulant (15 mM 
NaCl, 155 mM trisodium citrate, 30 mM citric acid, 20 mM disodium EDTA, pH 5.5). Larvae 
containing anti-coagulant were placed back on ice for 2 min prior to piercing the integument 
above the head using a 27-gauge hypodermic needle. Haemolymph was collected into pre-
chilled, sterile microcentrifuge tubes. For haemocyte viability, haemolymph was extracted in 
the absence of anti-coagulant and mixed in a ratio of 1:5 with 0.4% trypan blue (w/v in PBS) 
and incubated at room temperature for 1 to 2 min. In all cases, haemolymph samples were 
applied to an improved Neubauer haemocytometer for cell enumeration using bright-field 
optics of a compound microscope. Two technical replicates were performed per sample. 
Haemocytes were considered dead when the cytoplasm stained positively for trypan-blue 
(Strober, 2015). 
2.3.5 Detoxification-associated assays 
Haemolymph was extracted (as stated above) and pooled from three larvae at 4, 24, 48 and 
72 h after being force-fed indomethacin. Haemolymph was centrifuged at 500×g for 5 min at 
4 °C to pellet the haemocytes. Approximately, 2.5 × 105 haemocytes from each treatment/time 
point were added to the lysis buffer (50 mM potassium phosphate, 2 mM EDTA, 1 mM DTT 
and a proteinase inhibitor cocktail (Roche cOmpleteTM Mini kit)) and centrifuged at 
14,000 × g for 10 min at 4 °C. Supernatants were retained and stored at − 80 °C. Midgut tissues 
from three larvae per treatment/time point were dissected out and washed in PBS. 
Approximately, 30 mg of tissue was placed in 1 ml lysis buffer and homogenised for ~ 1 min 
(using a borosilicate mini glass homogeniser) prior to centrifugation and storage as described 
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above. Protein concentrations of haemolymph and midgut samples were determined using the 
Biuret method with bovine serum albumin (BSA, 0–20 mg/ml) as a standard (Gornall et al., 
1949).  
Superoxide dismutase (SOD) activity 
SOD activity (EC 1.15.1.1) was determined using the method described by Dubovskiy et al. 
(2008). Briefly, 80 µL of sample (haemolymph or homogenised midgut) was mixed with 
reaction solution (500 µL PBS containing 70 µM NBT, 125 µM xanthine), followed by the 
addition of 20 µL xanthine oxidase solution (5 mg BSA, 15 µL xanthine oxidase (20 units/mL) 
per ml PBS), and incubated for 20 min at 28 °C. Total assay volume was 600 µL. Xanthine 
oxidase catalyses xanthine to produce superoxide anions (O2
−), which reduce NBT to a 
formazan dye. The inhibition of NBT reduction is indicative of SOD activity, which is 
monitored spectrophotometrically at 560 nm. SOD activity is presented as the increase in 
absorbance (560 nm) per min per mg protein. 
Glutathione S-transferase (GST) activity 
GST activity (EC 2.5.1.18) was determined using the method described by Dubovskiy et al. 
(2008). Briefly, 20 µL of sample was mixed with 500 µL GST assay solution (1 mM 
glutathione, 1 mM 1-chloro-2,4-dinitrobenzene (DNCB) dissolved in PBS) and incubated at 
28 °C for 5 min. The reaction of DNCB and glutathione is catalysed by GST, producing 5-(2,4-
dinitrophenyl)-glutathione—detectable at 340 nm. GST activity is presented as the increase in 
absorbance (340 nm) per min per mg protein. 
Lipid peroxidation (malondialdehyde levels) 
Oxidative damage of lipids leads to the formation of malondialdehyde (MDA), which was 
monitored using a colorimetric kit (Abcam [Cat. No. ab118970], Cambridge UK). Midgut 
homogenates (30 µl) and/or haemocyte (2.5 x105) samples were mixed with 300 µl MDA lysis 
solution for 5 – 10 minutes at room temperature. Approximately 200 µl of lysed sample was 
added to 600 µl thiobarbituric acid and further incubated at 95oC for 1 hour. Lipid peroxidation 
was recorded as an increase in absorbance (532 nm) per mg protein and converted to 
concentration (nmol) of MDA (molar coefficient 1.56 x105 M-1 cm-1) using the standard curve 
recommend by the supplier.   
2.3.6 Gut permeability assessments 
Fluorescently tagged, carboxylate-modified latex microspheres (1 × 106) of 0.5 µm, 1 µm, 
2 µm and 6 µm in diameter were resuspended in 10 µL PBS (control) or 10 µL indomethacin 
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solution (1 or 7.5 µg dose) to form co-inoculates (thereby avoiding piercing an insect twice). 
Larvae were force-fed 10 µL of each co-inoculate and incubated at 30 °C until haemolymph 
and faeces were collected from each treatment group at 4, 24, 48 and 72 h. Faeces were 
homogenised in 1 mL PBS pH 7.4. The number of microspheres in the haemolymph/faeces 
was enumerated using a fluorescent microscope (Olympus Bx43f). 
2.3.7 Quantifying bacterial colony forming units in larval faeces 
The faecal loads of control and indomethacin-inoculated larvae (0 - 7.5 µg /larva) were 
collected from Petri dishes at 4, 24, 48 and 72 hours post-treatment. Faeces were weighed prior 
to homogenisation in PBS (pH 7.4) to achieve 0.1 mg of faeces mL-1. Approximately 200 µL 
of each homogenate were spread across pre-poured nutrient agar (Thermo Scientific) and 
incubated at 30oC for up to 48 hours prior to counting.  
2.3.8 Histopathology of the insect alimentary canal 
Larvae force-fed indomethacin (7.5 µg per insect) or PBS (negative control) were killed at 4, 
24, 48 and 72 h post-inoculation by intrahaemocoelic injection of 100 µL 10% buffered 
formalin, immediately prior to submersion in the same solution for 24 h. Larvae were cut into 
three sections, head, middle and posterior (anus), and stored in 70% ethanol prior to wax 
embedding. Briefly, each sample was dehydrated using an ethanol series, 70%, 80% and 90% 
for 1 h each, followed by 3× 1 h 100% ethanol washes. Dehydrated samples were washed twice 
in HistoClear or HistoChoice (Sigma Aldrich) for 1 h each to remove any remaining residues. 
Samples were resuspended in 50:50 HistoChoice: paraffin wax for 1 h prior to complete wax 
embedding. Embedded samples were cut into ~ 6 µm sections using a microtome, adhered to 
glass slides with egg albumin solution (~ 1% w/v) and dried for 24 h before staining. Loaded 
slides were stained using Cole’s haematoxylin and eosin. 
Slides were dewaxed using Histochoice/Histoclear for 15 mins prior to washing in absolute 
ethanol for 2 min, followed by 1 min in 90% ethanol and 1 min in 70% ethanol before staining 
in Cole’s haematoxylin for 13 min. Once stained in haematoxylin, slides were then washed in 
Scotts’ solutions for 2 min to stain nuclear material blue. Samples were washed in water for 10 
seconds to remove any excess stain. At this point, several slides were selected and viewed 
under a microscope to check the staining before proceeding with Eosin. Samples were 
dehydrated in 70% ethanol for 1 min, followed by Eosin for 6 min. Once stained in Eosin, 
samples were dipped in 70% ethanol for a few seconds to remove excess stain. Slides were 
viewed under a microscope at this point to check the stain was sufficient. Slides were further 
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dehydrated in 90% ethanol for 10 seconds and then in absolute ethanol for 5 min twice. Finally, 
slides were washed three times in fresh Histochoice/Histoclear each for 5 min three times prior 
to coverslip mounting using DPX. Mounted slides were transferred to a heating rack for 10 min 
before being placed in an incubator at 40 °C until dry, and the DPX had set.  
2.3.9 X-ray microtomography/microscopy of Galleria mellonella 
Larvae force-fed PBS were killed at 72 h and fixed with 10% formalin for 30 h, followed by 
dehydration in 100% ethanol for 24 h. Samples were submerged in Lugol’s iodine (PRO.LAB 
Diagnostics) for 2 weeks and washed with 70% ethanol prior to microscopy. Insect samples 
were analysed via X-ray microscopy (XRM) using a lab-based Zeiss Xradia 520 (Carl Zeiss 
XRM, Pleasanton, CA, USA) X-ray microscope attached to a CCD detector system with 
scintillator-coupled visible light optics, and tungsten transmission target. The specimen was 
placed in a plastic screw-top microcentrifuge tube and submerged in 75% ethanol to prevent 
the tissues from drying out. To achieve a higher resolution over the entire organism, the insect 
was imaged along its ~ 25 mm length at high resolution, using an overlap-scan and stitching 
procedure including five individual scans, with 44% overlap between each scan. An X-ray tube 
voltage of 80 kV and a tube current of 87 µA were used with an exposure of 1000 ms and a 
total of 3201 projections. An objective lens giving an optical magnification of 0.4 was selected 
with binning set to 2, producing an isotropic voxel (3-D pixel) size of 8.5635 µm. The 
individual tomograms were reconstructed from 2-D projections and stitched into a single large 
volume using a Zeiss commercial software package (XMReconstructor, Carl Zeiss), utilising a 
cone-beam reconstruction algorithm based on filtered back-projection. XMReconstructor was 
also used to produce 2-D grey scale slices for subsequent analysis. Drishti and Drishti Paint 
software V2.6.4. (Limaye, 2012) was employed to highlight regions of interest and digitally 
segment the alimentary canal. 
2.3.10 Data handling 
All data were gathered from experiments carried out on at least three independent occasions 
and are represented by mean values ± standard error (see individual figure legends for sample 
sizes). D’Agostino and Pearson normality tests were performed, and if necessary, data were 
square-root transformed. Results from survival studies were analysed using the log-rank 
(Mantel-Cox) test for comparing curves, whereas larval pupation levels, total haemocyte 
counts, cell deaths, and faecal/haemolymph microsphere loads were analysed using 2- or 3-
way ANOVA with Tukey’s multiple comparison tests in GraphPad Prism v7. A Pearson’s 
Correlation test was employed to assess the relationship between microsphere size (0.5–6 µm) 
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and their presence in the haemolymph of control larvae. Enzyme assays, GST and SOD, were 
analysed in ‘R’ studio using General Liner Hypotheses (ghlt). In all cases, differences were 
considered significant when P ≤ 0.05. Histology slides were single-blind assessed using paired 
treatment (n = 13) and control (n = 13) samples from 4 to 72 h. A grading system (1–4) was 
used to categorise the extent of tissue damage(s) or lack thereof by modifying the guidelines 
developed by Watanabe et al. (2017):(Watanabe et al., 2017) 
1) discrete change with no more than 0 – 2 tissue aberrations per slide 
2) discrete changes of 3 to 5 tissue aberrations per slide 
3) spatial change representing >25% damage (the alteration is dramatic) 
4) global change of >50% of a specific tissue type or the entire slide.   
 
Drishti and Drishti Paint V2.6.4. (Limaye, 2012) and ImageJ (Abràmoff et al., 2004) software 
were used to process/present microscopy findings. Images were adjusted for colour balance 
and contrast/brightness only. 
 
2.4 Results 
2.4.1 Evaluating the relative toxicity of indomethacin on Galleria mellonella 
Survival 
Intrahaemocoelic injection of indomethacin had no measurable negative impacts on larval 
survival across the concentration range 0.5–7.5 µg/larva (0% mortality (Figure 2.1a), which is 
the equivalent to 2–30 mg/kg in rodents. Oral administration of indomethacin (force-feeding) 
in excess of 2.5 µg/larva led to a 7–10% decline in survival within 72 h (Figure 2.1b) but was 
not found to be statistically significant overall (log-rank (Mantel-Cox) 
test; X2(6) = 11.71, P = 0.0688). Further inspection of the survival curves revealed no statistical 
differences between the PBS/DMSO controls and either 2.5 µg/larva 
(X2(1) = 2.034, P = 0.1538) or 5–7.5 µg/larva (X2(1) = 3.105, P = 0.0780). 
Development 
Approximately 87% of untreated larvae transitioned into pupae after 6 days incubation at 30 °C 
(experimental temperature)—increasing to 97% by day 10 (Figure 2.2). No more than 40% 
of G. mellonella force-fed indomethacin (0.5–7.5 µg/larva) or PBS (+5% DMSO, absent 
indomethacin) were observed pupating at day 6. By day 10, numbers of pupae increased to 80–
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90% for injected larvae (Figure 2.2a) and ≤ 63% for force-fed larvae (Figure 2b). Using a three-
way ANOVA, we determined time (Days 6 and 10) and inoculation method (FF and INJ) to 
account for 38% (F(1, 24) = 50.02, P < 0.0001) and 41% (F(1, 24) = 54.19, P < 0.0001) of the 
variation, respectively. Less than 0.5% of the variation within the data can be attributed to 
treatment: PBS + 5%DMSO (negative control), 1 µg (low dose) and 7.5 µg (high dose) 
indomethacin per larva (F(2, 24) = 0.0833, P = 0.92). Tukey’s multiple comparison (post hoc) 
tests revealed statistical differences between the untreated insects and those force-fed 
indomethacin or PBS only (Figure 2.2b), with no differences detected between mean values of 
injected insects at any time-point. These data suggest the route of administration alone can 
delay the onset of pupation, and it is unlikely due to indomethacin exposure. 
 
Figure 2.1 Survival of Galleria mellonella larvae following intrahaemocoelic injection (a) or 
force-feeding (b) of indomethacin, 0.5–7.5 µg/larva.Post-inoculation, larvae were maintained 
in darkness at 30 °C for 72 h. Larvae that were unresponsive to being rolled over or prodded 
were considered dead. Values are expressed as mean ± SE (n = 30 per treatment, 420 in total). 
Inset: images demonstrate the inoculation method for each G. mellonella larva. It should be 
noted that direct injection of indomethacin or PBS with 5% DMSO (control) did not lead to 





Figure 2.2 Development (pupation) of Galleria mellonella larvae following inoculation with 
indomethacin, 0.5–7.5 µg/larva. Larvae received indomethacin via intrahaemocoelic injection 
(a) or force feeding (b) and were maintained subsequently in darkness at 30 °C for 10 days. 
The number of larvae undergoing pupation was recorded. Inset (a): typical appearances of a 
healthy larva (left image) and a moth pupa (right image). Values are expressed as mean ± SE 
(n = 30 per treatment, 390 in total across both inoculation methods). Symbol: **P < 0.01 when 
comparing untreated to all other treatments at the respective time points. The negative control 





Circulating blood cells (haemocytes) 
To investigate further any potential non-target effects of indomethacin, immune cell 
(haemocyte) numbers were monitored as well as levels of cell death within the insect 
haemolymph (i.e., blood). Total haemocyte counts varied little in untreated and PBS (+5% 
DMSO) control insects over the 72-h experimental period, 2.5–3 × 106/mL and 2.7–
3.7 × 106/mL, respectively (Figure 2.3). At 24 h post-inoculation, all concentrations of 
indomethacin injected into the haemolymph led to substantial increases in haemocyte numbers 
(up to 5 × 106/mL) compared to the untreated/control (< 2.8 × 106/mL; Figure 2.3a). Force-
feeding indomethacin led to increased circulating haemocyte numbers at the highest dose of 
7.5 µg/larva only (4.4 × 106/mL; Figure 2.3b). In all cases, haemocyte numbers returned to 
control levels by 48 h. A 2-way ANOVA revealed treatment to account for 15–19% of the 
variation within the data (INJ—F(4, 40) = 4.488, P = 0.0043; FF—F(4, 
40) = 2.988, P = 0.030). Time accounted for < 5% of the variation in force-fed insects 
(Time, F(3, 40) = 1.033, P = 0.3884) but ~30% for injected insects (Time, F(3, 
40) = 11.84, P < 0.0001). These data likely reflect the unimpeded exposure of haemocytes to 
indomethacin when it is administered directly into the haemocoel (body cavity), whereas the 
gut presents a natural barrier when administered via force-feeding. 
Concerning cytotoxicity, proportions of haemocytes staining positively for trypan-blue (i.e., 
dead or dying) ranged from 7 to 12% for the duration of the experiment—regardless of the 




Figure 2.3 Haemocyte responses of Galleria mellonella larvae following inoculation of 
indomethacin, 1–7.5 µg/larva. Larvae received indomethacin via intrahaemocoelic injection 
(a) or force feeding (b) and were maintained subsequently in darkness at 30 °C for 3 days. 
Total haemocyte counts were performed, and haemocyte viability was determined using the 
trypan blue exclusion assay (dead cell numbers are represented by the blue bars in a and b). 
Values are presented as the mean ± SE (n = 36 per treatment, 324 in total across both 
inoculation methods). Unshared letters (x, y) represent significant differences (P ≤ 0.05) 
determined by Tukey’s multiple comparison tests. The negative control consisted of force 






Table 2.1 Proportions of haemocytes staining positively for Trypan-blue (i.e., cell death) when 
treated with indomethacin (1 – 7.5 g/larva) or PBS.  
 
 4 hours 24 hours 48 hours 72 hours 
untreated 9.9% 8.3% 9% 10.2% 
     
Injection     
PBS + 5% DMSO 8.5% 8% 10.6% 10.3% 
1 g/larva 9.8% 10.7% 12.1% 10.5% 
5 g/larva 9.2% 10.7% 9.4% 11% 
7.5 g/larva 10.8% 11.9% 11.9% 8.8% 
     
Force feeding     
PBS + 5% DMSO 11.3% 9% 8.1% 9.4% 
1 g/larva 10.8% 7.2% 10.8% 10.3% 
5 g/larva 8.9% 8.5% 9.2% 9% 
7.5 g/larva 7.1% 8.6% 9.3% 9.2% 
 
 
2.4.2 Characterising the effects of indomethacin on the midgut of Galleria mellonella 
Alimentary canal mapping 
A simple 3-step process of fixing whole insects for <30 hours in 10% unbuffered formalin, 
dehydration in 100% ethanol for 24 hours and staining in 100% Lugol’s iodine for two weeks, 
was developed for G. mellonella (see Appendix A). The accumulation of iodine within the 
various tissue structures enabled whole organ identification and segmentation (Figure 2.4).  
Using X-ray microtomography, the alimentary canal and integumentary musculature of G. 
mellonella larvae (n = 3) were mapped over their entire ~ 25 mm lengths with a resolution of 
8.6 µm (Figure 2.5a – 2.5c). Like most insects, the alimentary canal can be sub-categorised 
into three regions: foregut, midgut and hindgut (Figure 2.5b). The midgut is distinguishable 
from the fore- and hind-guts due to the absence of a cuticle lining, and these measurements 
indicate that the midgut tissues make-up > 50% of the alimentary canal (n = 3) in this species. 
The midgut is arranged into pleats or folds of columnar epithelial cells and goblet cells that 
produce and maintain the peritrophic matrix (functional equivalent to the human mucus layer). 
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Visceral (striated) muscles surround the gut tissues (anchoring the cellular arrangements in 





Figure 2.4 Cross-sectional X-ray microtomography of the upper segment of a Galleria 
mellonella larva. The image is an example output of the fix/dehydrate/stain protocol developed 
here.  The musculature of the insect foregut is visible as is the gut lumen (Lu), body cavity 









Figure 2.5 X-ray microtomography of Galleria mellonella. a 3-dimensional render of a 
representative insect larva stained with Lugol’s iodine. Striated muscle fibres are distributed 
throughout the insect—muscles are attached to the integument and run through the cuticle 
layers. b The entire alimentary canal of the insect larva was highlighted by manually inspecting 
and colouring 1014 slices using Drishti software (Limaye, 2012). FG, foregut; MG, midgut; 
HD, hindgut. c Combined 3-dimensional render with the integument architecture coloured 
yellow and the alimentary canal coloured green. The body cavity (BC) and muscle fibres (MF) 











Indomethacin and NSAIDs broadly increase gastrointestinal ‘leakiness’ in humans and rodents, 
with tissue damage located in the small intestine and colon (Smecuol et al., 2001). In order to 
test whether indomethacin caused similar pathological symptoms in the insect alimentary 
canal, G. mellonella were force-fed inocula containing indomethacin (0, 1 or 7.5 µg/larva) and 
a selection of microspheres, 0.5–6 µm in diameter (Figure 2.6). In the absence of indomethacin 
(PBS [+ 5%DMSO] only), the majority of 6 µm and 2 µm spheres (36–58%) made their way 
down the alimentary canal and were defecated within 24 h (Figure 2.6a and 2.6b), whereas 
1 µm spheres (33%) were released later at 48 h (Figure 2.6c). The presence of indomethacin (1 
or 7.5 µg/larva) led to substantial increases in the number of microspheres (0.5–6 µm) detected 
in the haemolymph (blood) and concomitantly fewer were recovered from faeces. At 4 and 
24 h post-indomethacin treatment, 2.7–3.1 × 104(6 µm) spheres leaked from the gut into the 
haemolymph in comparison to the control, 1.0–1.4 × 104 (Figure 2.6a). Notably, the presence 
of microspheres in the haemolymph was recognised by phagocytic haemocytes and 
subsequently internalised (Figure 2.7). Independent of microsphere size, indomethacin 
exacerbated gut leakiness by 1.4- to 3-fold: 6 µm (F(2, 24) = 5.801, P = 0.0042), 2 µm (F(2, 
24) = 11.04, P < 0.0001), 1 µm (F(2, 24) = 21.48, P < 0.0001), and 0.5 µm (F(2, 
24) = 22.75, P < 0.0001) and accounted for 9–30% of the variation in haemolymph loads. In 
contrast, time accounted for the majority of variation, 25–51%, in faecal microsphere loads: 
6 µm (F(3, 24) = 17.38, P < 0.0001), 2 µm (F(3, 24) = 3.57, P = 0.0288), 1 µm (F(3, 
24) = 3.94, P = 0.0204), and 0.5 µm (F(3, 24) = 8.378, P = 0.0006). 
Overall, significantly fewer 0.5 µm spheres made their way into the faeces within 24 h and 
beyond (Figure 2.6d). This is likely due to the small size enabling movement across the gut 
barrier, and those that remain within the midgut may get caught-up in tissue folds (Figure 2.8), 
thereby delaying passage through the hindgut/rectum. By analysing the control data (absent 
indomethacin) across the 72-h period (Figure 2.9), a strong inverse correlation was found 
between microsphere size and haemolymph loads (Pearson 
Correlation; r = − 0.988, P = 0.0115, R2 = 0.9771) in support of this theory. Moreover, in the 
absence of indomethacin ~715,000 microspheres were found in the faeces over the 72 hours 




Figure 2.6 Gut permeability of Galleria mellonella larvae following force-feeding of 
indomethacin, 0–7.5 µg/larva. Permeability (or leakiness) was determined by the number of 
6 µm (a), 2 µm (b), 1 µm (c) and 0.5 µm (d) spheres found in the haemolymph and faeces 
between 4 and 72 h post-inoculation. Each larva was co-inoculated with 1 × 106 microspheres 
and indomethacin (1, 7.5 µg/larva) or PBS and incubated in the dark at 30 °C. Data represent 
the mean ± SE (n = 36, 432 in total across all four microsphere sizes). Symbol: *P < 0.05 when 
comparing PBS to indomethacin treatments at each respective time point. Unshared letters (a, 
b) represent significant differences (P < 0.05) determined by Tukey’s multiple comparison 
tests. The negative control consisted of force-feeding the insect with PBS (+ 5% DMSO) in the 




Figure 2.7 Latex microspheres (6 µm) in the haemolymph of Galleria mellonella co-inoculated 
with indomethacin (7.5 µg/larva). The top, middle and bottom panels represent images taken 
from 4, 24 and 48-hours post-inoculation, respectively. The white arrows point to spheres 
within the cytoplasm of phagocytic haemocytes (immune cells). The asterisk (*) signifies a 





Figure 2.8 Tissue (longitudinal) section of the Galleria mellonella midgut. The 




Figure 2.9 Gut permeability of Galleria mellonella larvae following force-feeding of 
microspheres (0.5 – 6 µm). The data presented are from the control (no indomethacin) larvae 
only over the entire experimental period (72 hours), i.e., the total microspheres recovered. 
There is an inverse correlation between microsphere diameter and haemolymph load – the 
larger a microsphere is the less likely it will make its way through the gut wall and into the 




Gastric damage of the midgut 
Faecal samples collected from G. mellonella larvae were assessed for putative dysbiosis upon 
exposure to indomethacin via force-feeding and/or intrahaemocoelic injection. Colony forming 
units (CFUs) increased dramatically at 24 hours post-inoculation of 7.5 µg when force-fed 
(~18,000 CFUs) and injected (~11,500 CFUs) into larvae when compared to untreated/control 
larvae (<5,500) (Figure 2.10). The increased microbial load may be due to a change in 
permeability or the gut being flushed out. Overall, CFUs recovered from insect faeces at 4 
hours were rather low, <1,300. These data mirror the transition time of microspheres through 
the alimentary when administered orally (Figure 2.6). Despite the apparent dose-dependent 
increases in CFUs observed in treated larvae (independent of inoculation route), time alone 
was revealed to be a significant factor (F(3, 72) = 4.23, P= 0.0082) and accounted for >12% of 
the variation within these data, whereas treatment was non-significant (F(8, 72) = 1.01, P = 
0.433). By 72 hours, the levels of CFUs in faeces returned to similar levels observed at 4 hours 
(Figure 2.10).  
The effects of force-feeding indomethacin (7.5 µg/larva) and PBS (+5%DMSO) on G. 
mellonella larvae were further examined using wax (H&E) histology. The larval midgut in the 
presence of PBS did not show any clear symptoms of damage or altered tissue morphology 
(Figure 11—upper panels). Uniform cellular arrangements of epithelial and goblet cells were 
observed, in addition to an intact basement membrane and visceral (striated) muscle layer. All 
control slides were considered grade 1 (0–2 discrete changes), with the exception of a single 
section at the 48-h time point that was assigned grade 2 (Figure 2.12). Following indomethacin 
treatment, varying levels of tissue damage and midgut degradation were visible within 4–48 h 
of all insects surveyed (Figure 2.11—lower panels). Tissue slides were assigned damage grades 
2 to 4 at 4 h, and grades 2 or 3 at 24 and 48 h (Figure 2.12) – representing at least five 
aberrations per slide (discrete, localised changes) to >50% compromised tissue (global damage; 
Figure 2.13). Deterioration of the larval gut manifested as sloughed epithelial cells, increased 
vacuolisation, partial/complete displacement of the gut lining into the lumen, cellular debris 
(or potential apoptotic bodies), membrane blistering/blebbing, nuclear condensation (pyknosis) 
and fragmentation (karyorrhexis) (Figures 2.11 and 2.13). By 72 h, several slides were graded 





Figure 2.10 Culturable colony-forming units from faeces of indomethacin-inoculated Galleria 
mellonella larvae. The heat map depicts mean values of CFUs visible on nutrient agar. Insects 
were force-fed or injected with indomethacin across the concentration range 1 – 7.5 g or PBS 
(+ 5% DMSO). Faeces were collected at each time point, homogenised, standardised to 0.1 mg 
per treatment group, and plated on nutrient agar. Faeces were collected on three independent 
occasions from petri dishes containing at least 10 insects each. FF, force-fed; INJ, 






Figure 2.11 Gross histopathology of the midgut tissues from control and indomethacin-treated 
Galleria mellonella. Photomicrographs depict transverse sections of the midgut architecture at 
4, 24, 48 and 72 h after force-feeding PBS (control—upper panels) or indomethacin (7.5 µg–
lower panels). Black boxes (broken lines) are used to highlight magnified regions of interest. 
Ap, apical; Ba, basolateral; BB, brush border; BC, body cavity; bl, blebbing/blistering of the 
cells; BM, basement membrane; c, columnar epithelial cell; g, goblet cell Lu, lumen; M, 
muscle; v, vacuole. An asterisk (*) denotes cellular damage and displacement into the lumen, 
and black arrows point to haemocytes (immune cells) within the body cavity (haemocoel). The 
negative control consisted of force-feeding the insect with PBS (+ 5% DMSO) in the absence 

















Figure 2.12 The extent of midgut tissue damage in Galleria mellonella force-fed indomethacin 
(7.5 µg/larva) or PBS. Histology slides were single blind assessed in pairs (treatment vs 
control) and subsequently assigned a grade (1 - 4) based on damage(s). Grade 1 indicates little 
to no damage, whereas Grade 4 represents global damage affecting >50% of tissue. Data have 
been compiled from assessments carried out at 4 (n = 8), 24 (n = 6), 48 (n = 6) and 72 (n = 6) 





Figure 2.13 Histopathology of compromised midgut tissues from Galleria mellonella force-
fed (7.5 µg) indomethacin. a Transverse section of the larval midgut at 4 h post-treatment. The 
photomicrograph displays severe global tissue damage, where almost the entire epithelium has 
dissociated (sloughed) from the basement membrane and visceral (Vi) muscle. The black 
arrows (all panels) signify the large number of cells displaced into the lumen (Lu). BC, body 
cavity (or haemocoel). b, c These photomicrographs are magnified regions of the black box 
and asterisk, respectively. The epithelial cells are showing clear signs of death: nuclear 
pyknosis (p) and cytoplasmic fragmentation (f), distinct vacuolisation (v) and cell 




Gut repair (detoxification) 
Administration of indomethacin by force feeding led to significant increases in glutathione-S-
transferase (F(4, 40) = 7.35, P = 0.0002) and superoxide dismutase (F (4, 
40) = 2.635 P = 0.0481) activities within the gut, but not in the haemolymph (GST; F(4, 
40) = 0.5449, P = 0.704 and SOD; F(4, 40) = 0.801, P = 0.515; Figure 2.14). Larvae that were 
inoculated with 7.5 µg indomethacin demonstrated consistently higher levels of GST activity 
in the gut, 2.3–3.2 Abs[340 nm]/min/mg, when compared to all other treatments/controls and 
timepoints (Figure 2.14a), whereas SOD activity peaked at 24 and 72 h, ~ 0.4 
Abs[560 nm]/min/mg (Figure 2.14c). A two-way ANOVA revealed time to be a significant 
factor regarding SOD activity (F(3, 40) = 4.266, P = 0.0105), but this was not the case for GST 
(F(3, 40) = 2.584, P = 0.067). These patterns of enzyme activity complement the restored 
nature of the midgut tissues seen at 72 h in the histology (Figure 2.11). Detoxification-
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associated activities in the haemolymph remained below 0.32 Abs[340 nm]/min/mg for GST 
and 0.15 Abs[560 nm]/min/mg for SOD (Figure 2.14b and 2.14d)—indicating that the adverse 
effects of indomethacin were restricted to the gut. Levels of malondialdehyde (MDA) – a by-
product of lipid peroxidation – varied considerably in the gut between 4 and 72 hours (Figure 
2.14e). The highest level of 0.29 nmol [MDA] mg[protein] was recorded in the untreated 
insects at 24 hours. Neither time (P = 0.0629) nor treatment (P = 0.165) were considered 
significant factors and accounted for <24% combined of the variation within the MDA data. In 
the haemolymph (Figure 2.15f), MDA levels remained consistently below 2.3 nmol [MDA] 
mg[protein], except for indomethacin treatments 5 and 7.5 g/larva at 4 hours, where levels 
rose to 3.5 and 4.1 nmol [MDA] mg[protein], respectively. Although time (P = 0.428) and/or 
treatment (P = 0.952) were not considered significant factors, and accounted for ~7% combined 
of the variation within the data, the higher levels of MDA in the haemolymph at 4 hours do 
complement the initial ‘leakage’ of microspheres seen at the equivalent dose of indomethacin 
(Figure 2.6). Despite recording sizeable variation amongst samples, intrahaemocoelic injection 
of indomethacin did not lead to significant changes (explained by time or treatment) in 
glutathione-S-transferase (gut, 0.4 – 4.4; haemolymph, 0.15 – 0.4) and superoxide dismutase 
(gut, 0.04 – 0.2; haemolymph, 0.1 – 0.4) activities, or levels of MDA (gut, 0.14 – 0.31; 
haemolymph, 1.12 – 2.65) (Figure 2.15). However, a dose of 1 µg indomethacin induced the 
largest increase in GST and SOD activities (~0.4 Abs/min/mg each) within 24 hours in the 




Figure 2.14 Detoxification-associated activities within Galleria mellonella following force-
feeding of indomethacin, 0–7.5 µg/larva. Glutathione S-transferase activity was determined in 
the midgut (a) and haemolymph (b) by the change in 5-(2,4-dinitrophenyl)-glutathione 
accumulation (A340 nm). Superoxide dismutase activity was determined in the midgut (c) and 
haemolymph (d) via the inhibition of NBT reduction (A560 nm). Malondialdehyde (MDA) 
levels were determined was determined in the midgut (e) and haemolymph (f) via increases in 
A532 nm. Data are presented as floating bars (min, max) with mean lines shown (n = 36 per 
treatment, 180 in total; 3 insects were pooled at each time point). Unshared letters (a, b) 
represent statistical differences (P < 0.05) as determined by Tukey’s multiple comparison tests. 
The negative control consisted of force feeding the insects with PBS + 5% DMSO in the 










Figure 2.15 Detoxification-associated activities within Galleria mellonella following 
intrahaemocoelic injection of indomethacin, 0–7.5 µg/larva. Glutathione S-transferase activity 
was determined in the midgut (a) and haemolymph (b) by the change in 5-(2,4-dinitrophenyl)-
glutathione accumulation (A340 nm). Superoxide dismutase activity was determined in the 
midgut (c) and haemolymph (d) via the inhibition of NBT reduction (A560 nm). 
Malondialdehyde (MDA) levels were determined was determined in the midgut (e) and 
haemolymph (f) via increases in A532 nm. Data are presented as floating bars (min, max) with 
mean lines shown (n = 36 per treatment, 180 in total; 3 insects were pooled at each time point). 
Unshared letters (a, b) represent statistical differences (P < 0.05) as determined by Tukey’s 
multiple comparison tests. The negative control consisted of injecting insects with PBS + 5% 










The relative toxicity of indomethacin was assessed in insect larvae via gavage (force-feeding) 
and intrahaemocoelic injection across a concentration range relevant to rodent models, 2–
30 mg/kg (0.5–7.5 µg/larva), and found negligible side effects in terms of survival, 
development or immune cytotoxicity (Figures 2.1, 2.2 and 2.3). When force-fed, larvae 
displayed broad signs of injury to the alimentary canal (Figures 2.6 – 2.13), e.g., a threefold 
increase in gut permeability and tissue degradation. Herein, considerable evidence confirms 
that the integrity of the midgut is compromised by indomethacin within 4 to 24 h, causing 
sufficient damage to activate repair/detoxification mechanisms (GST and SOD). The onset of 
indomethacin-associated gut leakiness has also been recorded within 24 h in humans and mice, 
alongside ulceration and epithelial cell shrinkage (Playford et al., 1999, Bjarnason and 
Takeuchi, 2009). The combined use of X-ray microtomography and wax histology provides 
novel insight into the gross anatomy of the G. mellonella digestive tract—highlighting the 
suitability of the midgut for comparative pathobiology.  
Indomethacin is a broad inhibitor of cyclooxygenase isozymes (COX1 and COX2), which are 
responsible for the initiation of prostaglandin synthesis (PGG2), and ultimately, the 
maintenance of inflammatory programmes and gastrointestinal mucosa (reviewed by Brune 
and Patrignani, 2015). A possible limitation of using indomethacin in G. mellonella larvae is 
the mode of action through the inhibition of COX-1 and 2 which may be different in G. 
mellonella (Summ and Evers, 2013). Although the therapeutic effects of indomethacin are not 
being investigated in this research, it is unclear what receptors or enzymes indomethacin may 
bind to in the larvae and thus what other effects it may have and how this could contribute to 
gut damage. Additionally, as COX-1 and 2 are involved in mucosal maintenance of the 
intestines and inflammation (Lanas and Sopeña, 2009), it is possible that indomethacin is 
binding to an alternative receptor or enzyme in the larvae and contributing to disruption of the 
gut integrity through alternative methods. For example, indomethacin induced disruption of 
intestinal epithelial cells through the inhibition of macroautophagy (Chamoun-Emanuelli et al., 
2019). Autophagy in G. mellonella larvae has been observed, and is an important part of 
homeostasis, therefore when this is disrupted it can result in dysbiosis, increased risk of 
infection, inflammation and cell death (Kazek et al., 2020). This could account for some of the 




In a previous study by Büyükgüzel et al., (2007), eicosanoid presence in the haemolymph was 
deemed essential for mediating nodule formation—a cellular defence reaction—during viremia 
(Büyükgüzel et al., 2007). When they injected 50 µg of indomethacin into the haemocoel, there 
was a significant reduction in the number of nodules formed. No measurable reduction in the 
phagocytic capacity of haemocytes in insects force-fed 7.5 µg indomethacin and latex 
microspheres (Supp. Figure 1) was recorded here, which is also in contrast to earlier findings 
by Mandato et al., (1997). The authors reported on a reduction in the phagocytic index of G. 
mellonella haemocytes when exposed to 10 µM indomethacin in vitro (Mandato et al., 1997). 
A likely explanation for this discrepancy is that the majority of force-fed indomethacin remains 
in the midgut of our insects, despite the microspheres leaking into the surrounding haemolymph 
(where they are targeted by haemocytes; Figure 2.7). The immune cells of insects, namely the 
haemocytes, share many mechanistic and structural similarities with the innate immune cells 
of vertebrates, including pathogen recognition receptor signalling and phagocytosis-associated 
respiratory burst (Renwick et al., 2007, Browne et al., 2013, Butt et al., 2016). Mandato et al., 
(1997) and Büyükgüzel et al., (2007) describe the immune-interference of indomethacin, and 
in addition to my observations of indomethacin-induced gut impairment, eicosanoid-like 
signalling should be added to the list of functional similarities between the innate immune 
systems of insects and vertebrates. Indomethacin is a weak acid and becomes soluble in a pH 
neutral or alkaline solution, when indomethacin is formed as a pharmaceutical to ensure correct 
drug delivery pH dependent polymers is used to control drug release (Akhgari et al., 2017, Tres 
et al., 2016). To avoid this interfering with experiments in G. mellonella larva 98.5% pure 
indomethacin was used and dissolved in 5% DMSO prior to inoculations. 
 
Galleria mellonella as an alternative animal model 
The fruit fly Drosophila melanogaster is a superior genetic resource and over the past decade 
has been manipulated to gain novel insight into stem cell fate, immunity, antibiosis and 
homeostasis in the gut (Buchon et al., 2009, Chandler et al., 2011, Broderick and Lemaitre, 
2012, Miguel-Aliaga et al., 2018). Only recently, the genome of G. mellonella was made 
available (Lange et al., 2018a), and the annotated version remains incomplete. Furthermore, 
despite wax-moth larvae being used widespread as a screening tool for novel therapeutics, 
pathogenicity, and toxicology (reviewed by (Tsai et al., 2016)), there remains a historical lag 
in molecular resources with the exception of some transcriptomic and miRNA data (Vogel et 
al., 2011, Mukherjee and Vilcinskas, 2014). The financial and ethical incentives for using 
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insect larvae over rodents and zebrafish are attractive, and so, I propose that vertebrates could 
be replaced partially for gut pathobiology. Waxmoth larvae are larger than traditional models 
like nematodes and drosophilids—this has two distinct advantages: (1) accurate doses can be 
administered orally (force-feeding), and (2) gram quantities of gut tissue can be obtained easily 
for downstream processing. Unlike other insect orders, the midgut of lepidopteran larvae 
represent the majority of tissue along the alimentary canal (mouth to anus; Figure 2.5) and 
contains a specialised cell type, namely the goblet cell, which is also found in the human 
intestine (Engel and Moran, 2013, Linser and Dinglasan, 2014). 
 
The most common larval inoculation technique is intrahaemocoelic injection of test 
compounds/microbes; however, force-feeding G. mellonella (i.e., gavage) is an emerging 
practice. When screening common food preservatives (e.g., potassium nitrate), Maguire et al., 
(2016) obtained comparable toxicology data (LD50) between insect larvae, human cell lines 
(HEp-2) and rats. Recently, Coates et al. (2019) provided evidence that larvae can also be used 
to assess the lethality and putative immune-toxicological effects of shellfish poisoning toxins 
(e.g., okadaic acid) at FDA-regulated levels in contaminated foods. Okadaic acid that was 
force-fed to insects disrupted midgut homeostasis, leading to detrimental levels of lipid 
peroxidation (malondialdehyde accumulation) in a dose-dependent manner—resembling 
symptoms found often in the standardised mouse bioassay. Lange et al., (2018b) proved that G. 
mellonella could differentiate between an enteric symbiont (Bacteroides vulgatus) and 
pathobiont (Escherichia coli), and mount a strong immune response involving reaction 
oxygen/nitrogen species. Oral administration of the pathogen stimulated the up-regulation of 
immune-recognition genes in insects (e.g., apolipophorin III) and mice (e.g., Cd14) alike. 
Interestingly, oral exposure of G. mellonella larvae to caffeine led to elevated levels of 
theobromine and theophylline in the haemolymph—suggesting that caffeine metabolism in this 
insect is similar to the process in mammals (Maguire et al., 2017). 
A better understanding of G. mellonella’s alimentary canal should assist insecticide 
development (e.g., boric acid and biopesticides, (Büyükgüzel et al., 2013, Grizanova et al., 
2014) as lepidopteran insects represent a sizeable number of devastating agricultural pests 
(e.g., Spodoptera littoralis; Linser and Dinglasan, 2014). A key difference between the 
digestive systems of vertebrates and insects is the presence of phenoloxidase (PO) enzymes 
(Whitten and Coates, 2017). Phenoloxidases are responsible for the early processing of pigment 
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precursors (quinones) into melanin, which plays several roles in development and immunity. 
Insect faeces are melanised upon release, and although the function of this is unclear, 
presumably it is due to gut phenoloxidase-activities and their oxidising/nitrosative by-products 
maintaining resident microbial populations from over-growing (Whitten & Coates, 2017). The 
gut microbiomes of insects are diverse and tend to be species specific influenced invariably by 
diet and environmental factors (Engel and Moran, 2013). Few studies have focussed on the G. 
mellonella gut microbiome, yet representatives of the Bacteroidetes, Firmicutes and 
Proteobacteria are homologous to the biota on microvilli of the human intestinal crypts 
(Mukherjee et al., 2013b; Dubovskiy et al., 2016). Further work is needed to profile the 
residents of the insect gut, including fungi, viruses and Archaea. This is a timely topic, as wax-
moth larvae are capable of degrading plastic (polypropylene; (Bombelli et al., 2017) likely 
facilitated by the microbial consortium of their alimentary canal. 
 
2.6 Concluding remarks  
The physiological effects of indomethacin on G. mellonella were investigated, providing 
compelling evidence that indomethacin exposure leads to tissue damage, cell death, gut 
leakiness, and REDOX imbalance in insect larvae. This mimics closely the pathological 
symptoms of their rodent counterparts. Herein, the functional/structural similarities of 
lepidopteran midgut tissues to those found in regions of the human gastrointestinal tract are 
described. These data reinforce the use of G. mellonella as a surrogate toxicology model, with 
a focus on screening nutraceuticals and food additives. 
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The entomopathogenic fungus Cordyceps sinensis and bovine colostrum are considered 
nutraceuticals (health food supplements) due to their anti-inflammatory, anti-apoptosis and gut 
restitution properties in rodent models. Crude extracts of C. sinensis have been used in 
traditional Chinese medicines for many years but the effective ingredients remain largely 
uncharacterised. Herein, the capacity of these nutraceuticals to alleviate gastric damages caused 
by indomethacin and/or the Gram-negative bacterial pathogen, Campylobacter jejuni, were 
investigated using the insect model, Galleria mellonella. Insect larvae were reared from eggs 
on diets supplemented with 10% (w/w) colostrum, 10% (w/w) C. sinensis (powder), or 5% 
colostrum and 5% C. sinensis combined. Fifth instar larvae from each diet regime were force-
fed indomethacin (7.5 µg/larva) or C. jejuni (1x106 - 3 x106 CFU/larva), and monitored for 
survival, development and gastric permeability.  
Insects reared on a C. sinensis-supplemented diet demonstrated reduced gut leakiness after 
indomethacin inoculation (by tracking fluorescent (latex) microspheres) and higher health 
indices after C. jejuni challenge between 24- and 72-hours post-treatment. Insects reared on a 
colostrum-supplemented diet, weighed significantly more than those receiving a ‘standard diet’ 
and some enhanced resistance to infection. The combined diet (5% of each nutraceutical) also 
yielded improved outcomes to the usually detrimental side effects of indomethacin, but was 
not as effective as either supplement alone. Herein, the reader will find evidence that the gut of 
G. mellonella was reinforced against chemical (indomethacin) and microbial (C. jejuni) 




‘Nutraceuticals’ is a broad term used to describe any dietary supplement (non-pharmaceutical) 
considered to contain bioactive compound(s) that can improve health (often available in tablet 
form). There is no specific regulation of nutraceuticals within Europe and the term can often 
overlap with ‘functional foods’ (Coppens et al., 2006), which can be described as enriched or 
fortified foods that possess properties beyond nourishment to include named health-benefits or 
disease prevention (Espín et al., 2007). The practice of consuming specific foods to improve 
health and treat ailments dates back to around 460 – 377 BC. For over 2,000 years, the study 
of  relationships between specific foods and their apparent medicinal properties have helped to 
drive innovation in health and quality of life (Andlauer and Fürst, 2002). This has resulted in 
the production of drugs such as Aspirin  (acetylsalicylic acid), which was extracted as salicylic 
acid from the Spiraea ulmaria plant (Cheng, 2007).  
One nutraceutical, Cordyceps sinensis, is an entomopathogenic fungus and its use can be dated 
back to the late 1400s in Tibet (Chen et al., 2013). Research conducted into the bioactive 
properties of C. sinensis extracts has revealed many therapeutic links, including anti-cancer 
and cardiovascular disease treatments (Li et al., 2006). Crucially, evidence points to both 
protective and reparative properties of Cordyceps spp. against NSAID-induced gastric damage 
and renal interstitial fibrosis (diabetic nephropathy) in rodent models (Marchbank et al., 2011, 
Liu et al., 2020). An emerging nutraceutical, bovine colostrum, is the first milk produced after 
birth, and is vital to the early development of new-borns as it contains antimicrobial peptides 
(AMPs), growth factors, and fats (Bagwe et al., 2015). Studies conducted within the last decade 
have linked colostrum intake to positive cancer outcomes, increased repair rates of cardiac 
muscle/vessels after induced myocardial infarction in rats (Kaur et al., 2014), and to ameliorate 
the effects of exercised-induced permeability of the gut (Davison et al., 2016). Prior to this, 
Döhler and Nebermann (2002) noted a 67% reduction in plasma endotoxin levels from rats 
infected orally with Escherichia coli and then treated with colostrum compared to those 
subjects that received a negative control (albumin). Similarly, (Kim et al., 2005) pre-treated 
rats with colostrum (for 5 days) prior to exposure to the ulcer-causing drug diclofenac. 
Diclofenac-induced damage, e.g., gut permeability, dysbiosis and bacterial translocation, were 
less pronounced in colostrum-treated rats and even more so when colostrum was co-
administered with glutamine.  
The vast majority of exploratory and clinical studies of gastrointestinal damage and integrity 
are carried out in rodents. After performing an extensive literature search for articles on Google 
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Scholar, between 2009 and 2018, using the key terms ‘indomethacin’, ‘ulcer’, ‘gut’ and 
‘rodents’, over 15,000 papers were highlighted. Within the first fifty listed results, an average 
of 64 mice was calculated (ranging from 8 to 250) per study. These were studies of the general 
pathology and toxicology of indomethacin and other toxins (e.g. see Chapter 4) on the rodent 
gut, and the screening of novel compounds for anti-oxidant and gut-repair properties. By 
extrapolation, this is an average of ~98,000 to 114,000 rodents per year. Therefore, there are 
substantial cost, time, and ethical incentives to find an alternative, non-mammalian model for 
studies of gastric damage and repair. The following chapter sought to enhance further the use 
of G. mellonella as a surrogate to rodents, and to build upon the success of Chapter 2 in 
establishing its potential. 
 
Firstly, the putative gut fortification properties of nutraceuticals were assessed in G. mellonella, 
by raising insects on diets supplemented with C. sinensis or bovine colostrum and subsequently 
exposing them to bacterial (Campylobacter jejuni) and chemical (indomethacin) disruptors. 
The enteric pathogen, C. jejuni, is commonly transmitted through contaminated foods and can 
lead to diarrhoea, fever, abdominal cramps, and in extremis, gastroenteritis (van Putten et al., 
2009). Wax moth larvae can be maintained at human relevant temperature, 37oC, and so 
previous work has used this mini host to study the pathogenicity of C. jejuni isolates/strains 
(Senior et al., 2011). Secondly, the use of G. mellonella to triage existing and emerging 
pharmacological demulcents will be investigated using lansoprazole when co-administered 
orally with indomethacin.  Previous work has described the therapeutic effects of this proton 
pump inhibitor (lansoprazole) in reducing the severity of indomethacin-associated gastropathy 
in rats (Kuroda et al., 2006, Maity et al., 2008, Rai et al., 2011). 
 
3.3 Materials and Methods 
3.3.1 Reagents 
Unless stated otherwise, all chemicals and reagents were sourced from Sigma Aldrich (Dorset 
UK) in their purest form listed. Green and blue fluorescent (latex) microspheres ranging from 
0.5 to 6 µm in diameter were purchased from Polysciences, Inc. (Fluoresbite®). Stock solutions 
of indomethacin were prepared in 5% dimethyl sulfoxide (DMSO; v/v) and diluted in filter-
sterilized (0.2 μm) phosphate-buffered saline (PBS) pH 7.4. Mr John Rolfs (Pembrokeshire 
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Dairy Ltd., Wales UK) provided colostrum. Oxford Vitality, part of the Oxford Health 
Company Ltd., provided the C. sinensis extract. 
3.3.2 Galleria mellonella artificial food 
Galleria mellonella larvae were cultured on artificial food adapted from Cherkova et al., 
(2018). Components all purchased from Sainsbury’s unless stated otherwise: Corn meal (90 g), 
Wheat flour (50 g), Dried milk (50 g), Beeswax (50 g) (Thorne natural beeswax F0000), Honey 
(50 g), Glycerol (50 g) (Sigma Aldrich G5516), Dry yeasts (22 g) and Distilled water (50 g) 
(Chertkova et al., 2018). Dry components (Corn meal, wheat flour, dried milk and yeast) were 
combined and sterilised under UV for 15 minutes. Water, glycerol and beeswax were mixed 
and microwaved until wax is completely melted (every 30 second steps with regular stirring). 
Once melted, the honey is added and mixed thoroughly before being poured into the dry 
components and mixed until smooth. Once mixed, the food is spread into a tray and stored at 
4 °C for no more than 2 weeks. For nutraceutical studies, four diets were prepared: (1) standard 
recipe, (2) 10% (w/w) C. sinensis enhanced recipe, (4) 10% (w/w) colostrum enhanced recipe 
(extrapolated from (Davis et al., 2007), and (4) 5%:5% (w/w) colostrum: Cordyceps recipe.  
Table 3.1. Nutritional content of C. sinensis and colostrum powder (Data based on product 
packaging)  
 Cordyceps sinensis 
powder (50g) 
Colostrum Powder (50g) 
Kilo calories (kcal) 194 180 
Protein (g) 18.22 27.5 
Carbohydrate (g) 6.8 16.5 
Fat (g) 7.4 0.4 
 
3.3.3 Culturing Galleria mellonella  
To establish a G. mellonella culture, fifteen final instar larvae purchased from Livefoods Direct 
Ltd. were placed into a glass jar containing 20 g of food.  Filter paper was fixed to the lid of 
the jar to aid egg collections.  Larvae were maintained at 28-30 °C under a 12-hour light, 12-
hour dark cycle (Figure 3.1). Larvae were allowed to pupate (form cocoons), transition to adults 
(moths) and subsequently lay eggs. Food was added ad hoc, filter paper in jars was replaced 
weekly, and moths emerged, the jars were covered to protect the insects. Filter paper with eggs 
attached were transferred into a separate jar containing 20 g food, where larvae were allowed 
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to hatch and grow undisturbed (food was added ad hoc). Once larvae reached the 3rd or 4th 
instar stage, the populations were divided between two new jars in order to avoid overcrowding 
and spoilage. Dead or melanised larvae were removed daily (if necessary). These steps were 
repeated until sufficient numbers were provided for experimentation (Jorjão et al., 2018).  
When up-scaling for nutraceutical studies, larvae were reared on the standard diet until they 
reached 75-100 mg per larva (between 30 and 35 days old), then placed into new jars containing 
one of the four diet regimes mentioned above. Larvae were further maintained for 4 to 7 days 
on the supplemented diets, weighed, inspected and assigned randomly to Petri dishes for 
experimentation (chemical and microbial inoculations). 
3.3.4 Health indices of larvae exposed to biopharmaceuticals   
Aspirin is a common NSAID that is known to cause gastric damage in rats across the 
concentration range, 10 – 100 mg/kg (Wallace et al., 2004, Sanyal and Kaushal, 2005). The 
equivalent dosages for a 250 mg larva are 2.5 – 25 µg. Diclofenac sodium is another commonly 
used NSAID to treat arthritis and is understood to induce gastric ulcers, with some research 
suggesting colostrum can aid in reducing the side effects of diclofenac sodium (Kim et al., 
2005). Accordingly, diclofenac sodium was also incorporated into G. mellonella 
experimentation at concentrations ranging from 2.5 – 10 µg/larva (the equivalent being 10 – 
40 mg/kg in rodents; (Khazaeinia and Jamali, 2003, Reuter et al., 1994, van der Vijver et al., 
2013, Shaheen et al., 2013). To compare the effective ness of nutraceuticals, lansoprazole 
which is often prescribed alongside an NSAID as a neutralising agent, was used also. A 
concentration range of 20 – 100 mg/kg has been successfully administered to rats, therefore 
larvae were administered 5 – 25 µg (Al-Qarawi et al., 2005, Rodríguez et al., 2006, Higuchi et 
al., 2009).  
Healthy final instar G. mellonella larvae reared for 4 – 7 days on supplemented diets (10% C. 
sinensis, 10% colostrum and 5% each) were inoculated with indomethacin, lansoprazole, 
diclofenac salt and/or aspirin by intrahaemocoelic injection (INJ) or force-feeding (FF; gavage) 
using a sterile 27-gauge hypodermic needle (as described in chapter 2). The negative control 
consisted of PBS pH 7.4 containing 5 % DMSO. Post-inoculation, larvae were incubated in the 
dark at 30 °C. Individual larval health was assessed using a scoring system of 0 (dead) and 10 





Figure 3.1 Standard set-up for rearing Galleria mellonella. Jar lids are stainless steel with fixed 
meshes, 0.125 mm diameter holes. Standard honey-based diet is visible in the far right.   
 
 
Table 3.2 Health index scoring system for Galleria mellonella (developed by Loh et al., 2013) 
Category Feature Score 
Activity Movement without stimulation 3 
Moves once stimulated 2 
Minimal movement when stimulated 
(slow, moves ≤ 2 cm) 
1 
No movement 0 
Melanisation No melanisation 4 
< 3 Beige spots 3 
≥3 Beige spots 2 
Whole larvae brown with black spots 1 
Black larvae 0 
Cocoon 
formation  
Full cocoon 1 
Incomplete cocoon 0.5 
No cocoon 0 





3.3.5 Campylobacter jejuni culturing  
Campylobacter jejuni from ATCC - LGC Standards (Campylobacter jejuni subsp. jejuni 
(ATCC® BAA­224™)) was reconstituted with 1 ml Mueller Hinton broth (Sigma Aldrich). 
The bacterial suspension was aliquoted in sterile micro-centrifuge tubes with 15% (v/v) 
glycerol and stored at -70°C. Approximately, 100 µl of bacterial suspension was added to 300 
ml Mueller Hinton broth in a Corning® Erlenmeyer cell culture flask with vented cap and 
incubated at 37°C with constant agitation, 200 rpm overnight. Bacteria (100 µl) were sub-
cultured onto Mueller Hinton agar (2% w/v) and maintained anaerobically using a gas 
generation pack (Merck Anaerocult® P) at 37°C for 48 hours before colony forming units 
(CFUs) were counted.    
 
3.3.6 Health indices of Galleria mellonella larvae during bacterial infection  
Healthy larvae reared for 4 – 7 days on supplemented food (10% C. sinensis, 10% colostrum 
and 5% each of C. sinensis and colostrum combined) were inoculated with C. jejuni diluted in  
PBS (1x106 CFU/larva or 3x106 CFU/larva) by intrahaemocoelic injection (INJ) or force-
feeding (FF; gavage) using a sterile 27-gauge hypodermic needle (as described in chapter 2). 
The negative control consisted of PBS pH 7.4 containing 50% Muller-Hinton broth. Post-
inoculation, larvae were incubated in the dark at 30 °C. Individual larval health was assessed 
using a scoring system of 0 (dead) and 10 (healthy, full pupation) (Table 3.1) over a 72 hour 
period.  
 
3.3.7 Gut Permeability  
Fluorescently tagged, carboxylate-modified latex microspheres (1 × 106) of 2 µm and 6 µm in 
diameter were re-suspended in 10 µL PBS (control) or 10 µL indomethacin solution (7.5 µg 
dose) to form co-inoculates (thereby avoiding piercing an insect twice). Larvae were reared on 
nutraceutical enhanced food (10% colostrum, 10% C. sinensis or combined 5% colostrum with 
5% C. sinensis) for 4 – 7 days before being force-fed 10 µL of each co-inoculate and incubated 
at 30 °C until haemolymph and faeces were collected from each treatment group at 4, 24, 48 
and 72 hours. Faeces were homogenised in 1 mL PBS pH 7.4. To assess the microsphere load 
in the haemolymph, insects were chilled on ice for ~ 3 min prior to injection of 100 μL 
anticoagulant (15 mM NaCl, 155 mM trisodium citrate, 30 mM citric acid, 20 mM disodium 
EDTA, pH 5.5). Larvae containing anti-coagulant were placed back on ice for 2 min prior to 
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piercing the integument above the head using a 27-gauge hypodermic needle. Haemolymph 
was collected into pre-chilled, sterile micro-centrifuge tubes. The number of microspheres in 
the haemolymph/faeces was enumerated using a fluorescent microscope (Olympus Bx43f). 
 
3.3.8 Data handling  
All experiments were completed in triplicate on three separate occasions (refer to individual 
figure legends for sample sizes). Results are expressed as mean ± SE unless stated otherwise. 
Data were handled in GraphPad PRISM v8 and analysed using one- or two-way ANOVAs (or 
Kruskal-Wallis) with Tukey’s multiple comparison (post-hoc) tests. Statistical significance 




3.4.1 Larval development across nutraceutical-enhanced diets  
Regardless of the food recipe, standard or supplemented with nutraceuticals, larvae continued 
to grow and weighed significantly more with time (Figures 3.1 and 3.2).  The average weight 
of G. mellonella reared on colostrum-supplemented foods [10% w/w] was >200 mg, which 
equates to a 2.5-fold (>150%) increase over the 4-day period. Insects reared on the unaltered 
honey-based diet (control) increased in weight by 2-fold (~104%; P < 0.0001), whereas those 
reared on the C. sinensis diet [10% w/w] were 1.8-fold heavier (~85%; P < 0.0001). The 
combined supplement, 5% C. sinensis + 5% colostrum [w/w], resulted in the second highest 
gain of  ~120 % (2.2 fold; P = 0.0221) (Figure 3.3). These data indicate that the colostrum-
enhanced food may have greater nutritional value, containing more carbohydrates and protein 
than the standard food or the C. sinensis enhanced food (Table 3.1). There appears to be a dose-
dependent increase in larval weight when exposed to colostrum, full [10%] colostrum 
supplement versus the combined [5%/5%] colostrum/Cordyceps. Weight gain alone is not 
sufficient to assign health benefits to nutraceuticals, so further studies on larval development 
and susceptibility to infection were performed.   
The trend of increased weights of larvae (Figure 3.3) could not be used as a predictor of 
metamorphosis at day 7, i.e., numbers of pupating (or cocooned) larvae (Figure 3.4). Overall, 
diet supplementation appeared to significantly influence pupation levels (Kruskal-Wallis test; 
P = 0.0286). At ~16%, pupation levels of the colostrum/Cordyceps combination were 
significantly less than the standard diet (28.6%), or individual supplements (25-33%). 
Enhancing the food with C. sinensis results in much smaller larvae but a higher rate of 
metamorphosis, however the 5% each of C. sinensis/colostrum resulted in a much lower rate 





Figure 3.2 Representative Galleria mellonella larvae before (left panels) and after (right 
panels) rearing on nutraceutical enhanced food. Normal diet (A and B), 10% colostrum diet (C 






Figure 3.3 Weights of Galleria mellonella larvae after 4 days of being reared on nutraceutical-
enhanced food. (10% colostrum, 10% Cordyceps sinensis and 5% colostrum with 5% C. 
sinensis). Larvae were maintained in darkness at 30 °C. Values are expressed as mean ± SE 
(n = 60 per treatment, 240 in total). Unshared letters represent significant differences – 





Figure 3.4 Pupation levels of Galleria mellonella larvae after 7 days of being reared on 
nutraceutical-enhanced food. (10% colostrum, 10% Cordyceps sinensis and 5% colostrum with 
5% C. sinensis). Larvae were maintained in darkness at 30 °C for 7 days. Values are expressed 


















































3.4.2 Larval development and survival after nutraceutical inoculations 
To investigate further the effects of nutraceuticals on G. mellonella, larvae were directly force-
fed a range of C. sinensis or colostrum extracts across a concentration range of 0.5 – 8 mg 
(protein)/ml (PBS), which is 5 to 80 μg/larva (or, 20 – 320 mg/kg). As demonstrated in Chapter 
2 with indomethacin (Figure 2.2), fewer larvae were pupating by day 10 after force-feeding – 
regardless of the dose or nutraceutical used (Figure 3.5A and 3.5C). It is worth noting that the 
force-feeding approach appears to have some non-target effects (this is touched upon with 
relation to ‘flushing’ the gut in Chapter 4). Although, the 6mg/ml C. sinensis treatment was 
determined to be significantly different to the untreated larvae by day 10 (50% versus 93%, 
respectively), there was no clear dose-dependent response. For example, 73% had pupated 
when exposed to the highest dose of 8 mg/ml (Figure 3.5A). The majority of variation in the 
data for both C. sinensis and colostrum can be attributed to time (58% and 71%, respectively), 
whereas treatment accounts for 9.7% to <20%.  
Both doses of 6 and 8 mg/ml of C. sinensis extract decreased larval survival by 3-7% (Figure 
3.4B), but overall, survival was not significantly negatively affected by C. sinensis (X2(8) = 




Figure 3.5 Galleria mellonella larval development and survival post-nutraceutical force-
feeding. Larvae were force-fed 0.5 mg to 8 mg protein per ml (PBS) of Cordyceps sinensis (A 
and B) and colostrum (C and D). Larvae were maintained in darkness at 30 °C for 72 h. Insects 
that were unresponsive to being rolled over or prodded were considered dead. Values are 
expressed as mean ± SE (n = 30 per treatment, 420 in total). It should be noted that direct force-













3.4.3 Larval development and survival after pharmaceutical inoculations 
To investigate if nutraceuticals have any protective properties against pharmaceutically 
induced gastric damage in G. mellonella (in addition to indomethacin; Chapter 2), a further 
assessment of NSAIDs known to cause gastric damage, and a common demulcent 
(lansoprazole) known to protect against gastric inflammation, was conducted for added value. 
As observed previously (Figure 3.5), force-fed larvae had an overall reduction in pupation rates 
compared to the untreated control (Figure 3.6A, C, and E), however, the smallest effect was 
observed in lansoprazole-treated larvae (Figure 3.6A). The only apparent significant difference 
in development between untreated and Lansoprazole treated was at day 6 using 2.5 µg/larva (P 
= 0.0033) (Table B1 – Appendix). This is possibly due to damage that may have been caused 
by the operator’s handling at the lower dose. 
 Both NSAIDs, aspirin and diclofenac salt, had significantly reduced development from Day 6 
onwards compared to the untreated control (Figure 3.6 C and E) – determined from ANOVA 
and Tukey’s post-hoc tests. Importantly, no discernible dose-dependent impact on development 
was recorded. The lowest pupation level, when force-fed diclofenac salt, was observed at 5 
µg/larva with an average of 50% by day 10 compared to the control of 96% (P= 0.0009). 
However, this dose was not significantly different to any other NSAID dose or the negative 
control (PBS alone), in which 76% of larvae had pupated by day 10 (Table B1 - Appendix and 
Figure 3.6). Larvae force-fed aspirin demonstrated the lowest rate of pupation with 56% 
positive by day 10 in those inoculated with 2.5 µg/larva (2.5 µg/larva versus control; 
P=0.0113). Although not statistically significant at the highest concentration of 25 µg/larva, 
pupation was 7% higher on average than larvae inoculated with 2.5 µg/larva.  
For NSAIDs, the highest dose of 10 μg/larva reduced survival by 17% for aspirin and 7% for 
diclofenac by 72 hours (Figure 3.6). However, increasing the dose of aspirin to 25 μg/larva led 
to 100% survival; therefore, although survival was reduced overall (X2(6) = 21.25; P = 0.0017), 
no dose-dependent trend was observed (X2(1) = 1.308; P = 0.253). Survival trends for    and 
diclofenac were also found to be non-significant (X2(6) = 5.944; P = 0.43) and X2(61) = 2.0; P 





Figure 3.6 Galleria mellonella larval pupation (A, C and E) and larval survival 0-10 days post 
force-feeding (B, D and F). [Lansoprazole (A, B), Aspirin (C, D) and Diclofenac sodium (E, 
F)]. Larvae were maintained at 30 °C in darkness for 10 days post inoculation.  The number of 
larvae undergoing pupation was recorded. Values are expressed as mean ± SE (n = 30 per 
treatment, 480 in total). Symbol: *P < 0.03 when comparing untreated to all other treatments 
at the respective time points. The negative control consisted of force-feeding the insect with 




3.4.4 Effect of nutraceuticals on maintaining larval health   
No additional value was identified in replacing indomethacin (Figures 2.1 and 2.2) with aspirin 
or diclofenac salt based on the insect survival and pupation data here (Figure 3.6), so 
indomethacin (7.5 µg/larva) was selected to investigate the putative repair properties of 
nutraceuticals. Lansoprazole (7.5 µg/larva, ~30mg/kg) was also established to be a suitable 
(non-toxic) dose to compare to the potency of a pharmacological agent to the benefits of 
nutraceuticals.  
Larvae that were maintained on nutraceutical enriched foods were force-fed either 
indomethacin alone, lansoprazole alone, a co-inoculation of indomethacin and lansoprazole, or 
PBS (5% DMSO), and assessed for health (described in Table 3.1). Indomethacin treatment 
returned similar health indices for all rearing diets with the standard diet resulting in marginally 
higher average scores of 2.7 for activity and 3.7 for melanisation, followed by the combined 
colostrum/Cordyceps diet (5% + 5%),  which scored 2.7 for activity and 3.6 for melanisation 
(Figure 3.7). Larvae force-fed a combination of lansoprazole and indomethacin when reared 
on the standard food, displayed significant decreases in both activity (2.5; P = 0.0047) and 
melanisation (3.2; P = 0.0018) levels at 72 hours compared to the untreated control, which 
scored 3 and 4, respectively (Figure 3.67A). Surprisingly, the combination of 
indomethacin/lansoprazole led to the largest reduction in activity and melanisation – which 
may suggest that insects cannot handle the chemical load on their regular diet. Moreover, the 
PBS (negative control) inoculum did lead to decreases in activity and melanisation indices 
(e.g., Figure 3.7A, B, C) in line with indomethacin alone.    
Importantly, the co-inoculation of indomethacin and lansoprazole resulted in higher average 
health indices for both melanisation and activity over the 72 hours period compared to 
indomethacin alone for all supplemented foods (Figure 3.7 C to H). Larvae maintained on the 
combined diet of colostrum/Cordyceps (Figure 3.7 G and H) appeared to be more resilient to 
indomethacin across both indices when compared to 10% of either nutraceutical alone - this  




Figure 3.7 Health indices of Galleria mellonella larvae reared on nutraceutical-enhanced foods 
and exposed to indomethacin and/or lansoprazole. Larvae were reared on normal food (A and 
B), 10% colostrum enhanced (C and D), 10% Cordyceps sinensis enhanced (E and F) and 5% 
colostrum with 5% C. sinensis enhanced (G and H). Larval health was scored (Table 3.1) by 
assessing larvae movement (A, C, E and G), melanisation (B, D, F and H). Values are presented 
as mean ± SE (n =30 per treatment, 600 total). Unshared letters represent significant differences 
(P ≤ 0.05) determined by Tukey's multiple comparisons tests. The negative control consisted 




3.4.5 Effect of nutraceuticals on improving gut permeability  
As observed in chapter 2, indomethacin can increase gut permeability through tissue damage 
(Figure 2.6), therefore it was important to assess if nutraceuticals could tackle the negative 
impacts of indomethacin on the gut. Larvae reared on the standard diet had more microspheres 
(6 µm and 2 µm) detectable in the haemolymph at 4 -24 hours after indomethacin force-feeding 
compared to the PBS control, equating to an increase of ~1x105 to 1.5 x105 microspheres 
(Figure 3.8 A and B). For all treatments, the highest number of spheres present in the 
haemolymph occurs within the first 4 hours (for 6 μm) and 24 hours (for 2 μm), suggesting the 
initial damage allows spheres to become displaced from the gastrointestinal tract. Larvae reared 
on each enhanced diet had a more gradual flow of 6 µm microspheres into the haemolymph 
over the 72 hours, and crucially, no measurable differences were detected in the numbers of 
haemolymph microspheres in any nutraceutical diet in the absence or presence of indomethacin 
(Figure 3.8 C, G, E). These data indicate that the nutraceuticals may have a positive impact on 
gut resilience to NSAID-associated leakage.  This could also suggest that the nutraceuticals-
enhanced diets are superior to the standard diet used in this chapter, and the bait-shop larvae 
used in Chapter 2 (Figure 2.6). 
Larvae inoculated with indomethacin had large variation of 6 µm spheres found in the faeces 
for all treatments (Appendix B, figure B3). However, larvae that were reared on 10% C. 
sinensis had a peak of 87,500 microspheres/larva (6 µm) in the faeces at 24 hours post 
inoculation, whereas other indomethacin force-fed larvae peaked at 48 hours. Furthermore, 
larvae that were reared on 10% C. sinensis and inoculated with PBS peaked at 48 hours 
(1.2x105 microspheres/larva), whereas all other larvae inoculated with PBS had a gradual 
increase from 4-48 hours followed by a peak at 72 hours (see Appendix B). This could indicate 
that the C. sinensis enhanced diet increases the rate of defecation in larvae (possibly through 
increased gut motility (Table B2, B3 a and B3 b – Appendix B).  
Larvae inoculated with 2 µm spheres and indomethacin had higher numbers of microspheres 
in the haemolymph for the first 24 hours than those inoculated with PBS. Larvae maintained 
on a standard diet prior to indomethacin inoculation, had the highest number of spheres in the 
haemolymph for the first 24 hours, ~2.8x105 – 3x105 per larva, with a gradual decline over the 
following 48 hours (Figure 3.8B). Larvae maintained on a 10% colostrum or the 5%/5% 
combined diets had fewer microspheres in the haemolymph at 4 hours (2.4 x105 – 2x105 
microspheres/larva), similar in number to larvae inoculated with PBS (2x105 – 1.7x105 




Figure 3.8 Gut permeability of Galleria mellonella larvae reared on standard (A and B) and 
nutraceutical supplemented diets: 10% Colostrum (C and D), 10% C. sinensis (E and F) and 
5% C. sinensis with 5% colostrum (G and H). Larvae were force-feed indomethacin (7.5 µg) 
or PBS (control). Permeability was determined by the number of 6 µm (A, C, E, G –left panels) 
and 2 µm (B, D, F, H – right panels) spheres found in the haemolymph between 4 and 72 h 
post-inoculation. Each larva was co-inoculated with 1 × 106 microspheres and indomethacin or 
PBS and incubated in the dark at 30°C. Data represent the mean ± SE (n = 192, 768 in total 
across both microsphere sizes). The negative control consisted of force-feeding the insect with 
PBS (+ 5% DMSO) in the absence of indomethacin (0 µg/larva).  
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Cumulatively (over the 72 hour experimental period), the total number of 6 µm spheres found 
in the haemolymph of larvae reared on a standard diet followed by indomethacin inoculation 
was 5.4x105 – compared to ~3.7x105 microspheres/larva when inoculated with PBS alone 
(Figure 3.9A). This indicates indomethacin enhanced leakiness by >40%. A total of 1.67x105 
microspheres/larva were found in the faeces of those reared on the standard diet and exposed 
to indomethacin, which is similar to the 1.70x105 microspheres (faecal load) found in PBS-
inoculated larva (Figure B1 - Appendix).  
The fewest number of 6 µm spheres found in the haemolymph was from larvae reared on 10% 
C. sinensis enhanced food, ~ 3.3x105 microspheres/larva for both indomethacin and PBS 
inoculated larvae (Figure 3.9 E). Larvae reared on this diet  and inoculated with PBS had the 
most 6 μm spheres found in the faeces with a total average of 2.4x105, compared to 
indomethacin-treated where a total of 1.7x105 microspheres/larva (Figure 3.9 E). It is 
interesting to note that larvae reared on Cordyceps-supplemented diets and exposed to 2 μm 
spheres (Figure 3.9 F, H), had consistently more spheres detected in the haemolymph and 
faeces compared to the PBS controls. Larvae reared on the combined nutraceutical diet (Figure 
3.9G), resulted in almost identical numbers of 6 μm spheres between the treatment and control 




Figure 3.9 Total microsphere loads of Galleria mellonella reared on standard (A and B) and  
nutraceutical supplemented diets; 10% Colostrum (C and D), 10% C. sinensis (E and F) and 
5% C. sinensis with 5% colostrum (G and H). Larvae were force-fed either 6 µm (A, C, E, G 
–left panels) or 2 µm (B, D, F, H – right panels) with indomethacin or PBS (control). The data 
presented is the total microspheres recovered across the 72-hour period displayed in Figure 3.8. 
There is an inverse correlation between microsphere diameter and haemolymph load – the 
larger a microsphere is the less likely it will make its way through the gut wall and into the 




3.4.6 Impact of nutraceuticals on Campylobacter jejuni infection outcomes 
Insect larvae – reared on all diet regimes – were exposed to Campylobacter jejuni and assessed 
for health outcomes (according to Table 3.1). Increasing the dose of C. jejuni from 1 to 3 x106 
CFUs per larva led to a dose-dependent deterioration in health – regardless of inoculation route 
(Figure 3.10).  
Larvae reared on either the standard (Figure 3.10a A-C and Figure 3.10b A-C) or 
Cordyceps/colostrum combined (Figure 3.10a J-L and Figure 3.10b J-L) diets were most 
sensitive to the bacterium (3x106 CFU/larva) when force-fed, resulting in lower activity values 
(1.8 and 1.23, respectively), melanisation levels (1.43 and 0.93, respectively) and overall 
survival (average ~63% and ~33% at 72 hours, respectively). Ostensibly, the least impacted 
group were those reared on the 10% Cordyceps diet (Figure 3.10a and b G-I), survival levels 
were >65%, whereas the other diets, 10% colostrum and 5%-each Cordyceps/colostrum had 
reduced survival rates between 33% and 50% by 72 hours (Figure 3.10a and b, F and I).  
Force-feeding the gut-specific pathogen leads to higher survival rates, up to 80%, in the single 
supplemented diets (10% colostrum; Figure 3.10a F and 10% C. sinensis; Figure 3.10a I). 
These larvae also appear to be more sensitive to intrahaemocoelic injection of the gut 
pathobiont – having lower activity (~1.5 and ~2.1) and melanisation indices (~1.3 and ~1.7) 
when compared to those force-fed. The opposite trend is observed for the standard and 
combined Cordyceps/colostrum diets where the lowest survival rates were recorded when the 
pathogen was force-fed (Figures 3.9C and 3.9L, respectively). This is also the case for their 
activity and melanisation levels. These data are intriguing as they suggest investment in 
fortifying the gut may be at the expense of haemolymph-based defences (i.e., a trade-off).   
Although C. sinensis reared larvae are more resistant to C. jejuni when administered orally, it 
is nearly as resistant to injection as the normal diet larvae, having activity index of just 0.13 
lower and survival of 7% lower, they also have a melanisation index of 0.7 higher than those 
on a normal diet and are not statistically different from one another. Therefore, larvae on a 
normal diet and a C. sinensis diet may have similar immune defence but larvae reared on C. 
sinensis could have a more resistant gut to infection than on a normal diet although not 
statistically significant.  
 
[For a complete list of statistical outputs, see Appendix Table B2 
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Figure 3.10a Health indices of Galleria mellonella larvae reared on supplemented food and 
force-fed with Campylobacter jejuni (1x106 and 3x106 CFU/larva). Larvae were reared on 
standard food (A, B and C), 10% colostrum (D, E, and F), 10% Cordyceps sinensis (G, H, I) 
or 5% each Cordyceps/colostrum combined (J, K, and L). Larvae were maintained 
subsequently in darkness at 30 °C for 72 hours. Larval health was recorded using movement 
(A, D, G and J), melanisation (B, E, H and K), and viability (C, F, I and L). Values are expressed 
as mean ± SE (n = 30 per treatment, 390 in total across both inoculation methods). The negative 






Figure 3.11b Health indices of Galleria mellonella larvae reared on supplemented food and 
injected with Campylobacter jejuni (1x106 and 3x106 CFU/larva). Larvae were reared on 
standard food (A, B and C), 10% colostrum (D, E, and F), 10% Cordyceps sinensis (G, H, I) 
or 5% each Cordyceps/colostrum combined (J, K, and L). Larvae were maintained 
subsequently in darkness at 30 °C for 72 hours. Larval health was recorded using movement 
(A, D, G and J), melanisation (B, E, H and K), and viability (C, F, I and L). Values are expressed 
as mean ± SE (n = 30 per treatment, 390 in total across both inoculation methods). The negative 




Rat models have been used successfully to characterise the protective and reparative properties 
of colostrum and C. sinensis against NSAID-induced gastric damage (Marchbank et al., 2011). 
Herein, the putative therapeutic properties of nutraceuticals, C. sinensis and colostrum extracts, 
were assessed using an insect model (G. mellonella) for the first time.  
NSAIDs are prescribed for managing arthritis and musculoskeletal injuries, however long term 
use of causes about 4% of patients to develop gastrointestinal injuries such as ulceration 
(MacDonald et al., 1997, Paulus, 1988, Langman et al., 1985). Lansoprazole is a proton pump 
inhibitor often used alongside an NSAID to prevent GI damage (Higuchi et al., 2009, Maity et 
al., 2008). Specifically, indomethacin-induced damage in rats can be abated by lansoprazole – 
attributed to a reduction in oxidative stress of the mucosa (Kuroda et al., 2006, Yoda et al., 
2010). There is some literature describing localised inflammation (colitis) and diarrhoea 
associated with lansoprazole treatment (~3-8%), but these are rare (Matsukawa et al., 1997, 
Mukherjee, 2003, Sugano et al., 2012). Therefore, it is preferable to find other treatments to 
assist in managing NSAID induced gastric damage. The neutralising effects of lansoprazole on 
indomethacin were not apparent in insects reared on the standard or colostrum-supplemented 
diets. Surprisingly, the co-inoculum of indo/lansop led to significantly reduced activity and 
melanisation indices (Figure 3.7A and B).  
Lansoprazole, as with most proton pump inhibitors, requires protonation to become activated 
therefore activates in an acidic environment where it goes on to interact with cysteine residues 
Cys813 and Cys321 of the membrane transporters (Shin and Kim, 2013, Bosnjak et al., 2019). 
This is a potential limitation of using G. mellonella larvae as a gastric model for assessing 
pharmaceutical protection as their gut is very alkali and unlikely to provide protonation for 
lansoprazole to activate. This could be why there is no significant improvement on larval health 
when co-inoculating with lansoprazole and indomethacin compared to indomethacin 
inoculation alone (Figure 3.7). An additional consideration of using G. mellonella and 
lansoprazole is its mode of action, and whether it targets Cys813 and Cys321 on relevant 
proteins (Cytryńska et al., 2007).  
The relative toxicity of additional NSAIDs, aspirin and diclofenac acid, were assessed in G. 
mellonella larvae via gavage, with doses of 10 μg/larva (40 mg/kg) resulting in a significant 
decrease in survival. Diclofenac administration produced similar results in larvae compared to 
indomethacin across the same dose range (Figures 3.5 and 2.1). Inspired by Chapter 2, by co-
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inoculating 6 μm spheres with indomethacin, levels of gut leakiness were determined among 
insects reared on all diet regimes (Figure 3.8). Compared to the standard diet, larval guts 
appeared to be less leaky when reared on each nutraceutical-supplemented diet (Figure 3.8 and 
3.8). For some of the supplemented diets, there were still higher levels of microspheres overall 
in control larval faeces versus indomethacin-treated (Figure 3.9 C, E), but numbers recovered 
from the haemolymph showed no differences between treatment and control. From Chapter 2, 
it was apparent that phagocytes targeted microspheres displaced into the haemolymph (Figure 
2.7), and the smaller the microsphere the longer they will take to make their way through the 
GI tract and be defecated (Figures 2.8 and 2.9).  
Larvae were inoculated directly with increasing concentrations of nutraceutical extracts 
(standardised to protein levels across 0 – 80 μg/larva) to determine any potential toxic side-
effects. Beyond 60 μg/larva, the Cordyceps extract appeared mildly toxic - reducing survival 
up to 7% at 24 hours, but no further mortalities were recorded. Perhaps some residual bioactive 
factors are present in the extract and may be antagonising the insect. Cordyceps spp. are distinct 
entomopathogens, and some species like C. militaris are associated with necrotic haemocyte 
death, oxidative imbalance, and developmental arrest (Kryukov et al., 2015, Kryukov et al., 
2020). The latter observation is interesting as doses of  60 and 80 μg/larva resulted in the lowest 
pupation levels of those insects exposed to either colostrum or Cordyceps (<50% by day 10), 
whereas untreated and PBS force-fed insect pupation levels reached >90%. That being said, 
rearing insects on Cordyceps-supplemented diets yielded similar levels of pupation compared 
to larvae reared on the standard and colostrum-supplemented diets (Figure 3.4). Previously, 
dipping leaves in methanol extracts of C. militaris and allowing larvae of diamondback moth 
(Plutella xylostella) to feed on them resulted in high mortalities rates (Kim et al., 2002). The 
insecticidal activity was attributed to cordycepin – a 3’-deoxyadenosine – found to be in high 
concentration in the extracts. Due to the intimate host-pathogen interactions described for some 
insects and Cordyceps spp., future studies using Cordyceps extracts for nutraceutical 
assessments should proceed with caution in this non-mammalian model.  
Rearing larvae on diets supplemented with nutraceuticals led to weight gain, with colostrum 
proving superior (Figure 3.3), and differential rates of development (i.e., pupation; Figure 3.3) 
with the combined colostrum/Cordyceps [5%-5%] diet yielding the fewest pupated larvae. This 
is possibly due to the presence of growth factors in colostrum as well as the increased levels of 
protein and carbohydrates present in colostrum (Table 3.1). Previous studies have described 
so-called ‘melanic’ G. mellonella that have evolved enhanced resistance to fungal infection by 
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investing in frontline immune defences (thicker cuticles, higher levels of enzyme activity), 
however, these defences have a direct cost – melanic larvae are smaller, have a reduced lifespan 
and produce fewer offspring (Dubovskiy et al., 2013, Grizanova et al., 2019). Here, larvae 
reared on a Cordyceps-supplemented diet weighed the least (Figure 3.4) but demonstrated 
enhanced resistance to infection from C. jejuni, when administered by force-feeding. 
Conversely, larvae reared on the same diet are more susceptible to infection by 
intrahaemocoelic injection – this would suggest that fortifying the gut due to the perceived 
threat of Cordyceps signals in the diet, may have a trade-off with size and/or haemolymph 
based defences. By using both intrahaemocoelic injection and force-feeding, it allows the 
assessment of the dietary effects on susceptibility to infection. When injecting directly into the 
haemocoel, the assessment focuses on the immune response against C. jejuni. Conversely, 
when C. jejuni is delivered via force-feeding the experiment focusses on the overall defence to 
infection, including the physical defence of the gut and subsequent immune response. After 
rearing on a C. sinensis supplemented diet, the increased susceptibility to C. jejuni via 
intrahaemocoelic injection, and a reduced susceptibility when force-fed, therefore by 
comparing the results from inoculation methods it appears the C. sinensis extracts benefit the 
gut but does not give an overall enhanced defence to infection. C. jejuni can be cultured 
between 30 – 44 °C and has been studied using several in vivo models, including both G. 
mellonella land rats, making it a suitable pathogen to assess protective properties of 
nutraceuticals against bacterial infection (Senior et al., 2011). Rearing larvae on a single 
nutraceutical diet, either colostrum or C. sinensis, seemed to have prophylactic effects when 
force-fed an NSAID (known to cause gastric ulcers) and an enteric pathogen (C. jejuni). In 
fact, larvae raised on both diets containing Cordyceps extract (Figure 3.7 E-H) were the least 
sensitive to chemical damage (indomethacin), based on activity and melanisation endpoints.  
Colostrum has been identified as a potent nutraceutical, which can provide protection against 
gastrointestinal bacteria-induced septic shock in rats and to reduce the detrimental side effects 
of common NSAIDs in long-term pain sufferers (Playford et al., 2000, Playford et al., 2001, 
Playford et al., 1999). The apparent benefits observed in larvae did vary, with colostrum 
increasing larval weight and reducing some of the impact of C. jejuni infection on health indices 
(Figure 3.3 and 4.9). This may be due to the increased protein and carbohydrate content in 
colostrum compared to the fungal extract. Additionally, colostrum contains growth hormones 
which encourage damage repair. Interestingly, G. mellonella larvae reared on a low nutritional 
diet resulted in expedited pupation (Coskun et al., 2006). In contrast, work conducted in G. 
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mellonella larvae infected with the entomopathogenic fungus, Beauveria bassiana, reported 
that larvae on a low nutrition diet were more resistant to the fungal infection compared to the 
high nutritional diet (Kangassalo et al., 2015).  
A final point to note is that NSAID usage is linked intimately with disease outcomes of clinical 
importance, e.g., Campylobacter (formerly Helicobacter) pylori and group A streptococcal 
infections (Bryant et al., 2015, Stack et al., 2002). As G. mellonella has been proven to be a 
suitable host for studying the infectivity of such pathogens (Olsen et al., 2011, Loh et al., 2013, 
Giannouli et al., 2014), and NSAID-related damages (Emery et al., 2019), they could be used 
to for high- throughput screening nutraceutical and other antimicrobial blends prior to testing 
in rodents. 
 
3.6 Concluding remarks 
Common NSAIDs and nutraceuticals used in the study of gastroenterology in rats and humans 
appear to have similar broad symptoms of damage and repair seen in G. mellonella larvae – 
either by gavage or by raising larvae on supplemented diets. Both colostrum and C. sinensis 
extracts had positive impacts on larval health compared to a standard diet or control inoculum 
(PBS), but C. sinensis was superior when assessing resistance to oral infection using a gut 
specific pathogen, i.e., C. jejuni.  
Considering insects like G. mellonella are usually targeted by intact Cordyceps spp., it is 
necessary to investigate further how active compounds from fungal extracts of this traditional 
Chinese medicine could be leading to gut-fortification, and is it a similar mechanism to the 
therapeutic properties observed in vertebrates. Do these prophylactic properties extend to food 
poisoning toxins or idiopathic gastropathy?  
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Azaspiracids are a collection of marine lipophilic biotoxins that accumulate in edible shellfish 
tissues. Human consumption of contaminated shellfish leads to a gastrointestinal disorder 
referred to as azaspiracid shellfish poisoning – symptoms include nausea and stomach cramps. 
The cellular targets of azaspiracids are not well defined, and further compounded by a high rate 
of false negatives when screened in mice. In the following chapter, Galleria mellonella larvae 
were tested as an alternative toxicology model to determine the (1) differential toxicities of 
azaspiracids (AZA1 – AZA3), (2) their pathobiological effects, and (3) whether pre-exposure 
to a sublethal toxin dose enhances susceptibility to gastric infection (e.g., Campylobacter 
jejuni). A comparison is also made between AZA1 and the causative agent of diarrheic shellfish 
poisoning, namely okadaic acid. Physiologically relevant amounts of azaspiracids (5 – 200 
ng/larva; 20 – 800 g/kg) were administered via intrahaemocoelic injection (subcutaneous) and 
gavage (force-feeding). Health indices (survival, movement, and melanisation), tissue 
histology, and gut microbiome analysis (16S profiles) were used to assess intoxicated larvae 
between 4- and 96-hours. Each toxin – regardless of the route of inoculation, impacted larval 
survival negatively. Histopathology of the midgut depicted epithelial degeneration and cell 
death, including distinct pathologic symptoms between AZA1 and okadaic acid. A sub-lethal 
dose of AZA-1 (25 ng/larva) enhanced susceptibility to infection by the Gram-negative 
bacterium C. jejuni. Herein, the reader will find evidence that G. mellonella larvae can 
distinguish between the different azaspiracid congeners, and offer novel insight into the 













The azaspiracids (AZA) are a group of cyclic, polyether toxins produced by the dinoflagellate 
genera Azadinium and Amphidoma. These dinoflagellates are distributed globally, and are 
associated with >40 AZA analogues (Pelin et al., 2018). During bloom events, AZA1 and 
AZA2 are released routinely and accumulate in the tissues of commercially important shellfish, 
predominantly bivalves (reviewed by Hess et al., 2015), but crustacean (edible crab Cancer 
pagurus) intoxication has also been recorded (Torgersen et al., 2008). A study in bivalves found 
that during blooming events, the hosts become immune suppressed and more susceptible to 
disease and subsequent infection. It is possible that bioaccumulation of the toxins produced in 
blooms could affect negatively the responsiveness of the immune cells to subsequent infection 
(Lassudrie et al., 2020). Human consumption of contaminated shellfish can lead to a 
gastrointestinal disorder known as azaspiracid shellfish poisoning (AZP), which manifests as 
diarrhoea, stomach cramps and vomiting. Although these symptoms are similar to those caused 
by diarrheic shellfish poisoning (DSP), AZP pathobiology is distinct; necrosis and erosion of 
the small intestine, neurotoxicity, fatty acid build-up in the liver, and lymphopenia in the spleen 
(Ito et al., 2000; Abal et al., 2017). It is understood that a disruption to the intestinal epithelial 
layer increases the susceptibility to infection (Antonissen et al., 2014), therefore it is possible 
that even a transient disruption to the intestines cellular organisation could increase the chance 
of subsequent infections. Accordingly, AZP represents a substantial threat to human health and 
financial risk to shellfish producers. AZA-1, 2 and 3 are the only analogues subsumed by 
existing regulation (EFSA, 2008; FSA(UK), 2018) – the other 40 AZA congeners are 
considered metabolic derivatives.   
The mode of action of azaspiracids is currently unknown; some studies have shown AZA-2 to 
inhibit human Ether-à-go-go-Related Gene (hERG) and a hERG trafficking effect on cell 
surfaces. hERG encodes cardiac potassium channels and is considered to be one of the modes 
of action resulting in arrythmias and cardiotoxicity in rat models (Ferreiro et al., 2014). Using 
Caco-2 cells to study AZA-1, the toxin appeared to target steps in glycolysis and the Krebs 
cycle, resulting in an increased NADH concentration within cells, and eventually, cell death 
(Bodero et al., 2018). AZA are often compared to okadaic acid (OA), another lipophilic toxin 
that accumulates in edible shellfish tissues and causes diarrheic shellfish poisoning (DSP). OA 
is produced mainly by the dinoflagellate genera Prorocentrum and Dinophysis (Franchini et 
al., 2010). OA consumption causes diarrhoea, vomiting, stomach cramps and chills within 4 
hours of exposure – leading to the inhibition of serine-threonine phosphatases, and in extreme 
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cases,  the erosion of the small intestine and oedema (Dounay and Forsyth, 2002, Ito et al., 
2002b).  OA inhibition of serine-threonine phosphatases 1 and 2A (PP1 and PP2A) disrupts 
phosphorylation and dephosphorylation events, which are important for maintaining gap 
junctions and regulating the permeability of the intestine (Dietrich et al., 2019). 
The practice of using mice for general toxin detection (OA or AZA) is routine, involving tens 
of thousands of mice per year. Since 2011, the UK has moved towards highly sensitive mass 
spectrometry-based methods, however, rodents are still needed to characterise mechanisms of 
toxicity (cellular targets) and symptoms of intoxication because in vitro approaches do not 
provide this important information. As established in Chapter 2, wax moth larvae (Galleria 
mellonella) have increasingly replaced and reduced the need for mammals in infectious disease 
research for several reasons, including fewer ethical restrictions, experimental veracity and 
affordability. In a pilot study by Coates et al. (2019), okadaic acid lethality (LD50 values), 
cytotoxicity and REDOX imbalance – measured through malondialdehyde (MDA) 
accumulation – were highly similar between insects (G. mellonella) and mice. Like OA, the 
permitted upper regulatory limit for AZP contamination of shellfish products is 160 g 
(equivalents) per kg tissue (EFSA, 2008; FSA(UK), 2018), and so, toxin doses were prepared 
across the range 5 – 200 ng/larva (i.e., 20 – 800 g/kg).  
The aims of this chapter were to:  
(1) Establish the sensitivity of insect larvae to distinguish between different congeners of 
closely related toxins (Azaspiracids 1-3) using two inoculation methods (force-feeding 
and injection) as achieved in mice. Both inoculation methods are utilised due to the 
natural method of intoxication through ingestion and the traditional method of 
screening via injection.  
(2) Determine the extent of gut-specific damage induced by AZA1 compared to okadaic 
acid using a combination of tissue histopathology and microbial profiling (16S NGS 
sequencing)  
(3)  Assess the effects of low-dose (sub-lethal) toxin exposure, and subsequent 





4.3.1 Azaspiracid solution preparation 
Azaspiracid (AZA-1, 2 and 3) stocks (prepared in 100% methanol) were provided by Dr Jane 
Kilcoyne, Marine Institute, Ireland (Table 4.1). Methanol was evaporated under a stream of 
nitrogen, prior to toxins being re-suspended in filter-sterilised (0.2 m) phosphate buffered 
saline (PBS) pH 7.4 with 2% (v/v) ethanol. Biologically relevant doses ranging from 5 to 200 
ng/larva (20 – 800 g/kg) were prepared, which span the upper regulatory limit of 160 g/kg 
(EFSA, 2008; FSA(UK), 2018) – the equivalent being 40 ng/larva.  
 
Table 4.1 Re-suspended azaspiracid stock concentrations  
Toxin ID Concentration (µg/mL) Volume (mL) 
AZA-1 AIL-08-03 111.4 ± 2.2 1 
AZA-2 AIL-10-01 86.2 ± 0.9 0.5 
AZA-3 AIL-10-01 107.4 ± 0.9 0.5 
 
4.3.2 Assessment of Azaspiracid toxicity using a Galleria mellonella health index 
Healthy, final instar larvae (see section 2.3.2) were administered with AZA-1, 2 and 3 by 
intrahaemocoelic injection (INJ) or force-feeding (FF; gavage) using a sterile 27-gauge 
hypodermic needle (see section 2.3.3) across the concentration range 5 – 50 ng/larva for AZA1 
and AZA2, and 20 – 200 ng/larva for AZA3 (n = 30 per treatment/time point, n = 990 in total). 
The negative control consisted of PBS pH 7.4 containing 2 % (v/v) ethanol. Post-inoculation, 
larvae were incubated in the dark at 30 °C. The health of each larva was assessed over a 72-
hour period using a scoring system of 0 (dead) and 10 (healthy, pupated/cocooned) (Table 3.1) 
developed by Loh et al. (2013) for this insect species. The volume of each inoculum was 







4.3.3 Total haemocyte counts and cell sizes 
To further investigate the potential effects of AZA on larvae, haemocyte (immune cell) counts 
and sizes were assessed. Larvae were sacrificed at 4, 24, 48 and 72-hours post-injection with 
5, 25, or 50 ng/larva of AZA-1. This was conducted by cooling each larva on ice for ~3 minutes 
before injecting 100 µl of de-coagulant solution (section 2.3.4) into the last left proleg.  Larvae 
were then chilled for two minutes prior to using a 27-gauge needle to pierce the head and 
exsanguinate into a sterile microcentrifuge tube. Approximate 20 µl of haemolymph was used 
to conduct a total cell count on an improved Neubauer haemocytometer. Haemocyte 
diameters/sizes were measured using an Olympus Bx43f microscope and Olympus Soft 
Imaging Solutions cellSens software. Twenty cells/larva were measured alongside each total 
haemocyte count (n = 36 per treatment, 180 in total).  
4.3.4 Quantifying faecal microbes 
Microbial loads, i.e., culturable colony forming units (CFU), were assessed from the faeces of 
larvae that were force-fed AZA 1 to AZA 3 (5 - 200 ng/larva). Faeces were collected at 4, 24, 
48- and 72-hours post treatment. Faecal pellets were homogenised in 500 µl PBS, and 
standardised to 1 mg/ml. Approximately, 200 µl of faecal homogenate were spread across 
nutrient agar and incubated at 30°C for up to 48 hours.  After incubation, colonies were counted 
(section 2.3.7).  
4.3.5 Gut microbiome analysis of AZA 1 and okadaic acid-intoxicated larvae  
Randomly selected larvae (n = 3 per timepoint/treatment, 54 in total), inoculated with either 
AZA1, okadaic acid, or PBS (control), were sacrificed across 4 to 48 hours. The gut tissues 
(mouth to anus) were dissected from each larva, weighed, snap frozen in liquid nitrogen, and 
stored at -80°C before genomic DNA extraction using a Qiagen DNeasy Blood and Tissue Kit 
by following the manufacturer’s protocol. DNA yields were quantified using the Qubit high 
sensitivity assay kit, and standardised to 50 ng/l prior to sequencing. A sub-set of samples 
were chosen for 16S PCR amplification and visualisation through [2%] gel electrophoresis. For 
amplification of 16S V4 region the forward 515fmod (GTGYCAGCMGCCGCGGTAA) 
(Parada et al., 2016), and reverse 806rmod (GGACTACNVGGGTWTCTAAT) (Apprill et al., 
2015) primers were used. The PCR cycling conditions were modified from Helgesen (2017) 
and Walters et al (2015). Briefly, each PCR reaction mixture (25 μl) contained molecular-grade 
water (6.5 μl), Taq 2X master mix (New England Biolabs: M0270L) (12.5 μl), forward primer 
(1 μM, 2.5 μl), reverse primer (1 μM, 2.5 μl), and DNA (1.0 μl). PCR amplifications were 
carried out using a BioRad thermocycler under the following conditions: 96°C for 2 min for 1 
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cycle; 30 cycles of 96°C for 15 s, 50°C for 30 s, and 70°C for 90 s, and  a final single cycle at 
70°C for 10 min (Walters et al., 2015, Helgesen, 2017). Approximately, 5 μl of PCR product 
was combined with 1 μl of Gel loading buffer (sigma G2526-5ML), and loaded into a 1X TBE 
agarose [2% w/v] gel (10ml UltraPure™ TBE Buffer, 10X Fisher Scientific diluted in 90ml 
ultrapure water, and 5 μl of green safe premium (NZYtech)), The gel was run for 1 hour at 
80V. 
Purified DNA (25 µl of sample) with a concentration of 50 ± 2 ng/µl was used for sequencing. 
Eurofins Genomics (UK Limited) performed the next generation sequencing using an Illumina 
MiSeq platform targeting the V4 16S ribosomal RNA region (2 x 250 -300 bp) using the 
following primers: Forward: TACGGGAGGCAGCAG (Turner et al., 1999) Reverse: 
CCAGGGTATCTAATCC (Kisand et al., 2002), with no less than 100,000 reads per library. 
Amplicon generation, adapter addition, quality control, size selection, pooling, demultiplexing, 
removing of the primers and advanced bioinformatics were performed by Eurofins (raw data 
processing, read merging, quality filtering and chimera removal). De-multiplexing was carried 
out on all reads, which were approved by the standard Illumina chastity filter. Read merging 
was completed using the FLASH algorithms to create a consensus sequence using the greatest 
quality value and considered all overlaps and produced merged readings with the longest 
targeted region (Magoč and Salzberg, 2011). Where merging was not possible the forward 
reading was used, merged regions were then filtered, removing reads which were too long or 
short. Initial Microbiome profiling to remove chimeric reads was conducted using UCHIME 
followed by entropy decomposition analysis to form data sets of partition marker genes within 
operational taxonomic units (OTUs) (Schloss et al., 2011, Eren et al., 2015). Each OTU was 
then assigned to a taxonomy with a minimum of 70% sequence identity across a minimum 
representative sequence of 80% using DC-Megablast (Altschul et al., 1990). Finally, OTUs 
were processed using QIIME software (version 1.9.1) (Caporaso et al., 2010) using 0.97% 
homogeneity threshold for OTU selection. OTUs which had no taxonomic matches were 
categorised as “unclassified” and taxonomic units which had fewer than 0.1% reads were 
considered “other). OTUs at Phylum and Genus levels were visualised and analysed in R studio 
(see 4.2.10)  
4.3.6 Tissue histology of AZA and OA inoculated larvae  
First, larvae were force-fed low or high doses of AZA-1 (5 ng/larva and 37.5 ng/larva) and OA 
(6.25 ng/larva and 62.5 ng/larva). OA doses were determined previously by Coates et al. 
(2019). Second, larvae were sacrificed at 4, 24 and 48 hours post gavage and fixed in 10% 
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formalin (optimised in Appendix A) for 24 hours at room temperature. Third, fixed larvae were 
cut into three parts; head, middle and rear in preparation for paraffin wax embedding. Samples 
were dehydrated in 70% 80% and 90% each for one hour followed by three 1-hour 100% 
ethanol washes. 
Dehydrated samples were incubated in histoclear twice for 1 hour to remove any remaining 
fixative, followed by 50% histoclear: 50% paraffin wax for one hour. Samples were positioned 
in cartridges and filled with molten paraffin wax before being placed in a vacuum to drive the 
wax into the tissue and remove all air. Once vacuumed, samples were then orientated correctly 
and topped up with molten wax and allowed to set overnight. Once completely set, the wax 
block containing the samples were trimmed to the minimise cutting and staining areas. 
Trimmed blocks were sliced into 5 – 7 m sections using a microtome. Samples were loaded 
onto glass slides with water, and dried on a heating block to allow the wax ribbon to fully 
expand and stick to the surface of the glass slide – ready for hematoxylin and eosin staining. 
4.3.7 Culturing of Campylobacter jejuni 
Campylobacter jejuni from ATCC - LGC Standards (Campylobacter jejuni subsp. jejuni 
(ATCC® BAA­224™)) was reconstituted with 1 ml Mueller Hinton broth (Sigma Aldrich). 
The bacterial suspension was aliquoted in sterile microcentrifuge tubes with 15% (v/v) glycerol 
and stored at -70°C. Approximately, 100 µl of bacterial suspension was added to 300 ml 
Mueller Hinton broth in a Corning Erlenmeyer cell culture flask with vented cap and incubated 
at 37°C with constant agitation, 200 rpm overnight. Bacteria (100 µl) were sub-cultured onto 
Mueller Hinton agar (2% w/v) and maintained anaerobically using a gas generation pack 
(Merck Anaerocult® P) at 37°C for 48 hours before colony forming units (CFUs) were 
counted.    
4.3.8 Infecting Galleria mellonella larvae with Campylobacter jejuni   
Larvae were inoculated with 1x104, 1x105, 1x106 or 3x106 CFUs of C. jejuni per larva by 
intrahaemocoelic injection (INJ) or force-feeding (FF; gavage) using a sterile 27-gauge 
hypodermic needle. Bacterial inocula (CFU/larva) were extrapolated from Senior et al. (2011) 
where 106 CFUs injected into G. mellonella resulted in loss of gastric integrity within 24 hours. 
This level of damage within 24 hours is too severe for a susceptibility study, so a broader range 
of doses was selected (1x104 – 3x106) to gauge sub-lethal effects. The negative control 
consisted of PBS pH 7.4 containing 50% (v/v) Mueller Hinton broth. Post-inoculation, larvae 
96 
 
were incubated in the dark at 30°C and assessed for health indicators as stated above (Table 
4.2). 
4.3.9 Pre-treatment of Galleria mellonella with AZA or OA, followed by Campylobacter 
jejuni  
Larvae were pre-injected with a sublethal dose of AZA-1 (25 ng/larva) using a sterile 27-gauge 
hypodermic needle and incubated at 30 °C in darkness. After 24 hours, the same larvae were 
force-fed C. jejuni (1x104, 1x105, 1x106, 3x106 CFUs each). Controls consisted of 
injection/force-feeding the following combinations: PBS (2% ethanol) + PBS (50% Mueller 
Hinton broth); PBS (2% ethanol) + 1x104 CFU C. jejuni; AZA1 (25 ng/larva) + PBS (50% 
Mueller Hinton broth). Individual larval health was assessed as stated above (Table 4.2).  
4.3.10 Data handling  
Each experiment was repeated on at least three separate occasions. Results are expressed as 
mean ± SE (unless stated otherwise), and samples sizes can be found within the respective 
figure legends. Statistical analyses were completed using GraphPad PRISM v8 (except for the 
microbiome data); log-rank (Mantel-Cox) tests were carried out on survival curves, whereas 
two-way ANOVAs (with Turkey’s multiple comparison tests) were applied to cellular 
(haemocyte and CFUs) data. Statistical significance was determined when P ≤ 0.05. Histology 
slides were visualised and singled-blind assessed as outlined in section 2.3.10.   
Next generation sequencing (16S microbiome) data were analysed in R studio using the 
microbiome and vegan packages to carry out Chao-1 and Shannon indices and the randomised 
permutation test; adonis permanova (Bray- Curtis method with 999 permutations) was 
conducted to asses significance between microbiomes (Cree et al., 2016). Stress and dispersion 
tests were conducted and plotted to ensure the model was a good fit. All samples were filtered 
to remove contamination by using the reads present in the extraction blank. OTU reads in the 
extraction blank (≤ 200 reads) were removed from the samples to leave the remaining read 
abundance and all Eukaryotic OTUs such as those associated with arthropod signals and 
Chlorophyta were removed. Replicates were merged to create average OUT profiles for each 
time point and treatment. Two samples (untreated 24 h and PBS 48 h) were unsuccessfully 
sequenced, this is highlighted in the results (Tables 4.4 - 4.6 and Figure 4.11 B and C, Figure 




4.4.1 Survival, responsiveness (activity) and melanisation levels of intoxicated larvae 
Exposure of larvae to an azaspiracid, either by intrahaemocoelic injection or by gavage, had 
clear negative impacts on health indices (Figures 4.1 and 4.2, respectively). Both AZA1 and 
AZA3 reduced survival levels significantly (Table 4.2), whereas AZA2 did not appear as 
toxic/lethal across the concentration range 5 – 50 ng/larva, with no less than 93% survival 
(Figures 4.1F and 4.2F). It was the highest concentrations of AZA1 (37.5 and 50 ng/larva) that 
killed between 17 and 20% of insects by 96 hours. A clear dose-dependent response was 
observed for AZA3 lethality (20 – 200 ng/larva), resulting in 47% and 67% mortality by 96 
hours, through injection and force-feeding, respectively (Figures 4.1I and 4.2I). Decreases in 
both melanisation and activity indices at 4 hours-post inoculation for AZA1 and AZA3, and at 
48 hours for AZA2, were good predictors of survival outcomes (Figures 4.1 and 4.2). It is worth 
noting that a score of 4 indicates pale, non-pigmented insect integument, whereas a score of 1 
or 0 indicates highly melanised (black-brown), gross discolouration. Unsurprisingly, reduced 
movement and increased darkening (melanisation) correlated broadly with reduced survival. 
For example, in larvae forced-fed AZA3, doses of 100, 150 and 200 ng substantially reduced 
activity when compared to untreated and control (PBS) larvae responsiveness across the entire 
96-hour experimental period (Figure 4.1G, H and 4.2G, H). It was not until 48 hours post-
inoculation that survival rates dropped significantly between AZA3 doses 150 and 200 ng/larva 
and the untreated/control larvae, regardless of the inoculation route (Figures 4.1I and 4.2I). By 
force-feeding AZA3 at 20 – 200 ng/larva (40-800 μg/kg), an LD50 value of 881.4 μg/kg (773.1 
- 1028.2) at 48 hours post-inoculation was calculated.  
 
Table 4.2 Survival analyses of Galleria mellonella larvae exposed to azaspiracids. Values 
represent outputs from Log-rank [Mantel-Cox] tests. 
 AZA1 AZA 2 AZA 3 
Intrahaemocoelic 
injection 
X2 (6) = 20.9, P = 0.0019 
 
X2 (6) = 12.2, P = 0.0576 
 
X2 (6) = 60.9, P < 0.0001 
 





Figure 4.1 Health status of Galleria mellonella larvae following intrahaemocoelic injection of 
azaspiracids, 5 – 200 ng/larva. Larvae were inoculated with AZA-1 (panels A-C), 2 (panels D-
F) and 3 (panels G-I) and maintained in darkness at 30°C for 96 hours. Larval health was scored 
(see Table 4.2; Loh et al., 2013) by assessing movement (A, D and G), melanisation (B, E and 
H) and survival (C, F and I). Values are presented as mean ± SE (n =30 per treatment, 510 in 
total). Unshared letters represent significant differences (P ≤ 0.05) determined by Tukey's 
multiple comparisons tests. The negative control consisted of injecting larvae with PBS 




Figure 4.2 Health status of Galleria mellonella larvae following force-feeding (gavage) of 
azaspiracids, 5 – 200 ng/larva. Larvae were inoculated with AZA-1 (panels A-C), 2 (panels D-
F) and 3 (panels G-I) and maintained in darkness at 30°C for 96 hours. Larval health was scored 
(see Table 4.2; Loh et al., 2013) by assessing movement (A, D and G), melanisation (B, E and 
H) and survival (C, F and I). Values are presented as mean ± SE (n = 30 per treatment, 510 in 
total). Unshared letters represent significant differences (P ≤ 0.05). The negative control 








4.4.2 Total haemocyte counts and size(s) within the haemolymph of intoxicated larvae 
Injecting AZA-1 (10, 50 and 100 ng/larva) directly into the insect body cavity (haemocoel) 
induced significant changes in haemocyte numbers within 4 hours (Figure 4.3A), with time 
(F(3, 156) = 3.28 , P = 0.0225) and treatment (F(4, 156) = 3.84 , P = 0.0052) accounting for ~5% 
and ~7% of the variation within the data, respectively. Importantly, a reciprocal increase was 
observed also with the negative control (PBS), indicating the route of inoculation is likely 
responsible for this cellular response. Untreated insects had ~2.4 x106 haemocytes/ml at 4 
hours, whereas all three AZA1 doses and PBS had between 5.2 and 5.7 x106 haemocytes/ml. 
Haemocyte numbers continued to fluctuate between 24 and 72 hours. At 48 and 72 hours, cell 
numbers remained higher for AZA doses 37.5 and 50 ng/larva (4.2-5.2 x106/ml) compared to 
the untreated and negative control (3.2-3.8 x106/ml), but these were not significantly different 
(Figure 4.3A). 
To assess any putative changes in cell size, swelling or shrinkage, due to the presence of AZA1, 
haemocyte diameters were recorded (Figure 4.3B). The injection of AZA-1 did lead to an 
increase in the average diameter of haemocytes, with time (F(3, 3458) = 60.6 , P < 0.0001) and 
treatment (F(4, 3548) = 12.8 , P < 0.0001) considered significant factors. When referring to the 
highest dose of AZA1 (50 ng/larva), and untreated/negative control (PBS) insects from 4-48 
hours post injection, haemocytes were between 0.75 µm and 1.22 µm larger (P = 0.026 – 
0.001). Larger haemocytes tended to be granular or spherule cells (Figure 4.3C), and likely 
represented a switch in haemocyte sub-type composition. Interestingly, at 72 hours post-
inoculation, the haemocytes in untreated insects were 0.89 µm larger than those injected with 
5 ng/larva AZA-1 (P = 0.0127) (Figure 4.3B) – this could be attributed to some untreated 









Figure 4.3 Haemocyte responses of Galleria mellonella larvae following intrahaemocoelic 
injection of azaspiracid 1 across the concentration range, 5 – 50 ng/larva. Haemocyte counts 
(A) and sizes (B) were measured between 4- and 72-hours post-injection. Values represent 
means ± SE (n = 36 per treatment, 180 in total). Unshared letters represent significant 
differences (P ≤ 0.05) determined by Tukey's multiple comparisons tests. The negative control 
consisted of injecting larvae with PBS containing 2% ethanol. (C) phase contrast image of 
freshly withdrawn haemocytes without any de-coagulant. Several different morphotypes are 
visible, including spherule cells (black arrow). There are two plasmatocytes below the labelled 
spherule cell (either side), and one small spherule cell above. Note, spherule cells do not attach 
and spread and the nucleus is never visible except for the absence of the spherules in the 
cytoplasm. Most of the other cells visible are de-granulated granular cells (occurs when in 






4.4.3 Impact of azaspiracid exposure on CFUs within insect faecal loads 
There is large variation in total CFU numbers from G. mellonella faecal samples, however, two 
distinct colonies appear consistently: (1) small, punctate, yellowish colonies, and (2) larger 
cream coloured colonies (Figure 4.4). For insects exposed to AZA-1 and 2, there were 
significant increases in the numbers of CFUs from 4 to 48 hours, ranging from ~7,000-20,000 
to 28,500-33,500 in faecal loads (AZA1, time [F(2, 42) = 32.5 , P < 0.0001], treatment [F(6, 42) = 
2.44 , P < 0.041]; AZA2, time [F(2, 42) = 35.9 , P < 0.0001], treatment [F(6, 42) = 2.51 , P < 0.036]; 
Figure 4.5A and 4.5B). For both AZA1 and AZA2, time accounted for ~48% of the variation 
within the data, whereas treatment accounted for ~11%. Conversely, it was only the lower 
doses of AZA3, 20 – 100 ng/larva that led to large increases in CFU numbers (Figure 4.5C). 
For AZA3, time was revealed as a significant factor (F(2, 42) = 5.02, P = 0.011) and accounted 
for ~14% of the variation within the data, unlike treatment (F(6, 42) = 1.41 , P = 0.235).    
Untreated larvae yielded consistent levels of CFUs between 16,000 and 19,000. The negative 
control (PBS + 2% ethanol) did show increased CFU levels over time, but not to the same 
extent as azaspiracid-treated larvae.   
 
Figure 4.4 Typical appearance of bacterial colonies cultured from Galleria mellonella faeces. 
Faeces were collected from larvae, homogenised in PBS pH7.4 and inoculated onto nutrient 
agar, followed by incubation at 30 °C for 48 hours.  W refers to larger white colonies. Y refers 






Figure 4.5 Numbers of bacterial colony forming units in the faeces of azaspiracid-intoxicated insects. Larvae received AZA-1 (A), 2 (B) and 3 
(C) across the concentration range 5 - 200 ng/larva, and were maintained in darkness at 30 °C for 72 hours. Faecal samples were collected, 
homogenised in PBS and streaked onto nutrient agar, and incubated for 48 hours at 30 °C before counting. Values are presented as mean ± SE (n 
= 9 per treatment, 171 in total). Unshared letters represent significant differences (P ≤ 0.05) determined by Tukey's multiple comparisons tests. 





4.4.4 Histological examination of the insect midgut post-azaspiracid exposure   
Histology slides were prepared from insects force-fed PBS or AZA1, and single-blind assessed 
using the same modified grading system developed for chapter 2 (Figure 4.6). Midgut tissues 
examined from untreated and negative controls (PBS +2% ethanol) showed some variation in 
tissue architecture but contained few clear signs of damage; all slides were assigned grade 1 
(<2 discrete changes), apart for two PBS slides graded 2 (on each at 4 and 48 hours; Figure 
4.6). High doses of OA (62.5 ng/larva. (P < 0.0001) and AZA-1 (37.5 ng/larva. P = 0.008) 
caused significant damage to the larval mid-gut within the first 4 hours of force-feeding. 
Damage worsened during the 48 hours incubation although only significantly more for the high 
dose of OA (62.5 ng/larva). Lower doses of both OA (6.25 ng/larva) and AZA (5 ng/larva) 
inflicted discrete (or localised) damage, however, they were statistically significant compared 
to the untreated and negative control after 24 hours of OA and 48 hours for AZA1.  
Transverse and longitudinal sections along the midgut of PBS-treated larvae revealed an intact 
arrangement of epithelial cells, including columnar, goblet and regenerative cells (Figure 4.7 
A-H). Epithelial folds, involved in nutrient absorption, were identified easily (Figure 4.7B and 
4.7D), as were the brush borders (with peritrophic matrix), basement membrane, and 
underlying muscle tissue (Figures 4.7C, G, H). The midgut lumen appeared mostly free of 
cellular debris (Figure 4.7A, D, E), and there were few signs of haemocyte presence within the 
body cavity surrounding the midgut (Figure 4.7.C). Administration of higher doses of AZA1 
(37.5 ng/larva; Figure 4.8) or okadaic acid (62.5 ng/larva; Figure 4.9) resulted in moderate to 
extensive tissue damages within 4 hours post-inoculation (and were still obvious after 48 
hours). Common features of tissue degradation included displacement of cells into the midgut 
lumen, membrane blebbing/blistering, loss of cellular morphology, and nuclear aberrations 
(pyknosis, karyolysis, and karyorrhexis) associated with cell death.    
In AZA1 treated insects, extensive vacuolisation, elongation and desquamation of epithelia 
were observed (Figure 4.8A to 4.8I). Epithelial folds that were clearly intact at 4 hours (Figure 
4.8D) had deteriorated by 48 hours – almost complete tissue distortion (Figure 4.8H). There 
were signs of haemocyte recruitment (Figure 4.8C), presumably due to damage detection. 
However, the basement membrane and visceral muscle remained mostly intact. For insects 
treated with okadaic acid, entire regions sloughed into the lumen by 4 and 24 hours (Figure 
4.9A –D). In the body cavity, haemocytes were damaged and fragmented (Figure 4.9E), which 
indicates the toxin made its way across the protective layers of the midgut. By 48 hours, global 
tissue damage was apparent, and in extremis, the integrity of the entire midgut was 
105 
 
compromised by necrosis and gross melanisation (Figure 4.9G, H). Okadaic acid appears more 
toxic to the gastrointestinal tract of larvae. 
 
Figure 4.6 The extent of midgut tissue damage in Galleria mellonella after force-feeding 
AZA1 (5 and 37.5 ng/larva), okadaic acid (6.25 and 62.5 ng/larva), or PBS. Histology slides 
were single blind assessed in pairs (treatment vs control) and subsequently assigned a grade (1 
- 4) based on damage(s). Grade 1 indicates little to no damage, whereas Grade 4 represents 
global damage affecting >50% of tissue. Data have been compiled from assessments carried 
out at 4 (n = 9), 24 (n = 9) and 48 (n = 9) hours post-inoculation. Unpaired letters indicate 





Figure 4.7 Tissue sections of the Galleria mellonella midgut when force-fed PBS (2% v/v 
ethanol). Photomicrographs depict transverse and longitudinal sections at 4 (panels A, B, C), 
24 (panels D, E) and 48 (panels F, G, I) hours post-inoculation. Ap, apical; Ba, basolateral; BB, 
brush border; BC, body cavity; c, columnar (epithelial) cell; ef, epithelia fold(s); g, goblet cell; 




Figure 4.8 Tissue sections of the Galleria mellonella midgut when force-fed azaspiracid 1. 
Photomicrographs depict transverse and longitudinal sections at 4 (panels A, B, C, D, E), 24 
(panels F, G) and 48 (panels H, I) hours post-inoculation. Ap, apical; Ba, basolateral; BC, body 
cavity; BM, basement membrane; bl, blebbing/blistering; ef, epithelia fold(s); f, fragmentation; 
k, karyolysis; Lu, lumen; p, pyknosis; rc, regeneration cell; v, vacuolisation. Hashtags (#) 
denote haemocytes. Black arrows point to distorted architecture of epithelial folds. An asterisk 




Figure 4.9 Tissue sections of the Galleria mellonella midgut when force-fed okadaic acid. 
Photomicrographs depict transverse sections at 4 (panels A, B), 24 (panels C, D, E, F) and 48 
(panels G, H) hours post-inoculation. BC, body cavity; BM, basement membrane; bl, 
blebbing/blistering; ef, epithelia fold(s); f, fragmentation (karyorrhexis); k, karyolysis; Lu, 
lumen; n, normal nucleus; p, pyknosis; rc, v, vacuolisation; vi, visceral muscle tissue. An 
asterisk (*) indicates cellular displacement. Black stars highlight areas where damage has 
completely removed epithelia and exposed underlying muscle. Black arrows point to 





Figure 4.9 continued…  
[Panels G and H represent tissues at 48 hours post-inoculation of okadaic acid (62.5 ng/larva)] 
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4.4.5 Impact of azaspiracid-1 and okadaic acid inoculation on gut microbiota of the 
Galleria mellonella larvae 
Prior to next generation sequencing of the gut tissues, a subset of extracted DNA samples were 
amplified for the 16S V4 region through PCR and visualised on a agarose gel (for quality 
control). PCR amplicons from insect gut tissues were ~500 bp compared to the positive control 
(+ve) which was ~300 bp (Figure 4.10). A possible explanation for this difference might be 
that the primers are binding non-specifically or to host DNA, which may also explain the 
presence of a double band for the OA High sample. This nonspecific binding could be due to 
the annealing temperature being too low or requiring more specific primers.  
 
Figure 4.10 Agarose gel electrophoresis of PCR amplicons after 16S V4 region amplification 
from Galleria mellonella whole gut tissue. 
Exposure of AZA-1 or low OA did not cause gross changes in diversity when comparing Chao-
1 (richness) and Shannon (diversity) indices of microbial signals; however PBS and OA high 
have lower than average diversity indices of 354.3 and 336.3, respectfully (Table 4.3). For the 
PBS, this could be an effect of “flushing” due to the force feeding method or a direct effect of 
the high OA dose, however if this is the case you would expect all samples to have lower 
indices than the untreated control. OA high Shannon and Chao-1 indices are consistently lower 
during the entire sampling period, with a gradual decrease from 372 to 300 for the Chao-1 
index and 4.083 to 3.496 for the Shannon index. Such changes are not observed in the OA low 
dose or AZA-1 high dose. A similar trend is observed after AZA-1 low exposure, causing the 
Chao-1 index to decrease by 115 to an index of 423 by 48 hours. Conversely, AZA-1 high dose 
has an initial Chao-1 index of 366, which gradually increases to 461 after 48 hours. This data 
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may indicate that AZA-1 at the high dose causes a loss of diversity within the first 4 hours of 
exposure followed by a gradual improvement/recovery.  
At 48 hours, the OA low dose has a much higher Chao-1 index of 603 compared to all other 
samples. The untreated control and OA low have large variation over the 48-hour experiment 
for both Shannon and Chao-1 indices. Liu et al. (2020) report that OA-treated mice depict 
similar fluctuations in microbial diversity and richness over a ten-day period, becoming higher 
and then lower than the control. This fluctuation is observed here in both the low and high dose 
when comparing time points, however the fluctuation observed here is much greater than in 
Liu study. The lowest recorded values were for PBS 48 hour and untreated control 24 hour, 





Table 4.3 Diversity indices of the gut microbiome of Galleria mellonella larvae after 
azaspiracid and okadaic acid exposure. (n = 3 per treatment per time. Total = 52 technical 
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Although PBS and OA high have the lowest diversity indices, AZA-1 high and OA high are 
the only treatments to have a statistically significant difference in microbiome structure when 
compared to the untreated control (adonis P = 0.032 and adonis P = 0.003, respectfully; Table 
4.4). These results may indicate that the high oral dose of AZA-1 (75 ng/larva) and OA (62.5 
ng/larva) does in fact cause changes to the microbiome. As there is no statistical difference 
between time points within each treatment (Table 4.5), it suggests that the changes in 
microbiome in AZA-1 High and OA High occurs within the first 4 hours of inoculation and no 
significant subsequent alterations in microbiome are detected up to 24 hours.   
Table 4.4 Statistical differences of the gut microbiome structure in Galleria mellonella larvae 
after azaspiracid and okadaic acid exposure. Data represented as permutation test for adonis 
under reduced model and permutation test for homogeneity of multivariate dispersions 
following the Bray-Curtis method. (n = 9 per treatment, total = 52) (PBS and untreated n = 8 
per treatment) (PBS = 2 repeats at 48 hr, untreated = 2 repeats at 24 hr) 




















OA High vs 
OA Low 




Table 4.5 Statistical differences of the gut microbiome structure in Galleria mellonella larvae 
after azaspiracid and okadaic acid exposure when comparing 4, 24 and 48hr within each 
treatment. Data represented as permutation test for adonis under reduced model and 
permutation test for homogeneity of multivariate dispersions following the Bray-Curtis 
method. (n = 3 per treatment per time, total = 52) (PBS = 2 repeats at 48 hr, untreated = 2 
repeats at 24 hr) 
  Adonis Pr(>F) Dispersion Pr(>F) 
Untreated  0.778 0.001* 
PBS  0.49 0.122 
AZA-1 High 0.742 0.392 
AZA-1 Low 0.757 0.675 
OA High 0.976 0.887 
OA Low 0.327 0.085 
 
Firmicutes are Gram-positive bacteria and often represent the most predominant phylum found 
in mouse and human gastric microbiomes (Ley et al., 2006a).  When assessing the effects of 
AZA and OA on the individual populations of bacteria within the larval gut, the untreated 
control and AZA-low appear to have a much lower abundance of Firmicutes at 4 hours, making 
up less than half of the overall abundances and remains constant for the duration of the 
experiment (Figure 4.11). On the other hand, Firmicutes is the most prevalent phylum in all 
other treatments throughout the experiment, with OA Low being almost entirely Firmicutes 4 
hours post inoculation with a gradual decline to account for ~50% of the total population by 48 
hours. Conversely, the proportion of Firmicutes fluctuates largely in larvae exposed to PBS, 
accounting for ~60% at 4 hours, ~40% at 24 hours and increasing again to almost 100% by 48 
hours post inoculation (Figure 4.11). Another notable difference in Firmicutes proportion is in 
larvae inoculated with a high dose of OA, which have a sustained high proportion of Firmicutes 
accounting for 75% – 85% of the total microbiome from 4 - 48 hours.  
Untreated larvae have a much higher abundance of Bacteroidetes than all other treatments at 4 
hours (Figure 4.11 A), making up just over a quarter of the total abundance becoming the 
second most prevalent phylum for that group. In all other treatments, Bacteroidetes is the third 
(PBS and AZA High) or forth (OA High, AZA low and AZA High) most abundant phylum at 
4 hours accounting for less than 10% of the total proportion, with Proteobacteria being the 
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second most abundant. Interestingly, AZA-1 high exposed larvae have a notable increase in 
Bacteroidetes from ~7% at 4 hours to ~15% at 48 hours after inoculation. All other OA and 
AZA exposed larvae have a small increase in Bacteroidetes at 24 hours, which then return to 
similar levels as at 48 hours (Figure 4.11).  
Proteobacteria is the second or third most abundant phylum, however there is a large amount 
of variation as to what proportion it holds between each treatment group. OA High exposed 
larvae have a consistently low proportion of Proteobacteria, between ~9 – 14%. This is 
consistently lower than the proportion observed in the untreated and AZA low treated larvae. 
Surprisingly, PBS inoculated larvae have a similar proportion as to the untreated at 4 hours 
(~17%) and 24 (30%) hours post inoculation (Figure 4.11 A and B). However, 48 hours after 
inoculation Proteobacteria is almost entirely gone in the microbiome. This is not observed in 
any other treatment groups, conversely OA low exposed larvae have a very low proportion of 
Proteobacteria of ~6% which then increase to ~30% by 48 hours post exposure. The presence 
of Actinobacteria and Acidobacteria are likely to be due to bacteria in the culturing 






Figure 4.11 Microbial (16S) composition of the gut tissue from Galleria mellonella larvae 
exposed to OA and AZA-1. A comparison of the top 10 most abundant phyla depicted as 
relative abundance 4 hours (A), 24 hours (B) and 48 hours (C) after force-feeding. (n = 3 per 
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Untreated larvae – no PBS or toxin inoculation – displayed a different microbiome structure at 
the Genus level, when compared to all others, with a much lower proportion of Enterococcus 
(between 40-50% of total). Enterococcus accounts for >50% for all time points except for OA 
low at 48 hours where the proportion decreases to 40% (Figure 4.12). Interestingly, OA high 
exposed larvae have the largest proportion of Enterococcus accounting for ~85% of the total 
populations at 4 hours (Figure 4.12 A) and remains between 80- 95% for the duration of this 
experiment. This observation could explain the statistical difference between the untreated and 
OA high adonis p-value (Table 4.5) and clearly shows no substantial change over the 48-hour 
period. 
The untreated larvae also have a high proportion of Flavobacterium across all time points 
making up between 14 – 25% of the total abundance compared to the other treatments, which 
range between 1-14% (Figure 4.12). Interestingly, larvae treated with AZA have a larger 
proportion of Flavobacterium than OA high or low which could suggest different effects of the 
two toxins. Another  notable difference is the presence of Prevotella in  untreated  and the AZA  
low treated larvae at 4 hours (Figure 4.12 A), which declines  in 24 and 48 hour time points but 
increases in  AZA high  at 24 hours post inoculation (Figure 4.12 B). Prevotella is a member 
of the Bacteroidetes and can be a sign of microbiome imbalance – its presence in humans can 
be associated with a plant rich diet in humans (Ley, 2016, Si et al., 2017). Therefore, it’s 
presence here could be as a result of the larval diet or a disruption in the normal microbiome.  
Another notable genus is Staphylococcus at 4  and 24 hours (Figure 4.12 A and B), which is 
present at low levels in  the untreated and PBS  larvae at 4 hours  and then appears in all groups 
at a low level (less than 10% of total abundance) and then does not appear at 48 hours. Some 
species of Staphylococcus are pathogenic and are identified in Lepidoptera gut microbiota  in 
other studies (Paniagua Voirol et al., 2018). This could indicate a subsequent infection or an 




Figure 4.12 Microbial (16S) composition of the gut tissue from Galleria mellonella larvae 
exposed to OA and AZA-1. A comparison of the top 10 most abundant genus depicted as 
relative abundance 4 hours (A), 24 hours (B) and 48 hours (C) after force feeding. (n = 3 per 
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Untreated PBS AZA1 High AZA1 Low OA High OA Low 
Untreated PBS AZA1 High AZA1 Low OA High OA Low 
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4.4.6 Susceptibility of insect larvae to Campylobacter jejuni in the absence and presence 
of azaspiracid 1 
To determine a suitable inoculum of Campylobacter jejuni for insect susceptibility studies, 
initial viability tests were performed using 1x104 to 3x106 CFUs per larva (Figure 4.13). 
Exposure of insects to C. jejuni led to significant decreases in survival, either by force-feeding 
(X2 (5) = 50.96, P < 0.0001; Figure 4.13C), or intrahaemocoelic injection (X2 (5) = 60.4, P < 
0.0001; Figure 4.13F). For force-fed insects, lower doses of 1x104 and 1x105 bacteria reduced 
survival by no more than 7% at 72 hours post-inoculation. Conversely, higher doses of 1x106 
and 3x106 reduced survival rates by 40% (Figure 4.13C). Similar survival trends were observed 
for insects infected through injection – however, no mortalities were recorded for lower doses, 
and 1x106 reduced mortality by 20% at 72 hours (Figure 4.13F). Force-feeding of 1x106 
CFU/larva caused a more rapid reduction in survival with ~67% alive after 24 hours compared 
to ~85% alive in larvae injected the same dose.  
Exposure of larvae to C. jejuni also yielded reciprocal decreases in movement and melanisation 
indices (Figure 4.13 A, B, D, E). Both injection and force feeding produced a similar decrease 
in activity to a mean of 1.2 after 3x106 CFU/larva, which is significantly lower than the 
untreated and negative control (PBS) values of 3 and 4, respectively. By 24 hours post force-
feeding there is dose dependent reduction in melanisation and movement indices for 3x106 
(1.97 and 1.53) (P < 0.0001) and 1x106 (2.37 and 1.97; P < 0.0001 and 0.0002, respectively). 
These data reveal a clear, continuous deterioration in health over the experimental period, with 
an obvious dose-dependent response in larvae injected with the bacterium (Figure 4.13, D-F).     
The injection of insects with 25 ng/larva of AZA1, followed 24 hours later by force-feeding 
PBS (with 2% ethanol) did not cause any mortality (Figure 4.14C), which is in agreement with 
toxicity studies performed above (Figure 4.1C). Survival rates do not differ significantly when 
larvae are pre-treated with AZA-1 (25 ng/larva) followed by 1x104 CFUs when compared to 
PBS followed by 1x104 CFUs (X2 (3) = 5.2, P = 0.157; Figure 4.14C). AZA-1 (25 ng/larva) 
alone did not cause any significant reductions in either health index, however 4 hours after 
force-feeding C. jejuni there were significant reductions in movement and melanisation for all 
doses used, 1x104 to 3x106 (P < 0.0001; Figure 4.14A, B). All larvae pre-treated with AZA 
deteriorated faster and to a greater extent, compared to those that received C. jejuni alone 
(Figure 4.13). For example, doses of 1-3 x106 alone killed ~40% of larvae by 72 hours (Figure 
4.13C), whereas pre-exposure to a sublethal dose of AZA1 (25 ng/larva), killed ~40% by 4 
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hours and ~60% of larvae by 48 hours (Figure 4.14C). There is a 23% decrease in survival 
when larvae are pre-exposed to AZA1.  
There is some evidence to suggest the double inoculation approach (initial injection followed 
by force-feeding 24 hours later) did cause a decrease in the melanisation index, however this 




Figure 4.13 Health indices of Galleria mellonella larvae following force-feeding or 
intrahaemocoelic injection of Campylobacter jejuni. Insects received C. jejuni 1x104 to 3x106 
CFU/larva via force-feeding (A, B and C) or injection (D, E and F) and were maintained in 
darkness at 30 °C for 96 hours. Larval health was scored (see Table 4.2) by assessing movement 
(A and D), melanisation (B and E) and survival (C and F). Values are presented as mean ± SE 
(n = 30 per treatment, 330 in total across both inoculation methods). Unshared letters represent 
significant differences (P ≤ 0.05) determined by Tukey's multiple comparisons tests. The 
negative control consisted of force-feeing or injecting larvae with PBS containing 50% Mueller 
Hinton broth. 
untreated
1 x105 CFU/larva 1 x106 CFU/larva 3 x106 CFU/larva




Figure 4.14 Susceptibility of Galleria mellonella to Campylobacter jejuni after azaspiracid-1 pre-treatment. Larvae received a pre-treatment of 
AZA-1 (25 ng/larva) via injection, after 24 hours larvae then received C. jejuni (1x104-3x106 CFU/larva) via force feeding and were maintained 
in darkness at 30 °C for a further 72 hours. Larval health was scored (Table 4.2) by assessing movement (A), melanisation (B) and survival (C). 
Larvae were considered dead when they no longer responded to being rolled over. Values are presented as mean ± SE (n =30 per treatment, 240 
total). Unshared letters represent significant differences (P ≤ 0.05) determined by Tukey's multiple comparisons tests. The negative control 




Marine biotoxins, such as azaspiracids and okadaic acid, are known to induce gastric damage 
such as epithelial degeneration, ulcers and increased permeability in both humans and rodent 
models (Abal et al., 2017, Franchini et al., 2010) – yet, their impacts on non-target tissues (e.g., 
immune cells) are largely unknown. The aim of this chapter was to further investigate how 
generalizable G. mellonella is as a model for studying marine toxins, and whether a sub-lethal 
dose of AZA-1 increases larval susceptibility to gut specific bacterial infection (C. jejuni). The 
latter has not been determined in rodents, but represents an important question of human health. 
Toxicities of AZA-1, 2 and 3 were assessed successfully in G. mellonella larvae via 
intrahaemocoelic injection and gavage (force-feeding) across two biologically relevant 
concentration ranges of 5-50 ng/larva for AZA1/AZA2 and 20-200 ng/larva for AZA3. It is 
important to use both inoculation methods to assess if the effects are localised to the gut when 
force-feeding compared to intrahaemocoelic injection. By utilising both methods it also allows 
a comparison of effects between the traditional injection (screening toxicities) and the natural 
route of ingestion. Azaspiracid toxicological endpoints, e.g., LD50 value, differ depending on 
the route of administration in rodents – Table 4.6, however, a common observation is the AZA1 
is the most toxic of the three. AZA1 appears to be more toxic than AZA2 across a similar 
concentration range, and this is in agreement with a recent assessment of AZA oral toxicities 
ranking them AZA1>AZA2>AZA3 (Pelin et al., 2018b). Further still, the same authors 
calculated an LD50 value of 875 μg/kg for AZA3 at 24 hours post-gavage in mice – which is in 
close agreement with the LD50 value of 881.4 μg/kg that was calculated for AZA3 here. The 
azaspiracids are lipophilic toxins, and cause similar symptoms of gastrointestinal stress as 
another lipophilic toxin, okadaic acid. In a proof of concept study, Coates et al. (2019) 
demonstrated the capacity of G. mellonella larvae to assess the toxicity of okadaic acid, and 
calculated an oral LD50 value of ~239 μg/kg, which falls within the range of values obtained in 
mammalian models, 206-242 μg/kg. Although Coates et al. (2019) established several 
oxidative stress markers associated with okadaic acid intoxication, namely superoxide 
dismutase activity and malondialdehyde levels (i.e., lipid peroxidation) in the midgut, they did 
not assess tissue damage directly using histology. Here, the gut tissues of insect larvae were 
assessed histologically after exposure to 62.5 ng okadaic acid (i.e., ~250 μg/kg), and revealed 
severe damage to the midgut within 24 hours, and evidence of haemocyte cytotoxicity in the 
body cavity surrounding the GI tract (Figures 4.7 – 4.9). Force-feeding AZA-3 resulted in a 
higher rate of fatalities and greater reduction in health indices for the same concentrations 
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administered by intrahaemocoelic injection. The inoculation of AZA-2 did not cause a 
significant reduction in viability or health indices with this concentration range (5 – 50 
ng/larva), suggesting this is not as toxic as AZA1 in G. mellonella. Differences in health indices 
between inoculation methods also indicate the importance of using a biologically relevant 
method of administration to get more realistic responses. 
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Table 4.6 Azaspiracid administration, toxicology, and pathology in mice. 
Model Administration  Toxicity/Lethality  Pathologic features Reference  
CD-1 mice 
[female] 
Gavage AZA1; LD50 = 443 g/kg 
AZA2; LD50 = 626 g/kg 
AZA3; LD50 = 875 g/kg 
Enlarged pale liver; 
increased levels of K+ 
ions in blood; tissue 
alterations in the GI tract 
and spleen  






Intraperitoneal AZA1 = 200 g/kg 
AZA2 = 110 g/kg 
AZA3 = 140 g/kg 
Not described  (Satake et al., 
1998) 
(Ofuji et al., 
1999) 
ICR mice  
[male, ~25g] 
Gavage AZA1; 1 – 3000 g/kg 
 




Cell degeneration on 
villi; atrophic lamina 
propria; vacuolisation of 
epithelial cells; crypt 
irregularities; necrotic 
(B and T) lymphocytes 
in thymus, spleen and 
Peyer’s patches; 
bleeding, oedema, and 
cell infiltration of 
alveolar cells; interstitial 
pneumonia 
(Ito et al., 
2006, Ito et al., 
2000, Ito et al., 








Gavage AZA1; LD50 = 775 g/kg 
[LD10 = 570 g/kg] 
Pale liver; broader villi 
in duodenum with some 
neutrophil 
accumulation; apoptosis 
in lamina propria 






Gavage AZA1; 100 – 300 g/kg Cellular detachment in 
the duodenum villi; 
crypt expansion; 
necrosis of lamina 
propria 






Although there is no significant difference in total haemocyte counts upon exposure to AZA-
1, there was a significant increase in haemocyte size between 4 - 48 hours after the injection of 
AZA-1 (50 ng/larva). This effect has been observed in G. mellonella upon fungal 
(Conidiobolus coronatus ) infection and can be a sign cell swelling associated with apoptosis 
(Boguś et al., 2018). Larvae force-fed AZA-1 (37.5 ng/larva) and okadaic acid (62.5 ng/larva) 
displayed significant midgut damage with obvious nuclear aberrations – condensation, 
fragmentation and dissolution. Similar to histopathology after indomethacin (Chapter 2), there 
is variation in the level of damage observed from the severe total degradation of the epithelial 
layer to minor/regional abrasions and disorganisation. These changes to the larval midgut are 
similar to those found in rats with increased apoptosis and erosion of the epithelial layer  (Ito 
et al., 2002b, Dounay and Forsyth, 2002). In fact, AZA1 force-feeding of mice depicts similar 
displacement of duodenum villi, and cell death (Aasen et al., 2010, Aasen et al., 2011). 
An open question for marine toxicologists is the impact of chronic exposure to sub-lethal doses, 
or doses below the acceptable upper regulatory limits on human health. For azaspiracids and 
okadaic acids, the upper regulatory limit in the UK and EU is 160 μg/kg shellfish tissue. 
Recently, Ferreiro et al. (2016) exposed rats to AZA1 up to 55 μg/kg on four occasions across 
15 days, and observed structural and functional deterioration of cardiac tissue. In a follow-on 
study, Ferreiro et al. (2017) exposed rats to another lipophilic toxin, yessotoxin, via 
intraperitoneal injection on four occasions across 15 days (50 or 70 μg/kg), which resulted in  
immunotoxicity (lower lymphocyte counts, splenic damage/apoptosis viewed through 
histology, and reduced interleukin-6 levels in plasma). These two studies are evidence of 
subacute toxicity, that do not lead to the typical symptoms of shellfish poisoning, however, 
there does not appear to be any study reporting on the putative link between intoxication and 
increased risk of infection (Ferreiro et al., 2016, Ferreiro et al., 2017). Injecting G. mellonella 
with a sublethal dose of AZA-1 (25 ng/larva) increased their susceptibility to C. jejuni infection 
administered 24 hours later. Pre-exposure caused a significant decrease in larval health with 
lower activity and melanisation indices compared to C. jejuni force feeding alone (Figure 4.14). 
These results indicate the larval gut and/or immune system may be compromised and are less 
able to contain the bacterium. This is supported by the histopathology (Figures 4.7 – 4.9), where 
displacement and damage to the epithelium may facilitate pathogen movement across the gut 
and into the body cavity – causing septicaemia.  
To further investigate the effects of AZA and OA has on the G. mellonella gut it is important 
to assess the bacterial microbiome as it is understood that changes to the natural microbiome 
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can result in increased risk of infection, disease and alter the breakdown of food (Becattini et 
al., 2016). From studying colony forming units following AZA-1, 2 and 3 force feeding showed 
that there were significant changes from 4-48 hours after inoculation but only compared to PBS 
and not the untreated control. AZA-3 force feeding did not causing any significant difference 
compared to the control or concentrations, which is unexpected as the disruption to the mid-
gut observed in histology it is likely to observe changes in the microbiome from bacteria being 
“flushed out” of the gut through cellular sloughing (if all azaspiracid congeners have similar 
modes of toxicity).  It appears that there is an overall increase in CFU from 4-48 hours in all 
treatments with AZA-2 causing the biggest differences. This could be due to AZA-2 being less 
toxic to the larvae, but causing subtle changes to the gut without causing the degradation of the 
epithelial layer but enough to alter the microbiome. Next-generation sequencing of the 16S 
rRNA (v4) region was used to investigate the composition of the gastric microbiota. 
Similarly to observations in the mouse and human gastric microbiomes  (Ley et al., 2006a), 
most of Firmicutes present is attributed to the genus Enterococcus, which also dominated the 
haemolymph and skin of bait and research grade G. mellonella larvae (Allonsius et al., 2019). 
In this chapter, G. mellonella larvae were found to have a large proportion of Firmicutes in the 
microbiome with larvae exposed to high doses of OA having a consistent higher proportion of 
Firmicutes. Interestingly, Firmicutes presence is associated with diet in humans, with diets high 
in sugar and fat and in undernourished diets associated with greater proportions of Firmicutes 
than those having a balanced diet (Méndez-Salazar et al., 2018). This could suggest that larvae 
with high proportions of Firmicutes are storing more fat from their diet than the other larvae. 
Both OA low and high treatments impacted the abundances of Firmicutes and Bacteroidetes 
with initial low levels of Bacteroidetes and high levels of Firmicutes at 4 hours were similar to 
observations in rats when repeatedly exposed to low concentrations of OA (Liu et al., 2020). 
Low does exposure of rats to okadaic acid (80 μg/kg via gavage) over 30 days caused damage 
to the epithelium, and increased the relative abundance of bacterial pathobionts in the colon, 
compared to control rats (Liu et al., 2020). 
The genus Prevotella is one represented population of Bacteroidetes and has been linked with 
T helper cell mediated inflammation via the activation of Toll-like receptors (Larsen, 2017). 
Interestingly, G. mellonella larvae exposed to high dose of AZA-1 have a notable increase in 
Prevotella 24-48 hours after inoculation. This coincides with the period of observed 
histological damage in AZA-1 high inoculations, however there is no marked increase in 
Prevotella in OA exposed larvae. Perhaps this reflects the differential impacts of marine toxins.  
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A high proportion of Firmicutes and a low proportion of Bacteroidetes is an indicator of 
dysbiosis, in studies assessing dysbiosis in patients suffering from the neurodegenerative 
disorder Amyotrophic lateral sclerosis found all patients were affects by dysbiosis with a high 
proportion of Firmicutes and low proportion of Bacteroidetes (Rowin et al., 2017). This is also 
observed in other neurological disorders such as Parkinson’s disease (Sampson et al., 2016) 
and in gastric disorders such as IBD (Tamboli et al., 2004). AZA and OA both induce diarrhoea 
with erosion of the epithelial layer of the gut similar to that in IBD patients and indicate that 
AZA and OA exposure induce dysbiosis, which could in turn exacerbate inflammation within 
the gut. 
A high proportion of Proteobacteria is observed in patients with IBD and Crohn’s disease, 
although the mechanisms is unknown, it is considered to be as a result of inflammation of 
epithelial cells and increased oxygenation, favouring Proteobacteria (Rizzatti et al., 2017). 
Additionally, studies conducted in G. mellonella infected with the bacterium Bacillus 
thuringiensis found an increase in Proteobacteria and a reciprocal decrease in Firmicutes and 
Bacteroidetes (Dubovskiy et al., 2016) compared to uninfected control larvae.  Surprisingly, 
AZA high and OA exposed larvae had lower proportions of Proteobacteria than untreated and 
PBS larvae at 4 and 24 hours post inoculation, which indicate that dysbiosis and associated 
inflammation are different for chemical disruptors versus microbial disruptors of the gut. 
Sphingomonas is a proteobacterium present in AZA-1 low and PBS-treated insects at 24 hours 
post inoculation and AZA-1 high and OA low at 48 hours post inoculation. Sphingomonas is 
associated with inflammation via T helper cells activation and is theorised to be involved in 
the induction of natural killer cells in germ free mice once orally inoculated with conventional 
mouse faecal suspension (El Aidy et al., 2014). This could indicate that the larvae exposed to 
AZA and OA undergo dysbiosis associated with inflammation followed by re-colonisation 
driven by commensals such as Sphingomonas, which may promote inflammation.  
Although there are notable differences between intoxicated (AZA1, OA) larvae and the 
untreated larvae, there is rather a lot of variation across time/treatments. The overall 
observations supported with adonis statistical analysis indicate that both AZA and OA high 
have statistically significant microbiome structures that may in part be attributed to the high 
proportions of Prevotella and Sphingomonas as well as much higher proportions of 
Enterococcus. Surprisingly, PBS is not statistically different to untreated when conducting an 
adonis analysis, however, when comparing populations to the untreated, PBS appears less 
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diverse at 48 hours being almost entirely Enterococcus similarly as OA high. This may 
represent a flushing to the GI tract.  
 
4.6 Concluding remarks 
Work presented in this chapter has demonstrated that G. mellonella larvae are sensitive to 
physiologically relevant doses of AZA and OA, and that it is possible to asses toxicity through 
several endpoints. To further investigate the larval’ s ability to model human intestinal 
damages, and act as an alternative model it is important to also asses its ability to repair and 
respond to the protective effects of nutraceuticals against toxins such as AZA and 
pharmaceuticals such as indomethacin. 
Azaspiracids, notably AZA3, caused a dose dependent reduction in larval health indices such 
as movement and melanisation as well as increasing susceptibility to gastric bacteria C. jejuni 
resulting in further morbidity and in exitus. Additionally, AZA-1 and okadaic acid force-
feeding caused significant damage and disruption to the larval mid gut, similarly to those 
observed in indomethacin treated larvae. IN an experimental first, marine toxins appear to 
disrupt microbial community structure in the larval gut that mimics okadaic acid-induced 
changes in the rat colon. These findings expand the utility of G. mellonella as a platform for 
investigating subacute or chronic impacts of toxin exposure.    
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5.1 General Discussion  
This body of work represents an evaluation of the usefulness and accuracy of Galleria 
mellonella larvae as a substitute in vivo model for gut-related pathobiology. It was established 
that the indomethacin gastric damage (ulcer) assay of rodents could be recapitulated in G. 
mellonella (Chapter 2), dietary intervention with two nutraceuticals, Cordyceps sinensis and 
colostrum, can alleviate some gastric damage caused by chemicals and/or microbes (Chapter 
3), and gastropathy/toxicity of closely related marine toxins, okadaic acid and azaspiracids 
1,2,3 can be distinguished (Chapter 4).   
The approach in chapter two sought to replicate studies conducted in murine models (e.g., by 
Marchbank et al., 2011) to G. mellonella larvae using an NSAID known to cause gastric 
damage, allowing a direct comparison to mice, to optimise methodology, and to assess 
limitations of using an insect in this manner. Data presented in chapter two reveal G. mellonella 
larvae to have similar histopathological signatures to an equivalent oral dose of indomethacin 
as observed in rats, with sloughing of epithelial cells, apoptosis and membrane 
blebbing/ulceration (figures 2.11 – 2.13) all recorded. Moreover, increased gut permeability 
was seen within 24 hours in the larvae, which has also been documented in both humans and 
mice (Playford et al., 1999 and 2001; Bjarnason and Takeuchi, 2009). Such information 
positions G. mellonella as a suitable model for tracking damage and pathology induced by 
common pharmacological agents. However, the model is limited to observations within a 72-
hour period, as metamorphosis began from 72 hours after inoculation of the control saline, thus 
longer-term studies in excess of five days (final instar larvae) are less likely to produce reliable 
results. To overcome this, it could be possible to rear larvae and use them soon after they moult 
into the final instar; however, for the purposes of screening compounds for reparative 
properties, the 3-day window is sufficient.  
Another limitation for utilising G. mellonella in pharmaceutical studies are the differences in 
gut pH compared to human and murine models. The lepidopteran gut is alkaline, therefore it is 
perhaps not reliable for studying acid dependent pharmaceuticals, such as proton pump 
inhibitors which require acidic conditions to become their active forms  (Shin and Kim, 2013, 
Bosnjak et al., 2019). Although the focus on indomethacin in this study was in relation to the 
induction of gastric damage, due to the lack of COX-1 and 2 receptor characterisation in G. 
mellonella is not a fully developed platform yet for assessing the therapeutic properties of 
COX-1 and 2 targeting drugs such as NSAIDs (Summ and Evers, 2013). However, as the larvae 
demonstrates similar metabolic processes and digestive enzymes, resulting in similar metabolic 
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profiles (e.g.,  caffeine processing Maguire et al. (2017)), the larvae remain a suitable screening 
tool to asses gastric damage, toxicity, gut permeability and changes to microbial populations.  
The outcome of chapter 3 broadened the scope of G. mellonella to include testing the protective 
properties of C. sinensis and colostrum against indomethacin and C. jejuni infection. Larvae 
reared on enhanced diets with 10% C. sinensis or 10% colostrum, provided ostensible survival 
benefits with respect to indomethacin induced health decline. Some protection against gut 
permeability was provided when reared on the 10% C. sinensis enhanced diet, indicating a a 
greater capacity to recover. Larvae reared on a 10% colostrum enhanced diet showed protection 
against the initial increase in permeability within the first 4 hours of indomethacin gavage. 
These findings indicate the C. sinensis and colostrum may reinforce the gut against 
pharmaceutical- associated tissue degeneration (Figures 3.7 and 3.8), however, the dose range 
and potential for additive effects need to be investigated further. 
In the same chapter (3), larvae reared on the 10% colostrum enhanced diet were significantly 
heavier and more resistant to the adverse effects of C. jejuni infection – determined using an 
expanded health index rather than survival alone. Larvae reared on 10% C. sinensis 
supplemented diet were not as heavy, yet they were also more resistant to C. jejuni compared 
to those reared on a normal diet (figures 3.2 and 3.9).  This is not the case when larvae are 
injected directly into the haemocoel with C. jejuni, which suggests that nutraceuticals (notably 
Cordyceps) improves gut resistance (specifically) to bacterial infection. The next step would 
be to investigate the potential immune-modulation properties of these nutraceuticals.  
Chapter four describes the gut-specific damage caused by two groups of toxins known to 
induce diarrhoea-associated symptoms when consumed by humans, the azaspiracids (1 – 3) 
and okadaic acid. This chapter is unique, as it is the first to compare all these toxins 
simultaneously in a model system, and measure pathology and dysbiosis. Reassuringly, the G. 
mellonella proved sensitive enough to distinguish the toxicities of  AZA-1 and AZA-2, which 
is in agreement with the available literature (Pelin et al., 2018a). The LD50 value calculated for 
AZA-3 is highly similar to mice: 881.4 μg/kg and 875 μg/kg, respectively. Histological studies 
found larvae orally administered AZA-1 (37.5 ng/larva) and okadaic acid (62.5 ng/larva) 
experienced gastric damage similar to murine models and some common features with 
indomethacin-treated insects (figures 4.4 and 4.9), with clear signs of nuclear aberrations, loss 
of tissue structure, and epithelial cell erosion (Ito et al., 2002b, Aasen et al., 2010). This 
supports the use of G. mellonella larvae as a generalised model for marine toxicology, and 
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more broadly, hints at a conserved damage-response pathway along the alimentary canals of 
insects and mammals, including the maintenance of the mucosa (i.e., peritrophic matrix) by 
eicosanoids and derivatives (Emery et al., 2019; Chapter 2). Profiling the larval gut microbiome 
highlighted Enterococcus as the dominant OUT, which is comparable to  mouse and human 
intestinal studies (Ley et al., 2006a), and a recent microbiome atlas of G. mellonella larvae 
from bait-shop grade and scientific grade (Allonsius et al., 2019). Interestingly 4-24 hours after 
force-feeding AZA-1 and OA, the larvae had a larger proportion of Firmicutes coupled with a 
low abundance of Bacteroidetes compared to the untreated control. This imbalance is an 
indicator for dysbiosis (Rowin et al., 2017). Additionally, larvae force-fed a high concentration 
of AZA and OA had significantly different microbiome composition (figures 4.11 and 4.12). 
These findings demonstrate that G. mellonella is a suitable model, with the ability to observe 
not only phenotypic effects, i.e., survival as a single toxicological endpoint, but also changes 
in microbiome composition (which can be further expanded by profiling the faeces).  
Rats repeatedly exposed to AZA-1 at sub-lethal (below regulatory limits) showed deterioration 
of the cardiac tissue (Ferreiro et al., 2016), however no such test appears to have been 
conducted to review the susceptibility to infection. A key objective of chapter four was to assess 
the effect of a subacute dose of AZA-1 on the susceptibility to C. jejuni infection. Larvae that 
were pre-injected with AZA-1 below the regulated limits were more susceptible to C. jejuni 
infection within 24 hours, resulting in decreased activity and increased melanisation of the 
integument compared to larvae force-fed C. jejuni alone. This is an important finding as it 
suggests that regular consumption of shellfish with acceptable levels of AZA-1 toxin, and 
without showing symptoms of shellfish poisoning, are increasing their risk of collateral 
infection from a common enteric microbe. Consequently, further research into the potential 
long-term effects of the repeated consumption of “safe” concentrations of marine toxins (AZAs 
and OA) and bioaccumulation potential among tissues within humans is needed. An 
appropriate study design to utilise the G. mellonella model by rearing larvae on an artificial 
diet containing AZA or OA (similar to Chapter 3), and observing their microbiome, changes 
to movement, resistance to infection and larval development. Additionally, microdissection of 
larval organs such as the brain, gut and fat body and quantitating levels of AZA and OA would 
be highly valuable.  
Data presented here represent strong evidence for the use of G. mellonella as an in vivo tool 
for assessing established and emerging marine toxins at the tissue level – what remains unclear, 
and the natural next step for this work, is are the molecular targets of the toxins conserved 
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across insects, mice and humans? One novel approach would be to focus on cellular 
(haemocyte) bioenergetics, as it is an important factor for understanding the pathophysiology 
of cancer, cardiovascular disease and diabetes (Bradford et al., 2012). Changes in cellular 
energetics, and mitochondrial functioning can indicate general declines in organism health 
(Bradford et al., 2012). Therefore, experiments studying the bioenergetics of extracted G. 
mellonella haemocytes in the absence/presence of AZA, could reveal modes of action based 
on cellular respiration, and as mitochondria are inextricably linked to apoptosis – this may go 
some way to explain the cytotoxicity of AZA observed in the tissue histology (Figure 4.9). 
Mitochondrial membrane integrity could be assessed fluorescently using indicator dyes like 
MitoTracker ® CMTMRos, or individual components of the electron transport chain could be 
assessed using the Agilent Seahorse mitochondrial stress test (e.g., used for Drosophila brains; 
(Neville et al., 2018). 
Future experiments to explore the understanding of AZA mode of action would be to dissect 
targeted tissues such as the gut, liver and brain and study transcriptional signatures of stress 
and damage. A study by Manfrin et al. (2010) used transcriptomics to identify mRNAs 
encoding stress-associated proteins in the mussel Mytilus galloprovincialis which contained 
OA (Manfrin et al., 2010). Additionally, studies in Caco-2 cells have used transcriptomics to 
elude to modes of action of AZA and OA which found that AZA exposure resulted in an 
increase in expression for genes associated with cholesterol synthesis whereas OA exposure 
led to an increase in expression of genes involved in hypoxia (Bodero et al., 2018). This 
established technique could be used to investigate changes in gene expression within individual 
organs of G. mellonella larvae after being exposed to AZA to gain insight into its mode of 
action.  
 
5.2 Future Applications  
5.2.1 Galleria mellonella’s role in pharmaceutical development  
The research presented in this thesis has demonstrated G. mellonella larvae to be a strong tool 
for assessing a tissue-level response to pharmaceutical inoculation. G. mellonella larvae are 
currently used for toxicology studies, often those derived from fungi and bacteria, and used as 
virulence factors (Pereira et al., 2018, Fuchs et al., 2010, Reeves et al., 2004). Recently there 
has been increasing interest in using G. mellonella larvae to test antibacterial drugs (Cutuli et 
al., 2019). Results in this thesis indicate that G. mellonella larvae may also play a role in the 
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development of other pharmaceuticals such as anti-inflammatories; this would therefore reduce 
the use of mammalian models whilst providing a high-throughput and less expensive option. 
As G. mellonella are susceptible to the gastric damage caused by NSAID, larvae could be an 
effective screening tool for the assessment of risk of gastric damage induced by newly 
developed NSAID prior to administration in murine models. This would enable pre-clinical 
trials to evaluate the risk of gastric damage and quantify the amount of damage caused by the 
new drug at ranging concentrations quickly, cheaper and reliably (triaging sizeable libraries of 
compounds to a few promising candidates).  
There are limitations to the use of G. mellonella as a screening model in the pharmaceutical 
development process such as larval metamorphosis. One constraint is the lack of molecular and 
immunological resources. The genome of G. mellonella was sequenced recently (Lange et al., 
2018a), which is a major step forward, but CRISPR and RNAi based genetic manipulations, as 
well as established wild-type and transgenic lines are not available. Moreover, there are at least 
two G. mellonella morphotypes – a melanic strain and a non-melanic strain. These are 
geographic variants, with the melanic strain appearing more resistant to entomopathogens 
(Dubovskiy et al., 2013, Grizanova et al., 2019). “Research grade” larvae, to improve 
reproducibility are now available from a company called BioSystems Technology, which was 
founded in 2015. These hormone-free larvae are more expensive than bait grade larvae and 
were found to have a lower microbiome diversity in the gut compared to the bait grade larvae 
(Allonsius et al., 2019). Additionally, there are no standardised protocols of rearing or utilising 
G. mellonella as a screening model (each research group using their in-house protocols for 
diet), which limits uptake from the biomedical industry as there seems to be a lack of 
standardisation.   
 
5.2.2 Nutraceutical development  
Nutraceuticals such as C. sinensis and colostrum appear to improve health outcomes in larvae 
when challenged with chemical and microbial disruptors (Chapter 3). These results are 
supported by experiments conducted in murine models (Playford et al., 1999, Marchbank et 
al., 2011), it would therefore be advantageous to isolate the active compounds and cellular 
targets responsible for these attributes. In order to detect active compounds, various extraction 
processes could be used. Currently hot water extraction (HWE) is commonly used in the food 
and pharmacology industry due to it being nontoxic and lacking immunogenicity, it acts as a 
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polar solvent by the electrostatic attraction between its dipoles and the ion present (Chen et al., 
2013). HWE has been used to investigate many bioactive properties of C. sinensis and the 
method can be altered to achieve greater yields or conduct a more thorough extraction by 
increasing the temperature and duration of heating. A basic HWE can be conducted by boiling 
whole fruiting bodies in water for 30 minutes, a process used by Marchbank et al. (2011) to 
identify gastric reparative properties of C. sinensis in murine models. Although HWE is 
commonly used, there is concern that such heat could denature some bioactive compounds, 
therefore solvent extractions have also been used to assist extraction yield (Liu et al., 2010) in 
addition to changes in pressure and variety of enzymes (Yan et al., 2014). Liu et al., (2010) 
attempted to improve extraction efficiency using water combined with ethanol in a 1:1 v/v 
ratio. This approach was used to investigate C. sinensis protective properties against middle 
cerebral artery occlusion-induced focal cerebral ischemia in rats. Approximately, 240ml of 
water was heated to boiling for 3 hours with reflux, 80ml of water extract was then lyophilized 
giving a yield of 29%, prior to reconstitution in 160ml of ethanol, ultimately yielding 3.7g of 
dry powder. In their study it was found that different C. sinensis extractions resulted in a 
reduced serum antioxidant (lactate dehydrogenase) concentration compared to the rats which 
were not treated with any C. sinensis extract. Whereas other C. sinensis extracts significantly 
lower serum lactate dehydrogenase concentration (Liu et al., 2010). However the yield was no 
larger than other studies using a simpler hot water extraction with a shorter duration (Chen et 
al., 2013).  
C. sinensis extractions can then be analysed via high-performance liquid chromatography–
mass spectrometry (HPLC-MS/MS), which is used routinely in the authentication and quality 
assessment of C. sinensis extracts (Hu et al., 2015). Once the compounds and concentrations 
present have been identified, extractions can be administered to larvae repeating experiments 
described in this research, to determine if certain extractions with varying concentrations of 
compounds have greater protective effects against a panel of pharmaceutical, microbial or toxin 
tests (using insect larvae as the host). As C. sinensis appears to have a positive impact on gastric 
tissues, it would be beneficial to further investigate the potential therapeutic effects extracts of 
C. sinensis has against gastric diseases such as IBD and Crohn’s disease. A suitable 
advancement would be to administer C. sinensis extract to patients with gastric specific 
diseases, and monitor changes to their inflammatory markers such as IL-6 and colonic and 
intestinal tissue through endoscopy or biopsies.  
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A further investigation would be to explore if C. sinensis or colostrum has any additive or 
synergistic effects with current pharmaceuticals in use, e.g., lansoprazole and aspirin. Patients 
with Crohn’s disease are often treated with corticosteroids, however the long-term use of these 
are linked to higher mortality and complications such as Cushing’s syndrome (cortisol 
dysregulation) therefore when prescribed, corticosteroid-sparing drugs are also given once 
resistance of dependence is seen (Al-Jaouni et al., 2002, Benchimol et al., 2008). To avoid this, 
corticosteroids are usually prescribed as an initial treatment plan then given as frequent 
repeated courses to manage symptoms (D'Haens et al., 2008). Due to the difficulties associated 
with treating Crohn’s disease with corticosteroids it is essential to identify a better treatment 
plan where resistance is avoided, and remission is achieved more rapidly. C. sinensis 
extractions could be an alternative treatment to aid in reinforcing the gut structure and reducing 
permeability thus further protect the gut from pharmaceutical induced complications.   
 
5.2.3 Galleria mellonella as a biotoxin model  
This study produced substantial evidence to support G. mellonella larvae as an alternative 
model to rats and mice for some pharmaceutical, bacterial and marine toxins, all of which are 
encountered via an oral route and lead to gastric disorder. However, studies are required to 
assess the generalisability of G. mellonella as a model for toxins, as currently in the UK and 
EU, a validated in vivo model is absent (the mouse bioassay has been phase out for screening 
purposes, with the exception of neurotoxins). It is recognised among marine toxicology labs 
that the limitation of using sensitive in vitro and in chemico tools to screen toxins, is that only 
known lipphilic toxins are detected (diarrhoeic, azaspiracid), and they remain unsuitable for 
rare dangerous neurotoxins. Therefore, there is scope for an alternative in vivo model such as 
G. mellonella to help with screening, but also be further developed to identify toxin targets.  
 
 A further study to assess the sensitivity of G. mellonella larvae to distinguish between marine 
toxins would be to use pectenotoxins (PTXs). PTX are macrolactones created by 
dinoflagellates, e.g., Dinophysis, often found in the digestive glands of shellfish along with OA 
and are not associated with diarrhoea, however, appear to induce damage to the liver (Burgess 
and Shaw, 2001, Dominguez et al., 2010). Fourteen analogues of PTX have been described to 
date, with PTX-2 being the predominant precursor. Mouse toxicity assays have found large 
differences between mode of administration, with intraperitoneal injection having a much 
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greater toxic effect than oral administration, however, few toxicokinetic studies are available 
(Sandvik et al., 2020). Unlink OA, PTX does not inhibit PP2A but does appear to effect 
filamentous actin (F-actin) and induce apoptosis with PTX analogues having diverse toxicity 
and symptom ranges (Espiña et al., 2008). A study utilising G. mellonella larva to obtain 
specific toxicokinetic values for the different analogues – in manner similar to the azaspiracids 
herein (Chapter 4).  
The ultimate goal would be to have G. mellonella larvae approved an accepted assay for Food 
Standards to complement liquid chromatography/mass spectrometry (LC-MS/MS) monitoring 
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APPENDIX A  
Optimising fixation G. mellonella larvae  
Healthy final instar larvae were purchased from Livefoods Direct Ltd. Larvae weighing 
between 250 mg and 350 mg were selected for fixation trials. Carnoy’s fixative (60% ethanol, 
30% chloroform and 10% glacial acetic acid v/v) (Barbosa et al., 2014) and 10% unbuffered 
formalin fixative were trialled across 24, 48 and 72 hours to determine the most suitable 
fixation period. Additionally, several methods of fixation were tested as follows: 
intrahaemocoelic injection of fixative, piercing larvae cuticle whilst submerged in fixative, 
placing larvae in fixative and a combination of the three methods. Fixed larvae were dehydrated 
in 100% ethanol for 24 hours before dissection. As a result, it was determined that the most 
appropriate way of fixation, was 10% unbuffered formalin of which 20 µl was injected into 
each larva. Fixed insects were placed into 7 ml of 10% formalin and pierced with a needle to 
allow deeper tissue penetration of fixative over 28-30 hours. This method had limited shrinkage 
and hardening while thoroughly fixing the larvae.  
 
 
Table A1. Values of significance following a Tukey's multiple comparisons test for Galleria 
mellonella going through pupation after inoculation via force feeding (FF) or intrahaemocoelic 
injection (INJ) of indomethacin or PBS and the untreated control.  
6 days post inoculation  Mean 
Diff. 
95.00% CI of diff. Summary Adjusted 
P Value 
7.5 µg/larvae FF vs. Control -60 -96.66 to -23.34 **** <0.0001 
7.5 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
7.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 
7.5 µg/larvae FF vs. 0.5 µg/larvae 
INJ 
-36.67 -73.32 to -0.008652 * 0.0499 
7.5 µg/larvae FF vs. 5% DMSO INJ -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. Control -50 -86.66 to -13.34 *** 0.0007 
5 µg/larvae FF vs. 5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
2.5 µg/larvae FF vs. Control -60 -96.66 to -23.34 **** <0.0001 
2.5 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
2.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 
2.5 µg/larvae FF vs. 0.5 µg/larvae 
INJ 
-36.67 -73.32 to -0.008652 * 0.0499 
2.5 µg/larvae FF vs. 5% DMSO INJ -40 -76.66 to -3.342 * 0.0195 
1 µg/larvae FF vs. Control -60 -96.66 to -23.34 **** <0.0001 
1 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
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1 µg/larvae FF vs. 2.5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
1 µg/larvae FF vs. 0.5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
1 µg/larvae FF vs. 5% DMSO INJ -40 -76.66 to -3.342 * 0.0195 
0.5 µg/larvae FF vs. Control -50 -86.66 to -13.34 *** 0.0007 
0.5 µg/larvae FF vs. 5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
5% DMSO FF vs. Control -46.67 -83.32 to -10.01 ** 0.0023 
 
  7 days post inoculation Mean 
Diff. 
95.00% CI of diff. Summary Adjusted 
P Value 
7.5 µg/larvae FF vs. Control -46.67 -83.32 to -10.01 ** 0.0023 
7.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. Control -56.67 -93.32 to -20.01 **** <0.0001 
5 µg/larvae FF vs. 7.5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. 2.5 µg/larvae INJ -50 -86.66 to -13.34 *** 0.0007 
5 µg/larvae FF vs. 1 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. 0.5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
5 µg/larvae FF vs. 5% DMSO INJ -40 -76.66 to -3.342 * 0.0195 
2.5 µg/larvae FF vs. Control -60 -96.66 to -23.34 **** <0.0001 
2.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-53.33 -89.99 to -16.68 *** 0.0002 
2.5 µg/larvae FF vs. 1 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 0.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 
2.5 µg/larvae FF vs. 5% DMSO INJ -43.33 -79.99 to -6.675 ** 0.0069 
1 µg/larvae FF vs. Control -63.33 -99.99 to -26.68 **** <0.0001 
1 µg/larvae FF vs. 7.5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
1 µg/larvae FF vs. 2.5 µg/larvae INJ -56.67 -93.32 to -20.01 **** <0.0001 
1 µg/larvae FF vs. 1 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
1 µg/larvae FF vs. 0.5 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
1 µg/larvae FF vs. 5% DMSO INJ -46.67 -83.32 to -10.01 ** 0.0023 
0.5 µg/larvae FF vs. Control -53.33 -89.99 to -16.68 *** 0.0002 
0.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-36.67 -73.32 to -0.008652 * 0.0499 
0.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-46.67 -83.32 to -10.01 ** 0.0023 
0.5 µg/larvae FF vs. 1 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
0.5 µg/larvae FF vs. 5% DMSO INJ -36.67 -73.32 to -0.008652 * 0.0499 
5% DMSO FF vs. Control -43.33 -79.99 to -6.675 ** 0.0069 
5% DMSO FF vs. 2.5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
Control vs. 5 µg/larvae INJ 40 3.342 to 76.66 * 0.0195 
 
 
  8 days post inoculation  Mean 
Diff. 
95.00% CI of diff. Summary Adjusted 
P Value 
7.5 µg/larvae FF vs. Control -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. Control -53.33 -89.99 to -16.68 *** 0.0002 
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5 µg/larvae FF vs. 7.5 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
5 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 2.5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 1 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. 0.5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
5 µg/larvae FF vs. 5% DMSO INJ -36.67 -73.32 to -0.008652 * 0.0499 
2.5 µg/larvae FF vs. Control -53.33 -89.99 to -16.68 *** 0.0002 
2.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
2.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-46.67 -83.32 to -10.01 ** 0.0023 
2.5 µg/larvae FF vs. 1 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
2.5 µg/larvae FF vs. 0.5 µg/larvae 
INJ 
-36.67 -73.32 to -0.008652 * 0.0499 
2.5 µg/larvae FF vs. 5% DMSO INJ -36.67 -73.32 to -0.008652 * 0.0499 
1 µg/larvae FF vs. Control -53.33 -89.99 to -16.68 *** 0.0002 
1 µg/larvae FF vs. 7.5 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
1 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
1 µg/larvae FF vs. 2.5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
1 µg/larvae FF vs. 1 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
1 µg/larvae FF vs. 0.5 µg/larvae INJ -36.67 -73.32 to -0.008652 * 0.0499 
1 µg/larvae FF vs. 5% DMSO INJ -36.67 -73.32 to -0.008652 * 0.0499 
0.5 µg/larvae FF vs. Control -46.67 -83.32 to -10.01 ** 0.0023 
0.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-36.67 -73.32 to -0.008652 * 0.0499 
0.5 µg/larvae FF vs. 5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
0.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 
5% DMSO FF vs. Control -36.67 -73.32 to -0.008652 * 0.0499 
 
  
  9 days post inoculation  Mean 
Diff. 




7.5 µg/larvae FF vs. Control -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. Control -53.33 -89.99 to -16.68 *** 0.0002 
5 µg/larvae FF vs. 7.5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 2.5 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
5 µg/larvae FF vs. 1 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. 0.5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
2.5 µg/larvae FF vs. Control -50 -86.66 to -13.34 *** 0.0007 
2.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 5 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 





2.5 µg/larvae FF vs. 0.5 µg/larvae 
INJ 
-36.67 -73.32 to -
0.008652 
* 0.0499 
1 µg/larvae FF vs. Control -46.67 -83.32 to -10.01 ** 0.0023 
1 µg/larvae FF vs. 7.5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
1 µg/larvae FF vs. 5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
1 µg/larvae FF vs. 2.5 µg/larvae INJ -36.67 -73.32 to -
0.008652 
* 0.0499 
0.5 µg/larvae FF vs. Control -46.67 -83.32 to -10.01 ** 0.0023 
0.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-40 -76.66 to -3.342 * 0.0195 
0.5 µg/larvae FF vs. 5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
0.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-36.67 -73.32 to -
0.008652 
* 0.0499 





  10 days post inoculation  Mean 
Diff. 




7.5 µg/larvae FF vs. Control -36.67 -73.32 to -
0.008652 
* 0.0499 
5 µg/larvae FF vs. Control -53.33 -89.99 to -16.68 *** 0.0002 
5 µg/larvae FF vs. 7.5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 2.5 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 1 µg/larvae INJ -46.67 -83.32 to -10.01 ** 0.0023 
5 µg/larvae FF vs. 0.5 µg/larvae INJ -40 -76.66 to -3.342 * 0.0195 
5 µg/larvae FF vs. 5% DMSO INJ -36.67 -73.32 to -
0.008652 
* 0.0499 
2.5 µg/larvae FF vs. Control -50 -86.66 to -13.34 *** 0.0007 
2.5 µg/larvae FF vs. 7.5 µg/larvae 
INJ 
-43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 5 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 2.5 µg/larvae 
INJ 
-43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 1 µg/larvae INJ -43.33 -79.99 to -6.675 ** 0.0069 
2.5 µg/larvae FF vs. 0.5 µg/larvae 
INJ 
-36.67 -73.32 to -
0.008652 
* 0.0499 
1 µg/larvae FF vs. Control -36.67 -73.32 to -
0.008652 
* 0.0499 
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Assessing the potential toxicity of other pharmaceuticals  
There was no significant difference in survival between treatments or concentrations compared 
to control or other treatments. Larvae force fed the highest dose of Lansoprazole (10 µg/larva) 
had a 3% increase in morbidity by 72hours (figure B1a), those force-fed with 10 µg/larva of 
Aspirin had on average a 16% increase in mortality whereas the highest doses of Aspirin (25 
µg/larva) wasn’t quantifiably different to the control (figure B1b). All doses of Diclofenac salt 
had between 3-7% increase in mortality (figure B1c) compared to the control however this 
wasn’t statistically significant when conducting a Tukey's multiple comparisons test.  
 
Larvae that were force fed had an overall reduction in development compared to the control, 
however this was a smaller effect with larvae inoculated with Lansoprazole as the only 
significantly different for larvae inoculated with 2.5 µg/larva Lansoprazole 6 days post 
inoculation (P= 0.0033) (figure B2a and Table B1). This is possibly due to Lansoprazole being 
a protective and restorative pharmaceutical for gastric damage and at the lower dose, did not 
aid in healing potential physical damage caused by the inoculation method as quickly. On the 
other hand, both NSAID’s, Aspirin and Diclofenac salt had significantly reduced development 
from Day 6 onwards compared to the untreated control (figure B2 b and c). Similarly, to the 
indomethacin development study, neither Aspirin nor Diclofenac salt inoculation effects 
appear to be concentration dependent. The lowest rate of development when force fed 
Diclofenac salt was observed at a concentration 5 µg/larva with an average of 50% of larvae in 
pupation by day 10 compared to the control of 96% undergoing pupation (P= 0.0009) (figure 
B2c) however this isn’t significantly different when compared to other concentrations or PBS 
where 10 days post inoculation 76% of larvae were in metamorphosis (table B1 and figure B2). 
Larvae force fed Aspirin demonstrated the lowest rate of pupation with 56% undergoing by 
day 10 in those inoculated with 2.5 µg/larva (2.5 µg/larva /control (P=0.0113)). Although not 
statistically significant, at the highest concentration of Aspirin (25 µg/larva) pupation was 7% 






Figure B1 Survival of Galleria mellonella larvae after force feeding Lansoprazole (a), Aspirin 
(b) Diclofenac salt (c) 25 - 2.5 µg/larva. Larvae were anesthetised on ice prior to inoculation 
and kept at 30 °C in darkness for 72 hours. Larvae were deemed dead when no longer responded 





Figure B2. Galleria mellonella larval pupation 0-10 days post force feeding of a rage of 2.5–
25 µg/larva of Lansoprazole (A and B), Aspirin (C and D) and Diclofenac salt (E and ). Larvae 
were maintained at 30 °C in darkness for 10 days post inoculation.  The number of larvae 
undergoing pupation was recorded. Values are expressed as mean ± SE (n = 30 per treatment, 
480 in total). Symbol: *P < 0.03 when comparing untreated to all other treatments at the 
respective time points. The negative control consisted of force feeding or injecting the insect 
with PBS containing 5% DMSO. 
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Larvae inoculated with indomethacin had large variation of 6 µm spheres found in the faeces 
for all treatments. However, larvae which were reared on 10% C. sinensis had a peak of (87,500 
microspheres/larva) 6 µm microspheres in the faeces 24 hours post inoculation, whereas other 
indomethacin force fed larvae peaked at 48 hours. Furthermore, larvae which were reared on 
10% C. sinenesis and inoculated with PBS peaked (1.2x105 microspheres/larva) 48 hours after 
inoculation with whereas all other larvae inoculated with PBS had a gradual increase from 4-
48 hours followed by a peak at 72 hours (Figure B3). This could indicate that the C. sinensis 





Figure B3. Gut permeability of Galleria mellonella larvae reared on normal (A and B), 
nutraceutical supplemented food; 10% Colostrum (C and D), 10% C. sinensis (E and F) and 
5% C. sinensis with 5% colostrum (G and H) following force feeding of indomethacin, 
7.5 µg/larva. Permeability was determined by the number of 6 µm (A, C, E and G), 2 µm (B, 
D, F and H) spheres found in the faeces between 4 and 72 h post-inoculation. Each larva were 
co-inoculated with 1 × 106 microspheres and indomethacin (7.5 µg/larva) or PBS and 
incubated in the dark at 30°C. Data represent the mean ± SE (n = 192, 768 in total across both 
microsphere sizes). The negative control consisted of force-feeding the insect with PBS (+ 5% 
DMSO) in the absence of indomethacin (0 µg/larva).  
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Table B1. Values of significance following a Tukey’s multiple comparison test of Galleria 
mellonella going through pupation after force feeding Lansoprazole, Aspirin or Diclofenac salt 
comparing effects of the concentrations at 6-10 days post inoculation. 
Tukey's multiple comparisons test 95.00% CI of 
diff. 
Summary Adjusted P 
Value 
Day 6    
Control vs. Lansoprazole 2.5 µg/larva 7.870 to 78.80 ** 0.0033 
Control vs. Aspirin 10 µg /larva 11.20 to 82.13 *** 0.0009 
Control vs. Aspirin 7.5 µg /larva 4.537 to 75.46 * 0.0113 
Control vs. Aspirin 5 µg /larva 4.537 to 75.46 * 0.0113 
Control vs. Aspirin 2.5 µg/larva 4.537 to 75.46 * 0.0113 
Control vs. Diclofenac 10 µg /larva 11.20 to 82.13 *** 0.0009 
Control vs. Diclofenac 7.5 µg /larva 1.204 to 72.13 * 0.0345 
Control vs. Diclofenac 5 µg /larva 14.54 to 85.46 *** 0.0002 
Control vs. Diclofenac 3.75 µg /larva 11.20 to 82.13 *** 0.0009 
        
Day 7       
Control vs. Aspirin 10 µg /larva 11.20 to 82.13 *** 0.0009 
Control vs. Aspirin 2.5 µg/larva 4.537 to 75.46 * 0.0113 
Control vs. Diclofenac 5 µg /larva 17.87 to 88.80 **** <0.0001 
Control vs. Diclofenac 3.75 µg /larva 7.870 to 78.80 ** 0.0033 
        
Day 8       
Control vs. Aspirin 10 µg /larva 7.870 to 78.80 ** 0.0033 
Control vs. Aspirin 2.5 µg/larva 4.537 to 75.46 * 0.0113 
Control vs. Diclofenac 5 µg /larva 11.20 to 82.13 *** 0.0009 
Control vs. Diclofenac 3.75 µg /larva 1.204 to 72.13 * 0.0345 
        
Day 9       
Control vs. Aspirin 2.5 µg/larva 4.537 to 75.46 * 0.0113 
        
Day 10       
Control vs. Aspirin 2.5 µg/larva 4.537 to 75.46 * 0.0113 
Control vs. Diclofenac 5 µg /larva 11.20 to 82.13 *** 0.0009 





Table B2. Faeces weight from G. mellonella larvae reared on nutraceutical-enhanced foods 
and co-inoculated with 6 µm microspheres and indomethacin (n = 36, 108 in total) 
6 µm 4hr 24 hr 48 hr 72 hr Total faeces 
/larvae (mg) 
Standard food and 
Indomethacin 
0.49 1.00 0.51 0.53 2.53 
5% Colostrum and 
Indomethacin 
0.35 1.02 0.51 0.49 2.37 
5% C. sinensis and 
Indomethacin 
0.70 0.90 0.66 0.75 3.02 
5% + 5% combined 
and Indomethacin 
0.77 1.28 0.73 0.58 3.36 
Standard food and 
PBS 
0.58 0.82 0.40 0.36 2.17 
5% Colostrum and 
PBS 
0.52 1.19 0.86 0.57 3.13 
5% C. sinensis and 
PBS 
0.80 1.16 0.77 0.75 3.48 
5% + 5% combined 
and PBS 





Table B3 a. Faeces weight from G. mellonella larvae reared on nutraceutical-enhanced foods 
and co-inoculated with 2 µm microspheres and indomethacin. Data is expressed as weight of 
faeces/larvae, (n = 36, 108 in total) 
2 µm 4hr 24 hr 48 hr 72 hr Total faeces 
/larvae (mg) 
Standard food and 
Indomethacin 
0.35 1.26 0.60 0.88 3.08 
5% Colostrum and 
Indomethacin 
0.70 0.91 0.43 0.62 2.66 
5% C. sinensis and 
Indomethacin 
0.26 1.09 0.42 0.90 2.66 
5% + 5% combined and 
Indomethacin 
0.76 1.41 0.51 0.87 3.55 
Standard food and PBS 0.94 0.61 0.48 0.28 2.31 
5% Colostrum and PBS 1.22 1.06 0.60 0.80 3.69 
5% C. sinensis and PBS 0.86 1.16 0.65 2.52 5.19 
5% + 5% combined and 
PBS 





Table B2 b. Statistical significance using Tukey's multiple comparisons test of faeces weight 
from G. mellonella larvae reared on nutraceutical-enhanced foods and co-inoculated with 2 µm 
microspheres and indomethacin  
 
 
Table B3. Statistically significant results following a Tukey’s multiple comparison test of 
larvae movement, following force feeding (FF) or injection (INJ) of 1x106 or 3x106 C. jejuni 
or PBS or the untreated control (NT) 
Time Elapsed (Hours) Mean 
Diff. 
95.00% CI of diff. Summary Adjusted P Value 
24     
Normal NT vs. Normal FF 1x10⁶ 1.333 0.2013 to 2.465 ** 0.0039 
Normal NT vs. Normal FF 3x10⁶ 1.867 0.7347 to 2.999 **** <0.0001 
Normal NT vs. Colostrum FF 3x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
Normal NT vs. Colostrum INJ 3x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
Normal NT vs. C. sinensis FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Normal NT vs. C. sinensis INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal NT vs. Both FF 1x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
Normal NT vs. Both FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Normal NT vs. Both INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Normal PBS FF vs. Normal FF 1x10⁶ 1.333 0.2013 to 2.465 ** 0.0039 
Normal PBS FF vs. Normal FF 3x10⁶ 1.867 0.7347 to 2.999 **** <0.0001 
Normal PBS FF vs. Colostrum FF 3x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
Normal PBS FF vs. Colostrum INJ 3x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
Normal PBS FF vs. C. sinensis FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Normal PBS FF vs. C. sinensis INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal PBS FF vs. Both FF 1x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
 
Mean Diff. 95.00% CI of diff. Adjusted P 
Value 
Standard food and Indomethacin vs. 
5% C. sinensis and PBS 
-1.647 -3.289 to -0.004590 0.0489 * 
5% Colostrum and Indomethacin vs. 
5% C. sinensis and PBS 
-1.907 -3.549 to -0.2646 0.0121 * 
5% + 5% combined and 
Indomethacin vs. 5% C. sinensis and 
PBS 
-1.657 -3.299 to -0.01459 0.0465 * 
Standard food and PBS vs. 5% C. 
sinensis and PBS 
-2.243 -3.885 to -0.6013 0.0016 ** 
5% Colostrum and PBS vs. 5% C. 
sinensis and PBS 
-1.723 -3.365 to -0.08126 0.0331 * 
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Normal PBS FF vs. Both FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Normal PBS FF vs. Both INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Normal FF 1x10⁶ vs. Normal PBS INJ -1.333 -2.465 to -0.2013 ** 0.0039 
Normal FF 1x10⁶ vs. Colostrum NT -1.2 -2.332 to -0.06799 * 0.0227 
Normal FF 1x10⁶ vs. Colostrum PBS INJ -1.2 -2.332 to -0.06799 * 0.0227 
Normal FF 1x10⁶ vs. C. sinensis NT -1.367 -2.499 to -0.2347 ** 0.0024 
Normal FF 1x10⁶ vs. C. sinensis PBS INJ -1.3 -2.432 to -0.1680 ** 0.0062 
Normal FF 1x10⁶ vs. Both NT -1.333 -2.465 to -0.2013 ** 0.0039 
Normal FF 1x10⁶ vs. Both PBS FF -1.333 -2.465 to -0.2013 ** 0.0039 
Normal FF 1x10⁶ vs. Both PBS INJ -1.333 -2.465 to -0.2013 ** 0.0039 
Normal FF 3x10⁶ vs. Normal PBS INJ -1.867 -2.999 to -0.7347 **** <0.0001 
Normal FF 3x10⁶ vs. Normal INJ 1x10⁶ -1.2 -2.332 to -0.06799 * 0.0227 
Normal FF 3x10⁶ vs. Colostrum NT -1.733 -2.865 to -0.6013 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum PBS FF -1.433 -2.565 to -0.3013 *** 0.0009 
Normal FF 3x10⁶ vs. Colostrum PBS INJ -1.733 -2.865 to -0.6013 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis NT -1.9 -3.032 to -0.7680 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS FF -1.533 -2.665 to -0.4013 *** 0.0002 
Normal FF 3x10⁶ vs. C. sinensis PBS INJ -1.833 -2.965 to -0.7013 **** <0.0001 
Normal FF 3x10⁶ vs. Both NT -1.867 -2.999 to -0.7347 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS FF -1.867 -2.999 to -0.7347 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS INJ -1.867 -2.999 to -0.7347 **** <0.0001 
Normal PBS INJ vs. Colostrum FF 3x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
Normal PBS INJ vs. Colostrum INJ 3x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
Normal PBS INJ vs. C. sinensis FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Normal PBS INJ vs. C. sinensis INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal PBS INJ vs. Both FF 1x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
Normal PBS INJ vs. Both FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Normal PBS INJ vs. Both INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Normal INJ 1x10⁶ vs. Both FF 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal INJ 3x10⁶ vs. C. sinensis NT -1.133 -2.265 to -0.001326 * 0.0493 
Colostrum NT vs. Colostrum FF 3x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Colostrum NT vs. Colostrum INJ 3x10⁶ 1.567 0.4347 to 2.699 *** 0.0001 
Colostrum NT vs. C. sinensis FF 3x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Colostrum NT vs. C. sinensis INJ 3x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
Colostrum NT vs. Both FF 1x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
Colostrum NT vs. Both FF 3x10⁶ 2.067 0.9347 to 3.199 **** <0.0001 
Colostrum NT vs. Both INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Colostrum PBS FF vs. Colostrum INJ 
3x10⁶ 
1.267 0.1347 to 2.399 ** 0.0097 
Colostrum PBS FF vs. Both FF 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
Colostrum PBS FF vs. Both INJ 3x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Colostrum FF 1x10⁶ vs. Both FF 3x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
Colostrum FF 3x10⁶ vs. Colostrum PBS 
INJ 
-1.167 -2.299 to -0.03466 * 0.0337 
Colostrum FF 3x10⁶ vs. C. sinensis NT -1.333 -2.465 to -0.2013 ** 0.0039 
Colostrum FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.267 -2.399 to -0.1347 ** 0.0097 
Colostrum FF 3x10⁶ vs. Both NT -1.3 -2.432 to -0.1680 ** 0.0062 
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Colostrum FF 3x10⁶ vs. Both PBS FF -1.3 -2.432 to -0.1680 ** 0.0062 
Colostrum FF 3x10⁶ vs. Both PBS INJ -1.3 -2.432 to -0.1680 ** 0.0062 
Colostrum PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.567 0.4347 to 2.699 *** 0.0001 
Colostrum PBS INJ vs. C. sinensis FF 
3x10⁶ 
1.133 0.001326 to 2.265 * 0.0493 
Colostrum PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.4 0.2680 to 2.532 ** 0.0015 
Colostrum PBS INJ vs. Both FF 1x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
Colostrum PBS INJ vs. Both FF 3x10⁶ 2.067 0.9347 to 3.199 **** <0.0001 
Colostrum PBS INJ vs. Both INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Colostrum INJ 1x10⁶ vs. Both FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Colostrum INJ 3x10⁶ vs. C. sinensis NT -1.733 -2.865 to -0.6013 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
FF 
-1.367 -2.499 to -0.2347 ** 0.0024 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.667 -2.799 to -0.5347 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both NT -1.7 -2.832 to -0.5680 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS FF -1.7 -2.832 to -0.5680 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS INJ -1.7 -2.832 to -0.5680 **** <0.0001 
C. sinensis NT vs. C. sinensis FF 3x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
C. sinensis NT vs. C. sinensis INJ 3x10⁶ 1.567 0.4347 to 2.699 *** 0.0001 
C. sinensis NT vs. Both FF 1x10⁶ 1.467 0.3347 to 2.599 *** 0.0005 
C. sinensis NT vs. Both FF 3x10⁶ 2.233 1.101 to 3.365 **** <0.0001 
C. sinensis NT vs. Both INJ 3x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
C. sinensis PBS FF vs. C. sinensis INJ 3x10⁶ 1.2 0.06799 to 2.332 * 0.0227 
C. sinensis PBS FF vs. Both FF 3x10⁶ 1.867 0.7347 to 2.999 **** <0.0001 
C. sinensis PBS FF vs. Both INJ 3x10⁶ 1.333 0.2013 to 2.465 ** 0.0039 
C. sinensis FF 1x10⁶ vs. Both FF 3x10⁶ 1.333 0.2013 to 2.465 ** 0.0039 
C. sinensis FF 3x10⁶ vs. C. sinensis PBS INJ -1.233 -2.365 to -0.1013 * 0.015 
C. sinensis FF 3x10⁶ vs. Both NT -1.267 -2.399 to -0.1347 ** 0.0097 
C. sinensis FF 3x10⁶ vs. Both PBS FF -1.267 -2.399 to -0.1347 ** 0.0097 
C. sinensis FF 3x10⁶ vs. Both PBS INJ -1.267 -2.399 to -0.1347 ** 0.0097 
C. sinensis PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.5 0.3680 to 2.632 *** 0.0003 
C. sinensis PBS INJ vs. Both FF 1x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
C. sinensis PBS INJ vs. Both FF 3x10⁶ 2.167 1.035 to 3.299 **** <0.0001 
C. sinensis PBS INJ vs. Both INJ 3x10⁶ 1.633 0.5013 to 2.765 **** <0.0001 
C. sinensis INJ 1x10⁶ vs. Both FF 3x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
C. sinensis INJ 3x10⁶ vs. Both NT -1.533 -2.665 to -0.4013 *** 0.0002 
C. sinensis INJ 3x10⁶ vs. Both PBS FF -1.533 -2.665 to -0.4013 *** 0.0002 
C. sinensis INJ 3x10⁶ vs. Both PBS INJ -1.533 -2.665 to -0.4013 *** 0.0002 
Both NT vs. Both FF 1x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
Both NT vs. Both FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Both NT vs. Both INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Both PBS FF vs. Both FF 1x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
Both PBS FF vs. Both FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Both PBS FF vs. Both INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Both FF 1x10⁶ vs. Both PBS INJ -1.433 -2.565 to -0.3013 *** 0.0009 
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Both FF 3x10⁶ vs. Both PBS INJ -2.2 -3.332 to -1.068 **** <0.0001 
Both FF 3x10⁶ vs. Both INJ 1x10⁶ -1.333 -2.465 to -0.2013 ** 0.0039 
Both PBS INJ vs. Both INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
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Normal NT vs. Normal FF 1x10⁶ 1.733 0.6013 to 2.865 **** <0.0001 
Normal NT vs. Normal FF 3x10⁶ 2.133 1.001 to 3.265 **** <0.0001 
Normal NT vs. Normal INJ 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal NT vs. Colostrum FF 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal NT vs. Colostrum INJ 3x10⁶ 2.333 1.201 to 3.465 **** <0.0001 
Normal NT vs. C. sinensis FF 3x10⁶ 1.367 0.2347 to 2.499 ** 0.0024 
Normal NT vs. C. sinensis INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Normal NT vs. Both FF 1x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
Normal NT vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Normal NT vs. Both INJ 1x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Normal NT vs. Both INJ 3x10⁶ 1.967 0.8347 to 3.099 **** <0.0001 
Normal PBS FF vs. Normal FF 1x10⁶ 1.733 0.6013 to 2.865 **** <0.0001 
Normal PBS FF vs. Normal FF 3x10⁶ 2.133 1.001 to 3.265 **** <0.0001 
Normal PBS FF vs. Normal INJ 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal PBS FF vs. Colostrum FF 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal PBS FF vs. Colostrum INJ 3x10⁶ 2.333 1.201 to 3.465 **** <0.0001 
Normal PBS FF vs. C. sinensis FF 3x10⁶ 1.367 0.2347 to 2.499 ** 0.0024 
Normal PBS FF vs. C. sinensis INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Normal PBS FF vs. Both FF 1x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
Normal PBS FF vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Normal PBS FF vs. Both INJ 1x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Normal PBS FF vs. Both INJ 3x10⁶ 1.967 0.8347 to 3.099 **** <0.0001 
Normal FF 1x10⁶ vs. Normal PBS INJ -1.733 -2.865 to -0.6013 **** <0.0001 
Normal FF 1x10⁶ vs. Colostrum NT -1.6 -2.732 to -0.4680 **** <0.0001 
Normal FF 1x10⁶ vs. Colostrum PBS FF -1.3 -2.432 to -0.1680 ** 0.0062 
Normal FF 1x10⁶ vs. Colostrm PBS INJ -1.6 -2.732 to -0.4680 **** <0.0001 
Normal FF 1x10⁶ vs. C. sinensis NT -1.767 -2.899 to -0.6347 **** <0.0001 
Normal FF 1x10⁶ vs. C. sinensis PBS FF -1.4 -2.532 to -0.2680 ** 0.0015 
Normal FF 1x10⁶ vs. C. sinensis PBS INJ -1.7 -2.832 to -0.5680 **** <0.0001 
Normal FF 1x10⁶ vs. Both NT -1.733 -2.865 to -0.6013 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS FF -1.733 -2.865 to -0.6013 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS INJ -1.733 -2.865 to -0.6013 **** <0.0001 
Normal FF 3x10⁶ vs. Normal PBS INJ -2.133 -3.265 to -1.001 **** <0.0001 
Normal FF 3x10⁶ vs. Normal INJ 1x10⁶ -1.133 -2.265 to -0.001326 * 0.0493 
Normal FF 3x10⁶ vs. Colostrum NT -2 -3.132 to -0.8680 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum PBS FF -1.7 -2.832 to -0.5680 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum FF 1x10⁶ -1.3 -2.432 to -0.1680 ** 0.0062 
Normal FF 3x10⁶ vs. Colostrm PBS INJ -2 -3.132 to -0.8680 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum INJ 1x10⁶ -1.133 -2.265 to -0.001326 * 0.0493 
Normal FF 3x10⁶ vs. C. sinensis NT -2.167 -3.299 to -1.035 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS FF -1.8 -2.932 to -0.6680 **** <0.0001 
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Normal FF 3x10⁶ vs. C. sinensis FF 1x10⁶ -1.133 -2.265 to -0.001326 * 0.0493 
Normal FF 3x10⁶ vs. C. sinensis PBS INJ -2.1 -3.232 to -0.9680 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis INJ 1x10⁶ -1.2 -2.332 to -0.06799 * 0.0227 
Normal FF 3x10⁶ vs. Both NT -2.133 -3.265 to -1.001 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS FF -2.133 -3.265 to -1.001 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS INJ -2.133 -3.265 to -1.001 **** <0.0001 
Normal PBS INJ vs. Normal INJ 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal PBS INJ vs. Colostrum FF 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal PBS INJ vs. Colostrum INJ 3x10⁶ 2.333 1.201 to 3.465 **** <0.0001 
Normal PBS INJ vs. C. sinensis FF 3x10⁶ 1.367 0.2347 to 2.499 ** 0.0024 
Normal PBS INJ vs. C. sinensis INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Normal PBS INJ vs. Both FF 1x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
Normal PBS INJ vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Normal PBS INJ vs. Both INJ 1x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Normal PBS INJ vs. Both INJ 3x10⁶ 1.967 0.8347 to 3.099 **** <0.0001 
Normal INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.333 0.2013 to 2.465 ** 0.0039 
Normal INJ 1x10⁶ vs. Both FF 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
Normal INJ 3x10⁶ vs. Colostrum NT -1.367 -2.499 to -0.2347 ** 0.0024 
Normal INJ 3x10⁶ vs. Colostrm PBS INJ -1.367 -2.499 to -0.2347 ** 0.0024 
Normal INJ 3x10⁶ vs. C. sinensis NT -1.533 -2.665 to -0.4013 *** 0.0002 
Normal INJ 3x10⁶ vs. C. sinensis PBS FF -1.167 -2.299 to -0.03466 * 0.0337 
Normal INJ 3x10⁶ vs. C. sinensis PBS INJ -1.467 -2.599 to -0.3347 *** 0.0005 
Normal INJ 3x10⁶ vs. Both NT -1.5 -2.632 to -0.3680 *** 0.0003 
Normal INJ 3x10⁶ vs. Both PBS FF -1.5 -2.632 to -0.3680 *** 0.0003 
Normal INJ 3x10⁶ vs. Both FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Normal INJ 3x10⁶ vs. Both PBS INJ -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrum NT vs. Colostrum FF 3x10⁶ 1.367 0.2347 to 2.499 ** 0.0024 
Colostrum NT vs. Colostrum INJ 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Colostrum NT vs. C. sinensis FF 3x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Colostrum NT vs. C. sinensis INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Colostrum NT vs. Both FF 1x10⁶ 1.467 0.3347 to 2.599 *** 0.0005 
Colostrum NT vs. Both FF 3x10⁶ 2.633 1.501 to 3.765 **** <0.0001 
Colostrum NT vs. Both INJ 3x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Colostrum PBS FF vs. Colostrum INJ 
3x10⁶ 
1.9 0.7680 to 3.032 **** <0.0001 
Colostrum PBS FF vs. C. sinensis INJ 3x10⁶ 1.367 0.2347 to 2.499 ** 0.0024 
Colostrum PBS FF vs. Both FF 1x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Colostrum PBS FF vs. Both FF 3x10⁶ 2.333 1.201 to 3.465 **** <0.0001 
Colostrum PBS FF vs. Both INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Colostrum FF 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.5 0.3680 to 2.632 *** 0.0003 
Colostrum FF 1x10⁶ vs. Both FF 3x10⁶ 1.933 0.8013 to 3.065 **** <0.0001 
Colostrum FF 1x10⁶ vs. Both INJ 3x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Colostrum FF 3x10⁶ vs. Colostrm PBS 
INJ 
-1.367 -2.499 to -0.2347 ** 0.0024 
Colostrum FF 3x10⁶ vs. C. sinensis NT -1.533 -2.665 to -0.4013 *** 0.0002 
Colostrum FF 3x10⁶ vs. C. sinensis PBS FF -1.167 -2.299 to -0.03466 * 0.0337 
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Colostrum FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.467 -2.599 to -0.3347 *** 0.0005 
Colostrum FF 3x10⁶ vs. Both NT -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrum FF 3x10⁶ vs. Both PBS FF -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrum FF 3x10⁶ vs. Both FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Colostrum FF 3x10⁶ vs. Both PBS INJ -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrm PBS INJ vs. Colostrum INJ 
3x10⁶ 
2.2 1.068 to 3.332 **** <0.0001 
Colostrm PBS INJ vs. C. sinensis FF 3x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Colostrm PBS INJ vs. C. sinensis INJ 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Colostrm PBS INJ vs. Both FF 1x10⁶ 1.467 0.3347 to 2.599 *** 0.0005 
Colostrm PBS INJ vs. Both FF 3x10⁶ 2.633 1.501 to 3.765 **** <0.0001 
Colostrm PBS INJ vs. Both INJ 3x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Colostrum INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.333 0.2013 to 2.465 ** 0.0039 
Colostrum INJ 1x10⁶ vs. Both FF 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis NT -2.367 -3.499 to -1.235 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
FF 
-2 -3.132 to -0.8680 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis FF 
1x10⁶ 
-1.333 -2.465 to -0.2013 ** 0.0039 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
INJ 
-2.3 -3.432 to -1.168 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis INJ 
1x10⁶ 
-1.4 -2.532 to -0.2680 ** 0.0015 
Colostrum INJ 3x10⁶ vs. Both NT -2.333 -3.465 to -1.201 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS FF -2.333 -3.465 to -1.201 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS INJ -2.333 -3.465 to -1.201 **** <0.0001 
C. sinensis NT vs. C. sinensis FF 3x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
C. sinensis NT vs. C. sinensis INJ 3x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
C. sinensis NT vs. Both FF 1x10⁶ 1.633 0.5013 to 2.765 **** <0.0001 
C. sinensis NT vs. Both FF 3x10⁶ 2.8 1.668 to 3.932 **** <0.0001 
C. sinensis NT vs. Both INJ 1x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
C. sinensis NT vs. Both INJ 3x10⁶ 2 0.8680 to 3.132 **** <0.0001 
C. sinensis PBS FF vs. C. sinensis INJ 3x10⁶ 1.467 0.3347 to 2.599 *** 0.0005 
C. sinensis PBS FF vs. Both FF 1x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
C. sinensis PBS FF vs. Both FF 3x10⁶ 2.433 1.301 to 3.565 **** <0.0001 
C. sinensis PBS FF vs. Both INJ 3x10⁶ 1.633 0.5013 to 2.765 **** <0.0001 
C. sinensis FF 1x10⁶ vs. Both FF 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
C. sinensis FF 3x10⁶ vs. C. sinensis PBS INJ -1.333 -2.465 to -0.2013 ** 0.0039 
C. sinensis FF 3x10⁶ vs. Both NT -1.367 -2.499 to -0.2347 ** 0.0024 
C. sinensis FF 3x10⁶ vs. Both PBS FF -1.367 -2.499 to -0.2347 ** 0.0024 
C. sinensis FF 3x10⁶ vs. Both FF 3x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
C. sinensis FF 3x10⁶ vs. Both PBS INJ -1.367 -2.499 to -0.2347 ** 0.0024 
C. sinensis PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.767 0.6347 to 2.899 **** <0.0001 
C. sinensis PBS INJ vs. Both FF 1x10⁶ 1.567 0.4347 to 2.699 *** 0.0001 
C. sinensis PBS INJ vs. Both FF 3x10⁶ 2.733 1.601 to 3.865 **** <0.0001 
C. sinensis PBS INJ vs. Both INJ 1x10⁶ 1.2 0.06799 to 2.332 * 0.0227 
C. sinensis PBS INJ vs. Both INJ 3x10⁶ 1.933 0.8013 to 3.065 **** <0.0001 
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C. sinensis INJ 1x10⁶ vs. Both FF 3x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both NT -1.8 -2.932 to -0.6680 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS FF -1.8 -2.932 to -0.6680 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS INJ -1.8 -2.932 to -0.6680 **** <0.0001 
Both NT vs. Both FF 1x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
Both NT vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Both NT vs. Both INJ 1x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Both NT vs. Both INJ 3x10⁶ 1.967 0.8347 to 3.099 **** <0.0001 
Both PBS FF vs. Both FF 1x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
Both PBS FF vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Both PBS FF vs. Both INJ 1x10⁶ 1.233 0.1013 to 2.365 * 0.015 
Both PBS FF vs. Both INJ 3x10⁶ 1.967 0.8347 to 3.099 **** <0.0001 
Both FF 1x10⁶ vs. Both FF 3x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Both FF 1x10⁶ vs. Both PBS INJ -1.6 -2.732 to -0.4680 **** <0.0001 
Both FF 3x10⁶ vs. Both PBS INJ -2.767 -3.899 to -1.635 **** <0.0001 
Both FF 3x10⁶ vs. Both INJ 1x10⁶ -1.533 -2.665 to -0.4013 *** 0.0002 
Both PBS INJ vs. Both INJ 1x10⁶ 1.233 0.1013 to 2.365 * 0.015 
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Normal NT vs. Normal FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Normal NT vs. Normal FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Normal NT vs. Normal INJ 1x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Normal NT vs. Normal INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Normal NT vs. Colostrum FF 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal NT vs. Colostrum INJ 3x10⁶ 2.467 1.335 to 3.599 **** <0.0001 
Normal NT vs. C. sinensis FF 1x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Normal NT vs. C. sinensis FF 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal NT vs. C. sinensis INJ 3x10⁶ 1.933 0.8013 to 3.065 **** <0.0001 
Normal NT vs. Both FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Normal NT vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Normal NT vs. Both INJ 1x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal NT vs. Both INJ 3x10⁶ 2.167 1.035 to 3.299 **** <0.0001 
Normal PBS FF vs. Normal FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Normal PBS FF vs. Normal FF 3x10⁶ 2.2 1.068 to 3.332 **** <0.0001 
Normal PBS FF vs. Normal INJ 1x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Normal PBS FF vs. Normal INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Normal PBS FF vs. Colostrum FF 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal PBS FF vs. Colostrum INJ 3x10⁶ 2.467 1.335 to 3.599 **** <0.0001 
Normal PBS FF vs. C. sinensis FF 1x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Normal PBS FF vs. C. sinensis FF 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal PBS FF vs. C. sinensis INJ 3x10⁶ 1.933 0.8013 to 3.065 **** <0.0001 
Normal PBS FF vs. Both FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Normal PBS FF vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Normal PBS FF vs. Both INJ 1x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal PBS FF vs. Both INJ 3x10⁶ 2.167 1.035 to 3.299 **** <0.0001 
Normal FF 1x10⁶ vs. Normal PBS INJ -1.833 -2.965 to -0.7013 **** <0.0001 
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Normal FF 1x10⁶ vs. Colostrum NT -1.7 -2.832 to -0.5680 **** <0.0001 
Normal FF 1x10⁶ vs. Colostrum PBS FF -1.433 -2.565 to -0.3013 *** 0.0009 
Normal FF 1x10⁶ vs. Colostrm PBS INJ -1.7 -2.832 to -0.5680 **** <0.0001 
Normal FF 1x10⁶ vs. C. sinensis NT -1.7 -2.832 to -0.5680 **** <0.0001 
Normal FF 1x10⁶ vs. C. sinensis PBS FF -1.6 -2.732 to -0.4680 **** <0.0001 
Normal FF 1x10⁶ vs. C. sinensis PBS INJ -1.8 -2.932 to -0.6680 **** <0.0001 
Normal FF 1x10⁶ vs. Both NT -1.833 -2.965 to -0.7013 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS FF -1.833 -2.965 to -0.7013 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS INJ -1.833 -2.965 to -0.7013 **** <0.0001 
Normal FF 3x10⁶ vs. Normal PBS INJ -2.2 -3.332 to -1.068 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum NT -2.067 -3.199 to -0.9347 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum PBS FF -1.8 -2.932 to -0.6680 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrm PBS INJ -2.067 -3.199 to -0.9347 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum INJ 1x10⁶ -1.2 -2.332 to -0.06799 * 0.0227 
Normal FF 3x10⁶ vs. C. sinensis NT -2.067 -3.199 to -0.9347 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS FF -1.967 -3.099 to -0.8347 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS INJ -2.167 -3.299 to -1.035 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis INJ 1x10⁶ -1.2 -2.332 to -0.06799 * 0.0227 
Normal FF 3x10⁶ vs. Both NT -2.2 -3.332 to -1.068 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS FF -2.2 -3.332 to -1.068 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS INJ -2.2 -3.332 to -1.068 **** <0.0001 
Normal PBS INJ vs. Normal INJ 1x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Normal PBS INJ vs. Normal INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Normal PBS INJ vs. Colostrum FF 3x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
Normal PBS INJ vs. Colostrum INJ 3x10⁶ 2.467 1.335 to 3.599 **** <0.0001 
Normal PBS INJ vs. C. sinensis FF 1x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Normal PBS INJ vs. C. sinensis FF 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal PBS INJ vs. C. sinensis INJ 3x10⁶ 1.933 0.8013 to 3.065 **** <0.0001 
Normal PBS INJ vs. Both FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Normal PBS INJ vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Normal PBS INJ vs. Both INJ 1x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Normal PBS INJ vs. Both INJ 3x10⁶ 2.167 1.035 to 3.299 **** <0.0001 
Normal INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.333 0.2013 to 2.465 ** 0.0039 
Normal INJ 1x10⁶ vs. Both NT -1.133 -2.265 to -0.001326 * 0.0493 
Normal INJ 1x10⁶ vs. Both PBS FF -1.133 -2.265 to -0.001326 * 0.0493 
Normal INJ 1x10⁶ vs. Both FF 3x10⁶ 1.633 0.5013 to 2.765 **** <0.0001 
Normal INJ 1x10⁶ vs. Both PBS INJ -1.133 -2.265 to -0.001326 * 0.0493 
Normal INJ 3x10⁶ vs. Colostrum NT -1.667 -2.799 to -0.5347 **** <0.0001 
Normal INJ 3x10⁶ vs. Colostrum PBS FF -1.4 -2.532 to -0.2680 ** 0.0015 
Normal INJ 3x10⁶ vs. Colostrm PBS INJ -1.667 -2.799 to -0.5347 **** <0.0001 
Normal INJ 3x10⁶ vs. C. sinensis NT -1.667 -2.799 to -0.5347 **** <0.0001 
Normal INJ 3x10⁶ vs. C. sinensis PBS FF -1.567 -2.699 to -0.4347 *** 0.0001 
Normal INJ 3x10⁶ vs. C. sinensis PBS INJ -1.767 -2.899 to -0.6347 **** <0.0001 
Normal INJ 3x10⁶ vs. Both NT -1.8 -2.932 to -0.6680 **** <0.0001 
Normal INJ 3x10⁶ vs. Both PBS FF -1.8 -2.932 to -0.6680 **** <0.0001 
Normal INJ 3x10⁶ vs. Both PBS INJ -1.8 -2.932 to -0.6680 **** <0.0001 
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Colostrum NT vs. Colostrum FF 3x10⁶ 1.367 0.2347 to 2.499 ** 0.0024 
Colostrum NT vs. Colostrum INJ 3x10⁶ 2.333 1.201 to 3.465 **** <0.0001 
Colostrum NT vs. C. sinensis FF 3x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
Colostrum NT vs. C. sinensis INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Colostrum NT vs. Both FF 1x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
Colostrum NT vs. Both FF 3x10⁶ 2.633 1.501 to 3.765 **** <0.0001 
Colostrum NT vs. Both INJ 1x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
Colostrum NT vs. Both INJ 3x10⁶ 2.033 0.9013 to 3.165 **** <0.0001 
Colostrum PBS FF vs. Colostrum INJ 
3x10⁶ 
2.067 0.9347 to 3.199 **** <0.0001 
Colostrum PBS FF vs. C. sinensis FF 3x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Colostrum PBS FF vs. C. sinensis INJ 3x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Colostrum PBS FF vs. Both FF 1x10⁶ 1.433 0.3013 to 2.565 *** 0.0009 
Colostrum PBS FF vs. Both FF 3x10⁶ 2.367 1.235 to 3.499 **** <0.0001 
Colostrum PBS FF vs. Both INJ 1x10⁶ 1.133 0.001326 to 2.265 * 0.0493 
Colostrum PBS FF vs. Both INJ 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
Colostrum FF 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.367 0.2347 to 2.499 ** 0.0024 
Colostrum FF 1x10⁶ vs. Both FF 3x10⁶ 1.667 0.5347 to 2.799 **** <0.0001 
Colostrum FF 3x10⁶ vs. Colostrm PBS 
INJ 
-1.367 -2.499 to -0.2347 ** 0.0024 
Colostrum FF 3x10⁶ vs. C. sinensis NT -1.367 -2.499 to -0.2347 ** 0.0024 
Colostrum FF 3x10⁶ vs. C. sinensis PBS FF -1.267 -2.399 to -0.1347 ** 0.0097 
Colostrum FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.467 -2.599 to -0.3347 *** 0.0005 
Colostrum FF 3x10⁶ vs. Both NT -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrum FF 3x10⁶ vs. Both PBS FF -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrum FF 3x10⁶ vs. Both FF 3x10⁶ 1.267 0.1347 to 2.399 ** 0.0097 
Colostrum FF 3x10⁶ vs. Both PBS INJ -1.5 -2.632 to -0.3680 *** 0.0003 
Colostrm PBS INJ vs. Colostrum INJ 
3x10⁶ 
2.333 1.201 to 3.465 **** <0.0001 
Colostrm PBS INJ vs. C. sinensis FF 3x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
Colostrm PBS INJ vs. C. sinensis INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
Colostrm PBS INJ vs. Both FF 1x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
Colostrm PBS INJ vs. Both FF 3x10⁶ 2.633 1.501 to 3.765 **** <0.0001 
Colostrm PBS INJ vs. Both INJ 1x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
Colostrm PBS INJ vs. Both INJ 3x10⁶ 2.033 0.9013 to 3.165 **** <0.0001 
Colostrum INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.467 0.3347 to 2.599 *** 0.0005 
Colostrum INJ 1x10⁶ vs. Both FF 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
Colostrum INJ 1x10⁶ vs. Both INJ 3x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
Colostrum INJ 3x10⁶ vs. C. sinensis NT -2.333 -3.465 to -1.201 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
FF 
-2.233 -3.365 to -1.101 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis FF 
1x10⁶ 
-1.3 -2.432 to -0.1680 ** 0.0062 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
INJ 
-2.433 -3.565 to -1.301 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis INJ 
1x10⁶ 
-1.467 -2.599 to -0.3347 *** 0.0005 
Colostrum INJ 3x10⁶ vs. Both NT -2.467 -3.599 to -1.335 **** <0.0001 
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Colostrum INJ 3x10⁶ vs. Both PBS FF -2.467 -3.599 to -1.335 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS INJ -2.467 -3.599 to -1.335 **** <0.0001 
C. sinensis NT vs. C. sinensis FF 3x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
C. sinensis NT vs. C. sinensis INJ 3x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
C. sinensis NT vs. Both FF 1x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
C. sinensis NT vs. Both FF 3x10⁶ 2.633 1.501 to 3.765 **** <0.0001 
C. sinensis NT vs. Both INJ 1x10⁶ 1.4 0.2680 to 2.532 ** 0.0015 
C. sinensis NT vs. Both INJ 3x10⁶ 2.033 0.9013 to 3.165 **** <0.0001 
C. sinensis PBS FF vs. C. sinensis FF 3x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
C. sinensis PBS FF vs. C. sinensis INJ 3x10⁶ 1.7 0.5680 to 2.832 **** <0.0001 
C. sinensis PBS FF vs. Both FF 1x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
C. sinensis PBS FF vs. Both FF 3x10⁶ 2.533 1.401 to 3.665 **** <0.0001 
C. sinensis PBS FF vs. Both INJ 1x10⁶ 1.3 0.1680 to 2.432 ** 0.0062 
C. sinensis PBS FF vs. Both INJ 3x10⁶ 1.933 0.8013 to 3.065 **** <0.0001 
C. sinensis FF 1x10⁶ vs. C. sinensis PBS INJ -1.133 -2.265 to -0.001326 * 0.0493 
C. sinensis FF 1x10⁶ vs. Both NT -1.167 -2.299 to -0.03466 * 0.0337 
C. sinensis FF 1x10⁶ vs. Both PBS FF -1.167 -2.299 to -0.03466 * 0.0337 
C. sinensis FF 1x10⁶ vs. Both FF 3x10⁶ 1.6 0.4680 to 2.732 **** <0.0001 
C. sinensis FF 1x10⁶ vs. Both PBS INJ -1.167 -2.299 to -0.03466 * 0.0337 
C. sinensis FF 3x10⁶ vs. C. sinensis PBS INJ -1.5 -2.632 to -0.3680 *** 0.0003 
C. sinensis FF 3x10⁶ vs. Both NT -1.533 -2.665 to -0.4013 *** 0.0002 
C. sinensis FF 3x10⁶ vs. Both PBS FF -1.533 -2.665 to -0.4013 *** 0.0002 
C. sinensis FF 3x10⁶ vs. Both FF 3x10⁶ 1.233 0.1013 to 2.365 * 0.015 
C. sinensis FF 3x10⁶ vs. Both PBS INJ -1.533 -2.665 to -0.4013 *** 0.0002 
C. sinensis PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.9 0.7680 to 3.032 **** <0.0001 
C. sinensis PBS INJ vs. Both FF 1x10⁶ 1.8 0.6680 to 2.932 **** <0.0001 
C. sinensis PBS INJ vs. Both FF 3x10⁶ 2.733 1.601 to 3.865 **** <0.0001 
C. sinensis PBS INJ vs. Both INJ 1x10⁶ 1.5 0.3680 to 2.632 *** 0.0003 
C. sinensis PBS INJ vs. Both INJ 3x10⁶ 2.133 1.001 to 3.265 **** <0.0001 
C. sinensis INJ 1x10⁶ vs. Both FF 3x10⁶ 1.767 0.6347 to 2.899 **** <0.0001 
C. sinensis INJ 1x10⁶ vs. Both INJ 3x10⁶ 1.167 0.03466 to 2.299 * 0.0337 
C. sinensis INJ 3x10⁶ vs. Both NT -1.933 -3.065 to -0.8013 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS FF -1.933 -3.065 to -0.8013 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS INJ -1.933 -3.065 to -0.8013 **** <0.0001 
Both NT vs. Both FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Both NT vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Both NT vs. Both INJ 1x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Both NT vs. Both INJ 3x10⁶ 2.167 1.035 to 3.299 **** <0.0001 
Both PBS FF vs. Both FF 1x10⁶ 1.833 0.7013 to 2.965 **** <0.0001 
Both PBS FF vs. Both FF 3x10⁶ 2.767 1.635 to 3.899 **** <0.0001 
Both PBS FF vs. Both INJ 1x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
Both PBS FF vs. Both INJ 3x10⁶ 2.167 1.035 to 3.299 **** <0.0001 
Both FF 1x10⁶ vs. Both PBS INJ -1.833 -2.965 to -0.7013 **** <0.0001 
Both FF 3x10⁶ vs. Both PBS INJ -2.767 -3.899 to -1.635 **** <0.0001 
Both FF 3x10⁶ vs. Both INJ 1x10⁶ -1.233 -2.365 to -0.1013 * 0.015 
Both PBS INJ vs. Both INJ 1x10⁶ 1.533 0.4013 to 2.665 *** 0.0002 
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Table B4. Statistically significant results following a Tukey’s multiple comparison test of 
larvae melanisation, following force feeding (FF) or injection (INJ) of 1x106 or 3x106 C. jejuni 
or PBS or the untreated control (NT) 
Time Elapsed (Hours) Mean Diff. 95.00% CI of diff. Summary Adjusted P 
Value 
24     
Normal NT vs. Normal FF 1x10⁶ 0.8667 0.01755 to 1.716 * 0.0384 
Normal NT vs. Normal FF 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal NT vs. Colostrum INJ 3x10⁶ 1.167 0.3175 to 2.016 *** 0.0001 
Normal NT vs. C. sinensis FF 3x10⁶ 0.8667 0.01755 to 1.716 * 0.0384 
Normal NT vs. C. sinensis INJ 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal NT vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal NT vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
Normal NT vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal PBS FF vs. Normal FF 1x10⁶ 0.8667 0.01755 to 1.716 * 0.0384 
Normal PBS FF vs. Normal FF 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal PBS FF vs. Colostrum INJ 
3x10⁶ 
1.167 0.3175 to 2.016 *** 0.0001 
Normal PBS FF vs. C. sinensis FF 3x10⁶ 0.8667 0.01755 to 1.716 * 0.0384 
Normal PBS FF vs. C. sinensis INJ 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal PBS FF vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal PBS FF vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
Normal PBS FF vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal FF 1x10⁶ vs. Normal PBS INJ -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 1x10⁶ vs. C. sinensis NT -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 1x10⁶ vs. C. sinensis PBS INJ -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 1x10⁶ vs. Both NT -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 1x10⁶ vs. Both PBS FF -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 1x10⁶ vs. Both PBS INJ -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 3x10⁶ vs. Normal PBS INJ -1.3 -2.149 to -0.4509 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum NT -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum PBS FF -1 -1.849 to -0.1509 ** 0.0039 
Normal FF 3x10⁶ vs. Colostrm PBS INJ -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis NT -1.3 -2.149 to -0.4509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS FF -1.1 -1.949 to -0.2509 *** 0.0005 
Normal FF 3x10⁶ vs. C. sinensis PBS INJ -1.3 -2.149 to -0.4509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis INJ 1x10⁶ -0.9 -1.749 to -0.05088 * 0.0227 
Normal FF 3x10⁶ vs. Both NT -1.3 -2.149 to -0.4509 **** <0.0001 
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Normal FF 3x10⁶ vs. Both PBS FF -1.3 -2.149 to -0.4509 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS INJ -1.3 -2.149 to -0.4509 **** <0.0001 
Normal PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.167 0.3175 to 2.016 *** 0.0001 
Normal PBS INJ vs. C. sinensis FF 3x10⁶ 0.8667 0.01755 to 1.716 * 0.0384 
Normal PBS INJ vs. C. sinensis INJ 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal PBS INJ vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal PBS INJ vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
Normal PBS INJ vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal INJ 1x10⁶ vs. Both FF 3x10⁶ 1.133 0.2842 to 1.982 *** 0.0003 
Normal INJ 3x10⁶ vs. Both FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrum NT vs. Colostrum INJ 3x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Colostrum NT vs. C. sinensis INJ 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrum NT vs. Both FF 1x10⁶ 0.9333 0.08422 to 1.782 * 0.013 
Colostrum NT vs. Both FF 3x10⁶ 1.5 0.6509 to 2.349 **** <0.0001 
Colostrum NT vs. Both INJ 3x10⁶ 0.9333 0.08422 to 1.782 * 0.013 
Colostrum PBS FF vs. Colostrum INJ 
3x10⁶ 
0.8667 0.01755 to 1.716 * 0.0384 
Colostrum PBS FF vs. Both FF 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Colostrum FF 1x10⁶ vs. Both FF 3x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Colostrm PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.067 0.2175 to 1.916 ** 0.0011 
Colostrm PBS INJ vs. C. sinensis INJ 
3x10⁶ 
0.9 0.05088 to 1.749 * 0.0227 
Colostrm PBS INJ vs. Both FF 1x10⁶ 0.9333 0.08422 to 1.782 * 0.013 
Colostrm PBS INJ vs. Both FF 3x10⁶ 1.5 0.6509 to 2.349 **** <0.0001 
Colostrm PBS INJ vs. Both INJ 3x10⁶ 0.9333 0.08422 to 1.782 * 0.013 
Colostrum INJ 1x10⁶ vs. Both FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrum INJ 3x10⁶ vs. C. sinensis NT -1.167 -2.016 to -0.3175 *** 0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
FF 
-0.9667 -1.816 to -0.1175 ** 0.0072 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.167 -2.016 to -0.3175 *** 0.0001 
Colostrum INJ 3x10⁶ vs. Both NT -1.167 -2.016 to -0.3175 *** 0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS FF -1.167 -2.016 to -0.3175 *** 0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS INJ -1.167 -2.016 to -0.3175 *** 0.0001 
C. sinensis NT vs. C. sinensis FF 3x10⁶ 0.8667 0.01755 to 1.716 * 0.0384 
C. sinensis NT vs. C. sinensis INJ 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
C. sinensis NT vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
C. sinensis NT vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
C. sinensis NT vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
C. sinensis PBS FF vs. Both FF 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
C. sinensis FF 1x10⁶ vs. Both FF 3x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
C. sinensis FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-0.8667 -1.716 to -0.01755 * 0.0384 
C. sinensis FF 3x10⁶ vs. Both NT -0.8667 -1.716 to -0.01755 * 0.0384 
C. sinensis FF 3x10⁶ vs. Both PBS FF -0.8667 -1.716 to -0.01755 * 0.0384 
C. sinensis FF 3x10⁶ vs. Both PBS INJ -0.8667 -1.716 to -0.01755 * 0.0384 
C. sinensis PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1 0.1509 to 1.849 ** 0.0039 
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C. sinensis PBS INJ vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
C. sinensis PBS INJ vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
C. sinensis PBS INJ vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
C. sinensis INJ 1x10⁶ vs. Both FF 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both NT -1 -1.849 to -0.1509 ** 0.0039 
C. sinensis INJ 3x10⁶ vs. Both PBS FF -1 -1.849 to -0.1509 ** 0.0039 
C. sinensis INJ 3x10⁶ vs. Both PBS INJ -1 -1.849 to -0.1509 ** 0.0039 
Both NT vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Both NT vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
Both NT vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Both PBS FF vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Both PBS FF vs. Both FF 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
Both PBS FF vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Both FF 1x10⁶ vs. Both PBS INJ -1.033 -1.882 to -0.1842 ** 0.0021 
Both FF 3x10⁶ vs. Both PBS INJ -1.6 -2.449 to -0.7509 **** <0.0001 
Both FF 3x10⁶ vs. Both INJ 1x10⁶ -1.1 -1.949 to -0.2509 *** 0.0005 
Both PBS INJ vs. Both INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
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Normal NT vs. Normal FF 1x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Normal NT vs. Normal FF 3x10⁶ 1.5 0.6509 to 2.349 **** <0.0001 
Normal NT vs. Normal INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal NT vs. Colostrum FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal NT vs. Colostrum INJ 3x10⁶ 1.7 0.8509 to 2.549 **** <0.0001 
Normal NT vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Normal NT vs. C. sinensis INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Normal NT vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Normal NT vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Normal NT vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal PBS FF vs. Normal FF 1x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Normal PBS FF vs. Normal FF 3x10⁶ 1.5 0.6509 to 2.349 **** <0.0001 
Normal PBS FF vs. Normal INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal PBS FF vs. Colostrum FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal PBS FF vs. Colostrum INJ 
3x10⁶ 
1.7 0.8509 to 2.549 **** <0.0001 
Normal PBS FF vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Normal PBS FF vs. C. sinensis INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Normal PBS FF vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Normal PBS FF vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Normal PBS FF vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal FF 1x10⁶ vs. Normal PBS INJ -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 1x10⁶ vs. Colostrum NT -1.1 -1.949 to -0.2509 *** 0.0005 
Normal FF 1x10⁶ vs. Colostrum PBS FF -0.9 -1.749 to -0.05088 * 0.0227 
Normal FF 1x10⁶ vs. Colostrm PBS INJ -1.1 -1.949 to -0.2509 *** 0.0005 
Normal FF 1x10⁶ vs. C. sinensis NT -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 1x10⁶ vs. C. sinensis PBS FF -1.1 -1.949 to -0.2509 *** 0.0005 
Normal FF 1x10⁶ vs. C. sinensis PBS INJ -1.2 -2.049 to -0.3509 **** <0.0001 
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Normal FF 1x10⁶ vs. Both NT -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS FF -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS INJ -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 3x10⁶ vs. Normal PBS INJ -1.5 -2.349 to -0.6509 **** <0.0001 
Normal FF 3x10⁶ vs. Normal INJ 1x10⁶ -0.8667 -1.716 to -0.01755 * 0.0384 
Normal FF 3x10⁶ vs. Colostrum NT -1.4 -2.249 to -0.5509 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum PBS FF -1.2 -2.049 to -0.3509 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum FF 
1x10⁶ 
-0.9333 -1.782 to -0.08422 * 0.013 
Normal FF 3x10⁶ vs. Colostrm PBS INJ -1.4 -2.249 to -0.5509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis NT -1.5 -2.349 to -0.6509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS FF -1.4 -2.249 to -0.5509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis FF 1x10⁶ -0.9 -1.749 to -0.05088 * 0.0227 
Normal FF 3x10⁶ vs. C. sinensis PBS INJ -1.5 -2.349 to -0.6509 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis INJ 1x10⁶ -0.9667 -1.816 to -0.1175 ** 0.0072 
Normal FF 3x10⁶ vs. Both NT -1.5 -2.349 to -0.6509 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS FF -1.5 -2.349 to -0.6509 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS INJ -1.5 -2.349 to -0.6509 **** <0.0001 
Normal PBS INJ vs. Normal INJ 3x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
Normal PBS INJ vs. Colostrum FF 
3x10⁶ 
1 0.1509 to 1.849 ** 0.0039 
Normal PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.7 0.8509 to 2.549 **** <0.0001 
Normal PBS INJ vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Normal PBS INJ vs. C. sinensis INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Normal PBS INJ vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Normal PBS INJ vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Normal PBS INJ vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.067 0.2175 to 1.916 ** 0.0011 
Normal INJ 1x10⁶ vs. Both FF 3x10⁶ 1.333 0.4842 to 2.182 **** <0.0001 
Normal INJ 3x10⁶ vs. Colostrum NT -0.9333 -1.782 to -0.08422 * 0.013 
Normal INJ 3x10⁶ vs. Colostrm PBS INJ -0.9333 -1.782 to -0.08422 * 0.013 
Normal INJ 3x10⁶ vs. C. sinensis NT -1.033 -1.882 to -0.1842 ** 0.0021 
Normal INJ 3x10⁶ vs. C. sinensis PBS FF -0.9333 -1.782 to -0.08422 * 0.013 
Normal INJ 3x10⁶ vs. C. sinensis PBS INJ -1.033 -1.882 to -0.1842 ** 0.0021 
Normal INJ 3x10⁶ vs. Both NT -1.033 -1.882 to -0.1842 ** 0.0021 
Normal INJ 3x10⁶ vs. Both PBS FF -1.033 -1.882 to -0.1842 ** 0.0021 
Normal INJ 3x10⁶ vs. Both FF 3x10⁶ 0.9333 0.08422 to 1.782 * 0.013 
Normal INJ 3x10⁶ vs. Both PBS INJ -1.033 -1.882 to -0.1842 ** 0.0021 
Colostrum NT vs. Colostrum FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrum NT vs. Colostrum INJ 3x10⁶ 1.6 0.7509 to 2.449 **** <0.0001 
Colostrum NT vs. C. sinensis INJ 3x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Colostrum NT vs. Both FF 1x10⁶ 0.9667 0.1175 to 1.816 ** 0.0072 
Colostrum NT vs. Both FF 3x10⁶ 1.867 1.018 to 2.716 **** <0.0001 
Colostrum NT vs. Both INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Colostrum PBS FF vs. Colostrum INJ 
3x10⁶ 
1.4 0.5509 to 2.249 **** <0.0001 
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Colostrum PBS FF vs. C. sinensis INJ 
3x10⁶ 
0.9 0.05088 to 1.749 * 0.0227 
Colostrum PBS FF vs. Both FF 3x10⁶ 1.667 0.8175 to 2.516 **** <0.0001 
Colostrum PBS FF vs. Both INJ 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Colostrum FF 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.133 0.2842 to 1.982 *** 0.0003 
Colostrum FF 1x10⁶ vs. Both FF 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
Colostrum FF 3x10⁶ vs. Colostrm PBS 
INJ 
-0.9 -1.749 to -0.05088 * 0.0227 
Colostrum FF 3x10⁶ vs. C. sinensis NT -1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. C. sinensis PBS 
FF 
-0.9 -1.749 to -0.05088 * 0.0227 
Colostrum FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. Both NT -1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. Both PBS FF -1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. Both FF 3x10⁶ 0.9667 0.1175 to 1.816 ** 0.0072 
Colostrum FF 3x10⁶ vs. Both PBS INJ -1 -1.849 to -0.1509 ** 0.0039 
Colostrm PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.6 0.7509 to 2.449 **** <0.0001 
Colostrm PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.1 0.2509 to 1.949 *** 0.0005 
Colostrm PBS INJ vs. Both FF 1x10⁶ 0.9667 0.1175 to 1.816 ** 0.0072 
Colostrm PBS INJ vs. Both FF 3x10⁶ 1.867 1.018 to 2.716 **** <0.0001 
Colostrm PBS INJ vs. Both INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Colostrum INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
0.9333 0.08422 to 1.782 * 0.013 
Colostrum INJ 1x10⁶ vs. Both FF 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis NT -1.7 -2.549 to -0.8509 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
FF 
-1.6 -2.449 to -0.7509 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis FF 
1x10⁶ 
-1.1 -1.949 to -0.2509 *** 0.0005 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.7 -2.549 to -0.8509 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis INJ 
1x10⁶ 
-1.167 -2.016 to -0.3175 *** 0.0001 
Colostrum INJ 3x10⁶ vs. Both NT -1.7 -2.549 to -0.8509 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS FF -1.7 -2.549 to -0.8509 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS INJ -1.7 -2.549 to -0.8509 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both INJ 1x10⁶ -0.8667 -1.716 to -0.01755 * 0.0384 
C. sinensis NT vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
C. sinensis NT vs. C. sinensis INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
C. sinensis NT vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
C. sinensis NT vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
C. sinensis NT vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
C. sinensis PBS FF vs. C. sinensis INJ 
3x10⁶ 
1.1 0.2509 to 1.949 *** 0.0005 
C. sinensis PBS FF vs. Both FF 1x10⁶ 0.9667 0.1175 to 1.816 ** 0.0072 
C. sinensis PBS FF vs. Both FF 3x10⁶ 1.867 1.018 to 2.716 **** <0.0001 
C. sinensis PBS FF vs. Both INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
C. sinensis FF 1x10⁶ vs. Both FF 3x10⁶ 1.367 0.5175 to 2.216 **** <0.0001 
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C. sinensis FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-0.9 -1.749 to -0.05088 * 0.0227 
C. sinensis FF 3x10⁶ vs. Both NT -0.9 -1.749 to -0.05088 * 0.0227 
C. sinensis FF 3x10⁶ vs. Both PBS FF -0.9 -1.749 to -0.05088 * 0.0227 
C. sinensis FF 3x10⁶ vs. Both FF 3x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
C. sinensis FF 3x10⁶ vs. Both PBS INJ -0.9 -1.749 to -0.05088 * 0.0227 
C. sinensis PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.2 0.3509 to 2.049 **** <0.0001 
C. sinensis PBS INJ vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
C. sinensis PBS INJ vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
C. sinensis PBS INJ vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
C. sinensis INJ 1x10⁶ vs. Both FF 3x10⁶ 1.433 0.5842 to 2.282 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both NT -1.2 -2.049 to -0.3509 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS FF -1.2 -2.049 to -0.3509 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS INJ -1.2 -2.049 to -0.3509 **** <0.0001 
Both NT vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Both NT vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Both NT vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Both PBS FF vs. Both FF 1x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Both PBS FF vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Both PBS FF vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Both FF 1x10⁶ vs. Both FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Both FF 1x10⁶ vs. Both PBS INJ -1.067 -1.916 to -0.2175 ** 0.0011 
Both FF 3x10⁶ vs. Both PBS INJ -1.967 -2.816 to -1.118 **** <0.0001 
Both FF 3x10⁶ vs. Both INJ 1x10⁶ -1.133 -1.982 to -0.2842 *** 0.0003 
Both PBS INJ vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
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Normal NT vs. Normal FF 1x10⁶ 1.267 0.4175 to 2.116 **** <0.0001 
Normal NT vs. Normal FF 3x10⁶ 1.567 0.7175 to 2.416 **** <0.0001 
Normal NT vs. Normal INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal NT vs. Colostrum FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal NT vs. Colostrum INJ 3x10⁶ 1.733 0.8842 to 2.582 **** <0.0001 
Normal NT vs. C. sinensis FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal NT vs. C. sinensis INJ 3x10⁶ 1.267 0.4175 to 2.116 **** <0.0001 
Normal NT vs. Both FF 1x10⁶ 1.233 0.3842 to 2.082 **** <0.0001 
Normal NT vs. Both FF 3x10⁶ 2.067 1.218 to 2.916 **** <0.0001 
Normal NT vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Normal NT vs. Both INJ 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
Normal PBS FF vs. Normal FF 1x10⁶ 1.267 0.4175 to 2.116 **** <0.0001 
Normal PBS FF vs. Normal FF 3x10⁶ 1.567 0.7175 to 2.416 **** <0.0001 
Normal PBS FF vs. Normal INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal PBS FF vs. Colostrum FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal PBS FF vs. Colostrum INJ 
3x10⁶ 
1.733 0.8842 to 2.582 **** <0.0001 
Normal PBS FF vs. C. sinensis FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal PBS FF vs. C. sinensis INJ 3x10⁶ 1.267 0.4175 to 2.116 **** <0.0001 
Normal PBS FF vs. Both FF 1x10⁶ 1.233 0.3842 to 2.082 **** <0.0001 
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Normal PBS FF vs. Both FF 3x10⁶ 2.067 1.218 to 2.916 **** <0.0001 
Normal PBS FF vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Normal PBS FF vs. Both INJ 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
Normal FF 1x10⁶ vs. Normal PBS INJ -1.267 -2.116 to -0.4175 **** <0.0001 
Normal FF 1x10⁶ vs. Colostrum NT -1.167 -2.016 to -0.3175 *** 0.0001 
Normal FF 1x10⁶ vs. Colostrum PBS FF -0.9667 -1.816 to -0.1175 ** 0.0072 
Normal FF 1x10⁶ vs. Colostrm PBS INJ -1.167 -2.016 to -0.3175 *** 0.0001 
Normal FF 1x10⁶ vs. C. sinensis NT -1.167 -2.016 to -0.3175 *** 0.0001 
Normal FF 1x10⁶ vs. C. sinensis PBS FF -1.067 -1.916 to -0.2175 ** 0.0011 
Normal FF 1x10⁶ vs. C. sinensis PBS INJ -1.267 -2.116 to -0.4175 **** <0.0001 
Normal FF 1x10⁶ vs. Both NT -1.267 -2.116 to -0.4175 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS FF -1.267 -2.116 to -0.4175 **** <0.0001 
Normal FF 1x10⁶ vs. Both PBS INJ -1.267 -2.116 to -0.4175 **** <0.0001 
Normal FF 3x10⁶ vs. Normal PBS INJ -1.567 -2.416 to -0.7175 **** <0.0001 
Normal FF 3x10⁶ vs. Normal INJ 1x10⁶ -1.067 -1.916 to -0.2175 ** 0.0011 
Normal FF 3x10⁶ vs. Colostrum NT -1.467 -2.316 to -0.6175 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrum PBS FF -1.267 -2.116 to -0.4175 **** <0.0001 
Normal FF 3x10⁶ vs. Colostrm PBS INJ -1.467 -2.316 to -0.6175 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis NT -1.467 -2.316 to -0.6175 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis PBS FF -1.367 -2.216 to -0.5175 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis FF 1x10⁶ -0.9 -1.749 to -0.05088 * 0.0227 
Normal FF 3x10⁶ vs. C. sinensis PBS INJ -1.567 -2.416 to -0.7175 **** <0.0001 
Normal FF 3x10⁶ vs. C. sinensis INJ 1x10⁶ -0.9667 -1.816 to -0.1175 ** 0.0072 
Normal FF 3x10⁶ vs. Both NT -1.567 -2.416 to -0.7175 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS FF -1.567 -2.416 to -0.7175 **** <0.0001 
Normal FF 3x10⁶ vs. Both PBS INJ -1.567 -2.416 to -0.7175 **** <0.0001 
Normal PBS INJ vs. Normal INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Normal PBS INJ vs. Colostrum FF 
3x10⁶ 
1 0.1509 to 1.849 ** 0.0039 
Normal PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.733 0.8842 to 2.582 **** <0.0001 
Normal PBS INJ vs. C. sinensis FF 3x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Normal PBS INJ vs. C. sinensis INJ 3x10⁶ 1.267 0.4175 to 2.116 **** <0.0001 
Normal PBS INJ vs. Both FF 1x10⁶ 1.233 0.3842 to 2.082 **** <0.0001 
Normal PBS INJ vs. Both FF 3x10⁶ 2.067 1.218 to 2.916 **** <0.0001 
Normal PBS INJ vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Normal PBS INJ vs. Both INJ 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
Normal INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1.233 0.3842 to 2.082 **** <0.0001 
Normal INJ 1x10⁶ vs. Both FF 3x10⁶ 1.567 0.7175 to 2.416 **** <0.0001 
Normal INJ 1x10⁶ vs. Both INJ 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Normal INJ 3x10⁶ vs. Colostrum NT -1.2 -2.049 to -0.3509 **** <0.0001 
Normal INJ 3x10⁶ vs. Colostrum PBS 
FF 
-1 -1.849 to -0.1509 ** 0.0039 
Normal INJ 3x10⁶ vs. Colostrm PBS INJ -1.2 -2.049 to -0.3509 **** <0.0001 
Normal INJ 3x10⁶ vs. C. sinensis NT -1.2 -2.049 to -0.3509 **** <0.0001 
Normal INJ 3x10⁶ vs. C. sinensis PBS FF -1.1 -1.949 to -0.2509 *** 0.0005 
Normal INJ 3x10⁶ vs. C. sinensis PBS INJ -1.3 -2.149 to -0.4509 **** <0.0001 
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Normal INJ 3x10⁶ vs. Both NT -1.3 -2.149 to -0.4509 **** <0.0001 
Normal INJ 3x10⁶ vs. Both PBS FF -1.3 -2.149 to -0.4509 **** <0.0001 
Normal INJ 3x10⁶ vs. Both PBS INJ -1.3 -2.149 to -0.4509 **** <0.0001 
Colostrum NT vs. Colostrum FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrum NT vs. Colostrum INJ 3x10⁶ 1.633 0.7842 to 2.482 **** <0.0001 
Colostrum NT vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrum NT vs. C. sinensis INJ 3x10⁶ 1.167 0.3175 to 2.016 *** 0.0001 
Colostrum NT vs. Both FF 1x10⁶ 1.133 0.2842 to 1.982 *** 0.0003 
Colostrum NT vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Colostrum NT vs. Both INJ 1x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Colostrum NT vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Colostrum PBS FF vs. Colostrum INJ 
3x10⁶ 
1.433 0.5842 to 2.282 **** <0.0001 
Colostrum PBS FF vs. C. sinensis INJ 
3x10⁶ 
0.9667 0.1175 to 1.816 ** 0.0072 
Colostrum PBS FF vs. Both FF 1x10⁶ 0.9333 0.08422 to 1.782 * 0.013 
Colostrum PBS FF vs. Both FF 3x10⁶ 1.767 0.9175 to 2.616 **** <0.0001 
Colostrum PBS FF vs. Both INJ 3x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Colostrum FF 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
1 0.1509 to 1.849 ** 0.0039 
Colostrum FF 1x10⁶ vs. Both FF 3x10⁶ 1.333 0.4842 to 2.182 **** <0.0001 
Colostrum FF 3x10⁶ vs. Colostrm PBS 
INJ 
-0.9 -1.749 to -0.05088 * 0.0227 
Colostrum FF 3x10⁶ vs. C. sinensis NT -0.9 -1.749 to -0.05088 * 0.0227 
Colostrum FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. Both NT -1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. Both PBS FF -1 -1.849 to -0.1509 ** 0.0039 
Colostrum FF 3x10⁶ vs. Both FF 3x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
Colostrum FF 3x10⁶ vs. Both PBS INJ -1 -1.849 to -0.1509 ** 0.0039 
Colostrm PBS INJ vs. Colostrum INJ 
3x10⁶ 
1.633 0.7842 to 2.482 **** <0.0001 
Colostrm PBS INJ vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
Colostrm PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.167 0.3175 to 2.016 *** 0.0001 
Colostrm PBS INJ vs. Both FF 1x10⁶ 1.133 0.2842 to 1.982 *** 0.0003 
Colostrm PBS INJ vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
Colostrm PBS INJ vs. Both INJ 1x10⁶ 1 0.1509 to 1.849 ** 0.0039 
Colostrm PBS INJ vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Colostrum INJ 1x10⁶ vs. Colostrum INJ 
3x10⁶ 
0.9667 0.1175 to 1.816 ** 0.0072 
Colostrum INJ 1x10⁶ vs. Both FF 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis NT -1.633 -2.482 to -0.7842 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
FF 
-1.533 -2.382 to -0.6842 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis FF 
1x10⁶ 
-1.067 -1.916 to -0.2175 ** 0.0011 
Colostrum INJ 3x10⁶ vs. C. sinensis PBS 
INJ 
-1.733 -2.582 to -0.8842 **** <0.0001 
Colostrum INJ 3x10⁶ vs. C. sinensis INJ 
1x10⁶ 
-1.133 -1.982 to -0.2842 *** 0.0003 
203 
 
Colostrum INJ 3x10⁶ vs. Both NT -1.733 -2.582 to -0.8842 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS FF -1.733 -2.582 to -0.8842 **** <0.0001 
Colostrum INJ 3x10⁶ vs. Both PBS INJ -1.733 -2.582 to -0.8842 **** <0.0001 
C. sinensis NT vs. C. sinensis FF 3x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
C. sinensis NT vs. C. sinensis INJ 3x10⁶ 1.167 0.3175 to 2.016 *** 0.0001 
C. sinensis NT vs. Both FF 1x10⁶ 1.133 0.2842 to 1.982 *** 0.0003 
C. sinensis NT vs. Both FF 3x10⁶ 1.967 1.118 to 2.816 **** <0.0001 
C. sinensis NT vs. Both INJ 1x10⁶ 1 0.1509 to 1.849 ** 0.0039 
C. sinensis NT vs. Both INJ 3x10⁶ 1.3 0.4509 to 2.149 **** <0.0001 
C. sinensis PBS FF vs. C. sinensis INJ 
3x10⁶ 
1.067 0.2175 to 1.916 ** 0.0011 
C. sinensis PBS FF vs. Both FF 1x10⁶ 1.033 0.1842 to 1.882 ** 0.0021 
C. sinensis PBS FF vs. Both FF 3x10⁶ 1.867 1.018 to 2.716 **** <0.0001 
C. sinensis PBS FF vs. Both INJ 1x10⁶ 0.9 0.05088 to 1.749 * 0.0227 
C. sinensis PBS FF vs. Both INJ 3x10⁶ 1.2 0.3509 to 2.049 **** <0.0001 
C. sinensis FF 1x10⁶ vs. Both FF 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
C. sinensis FF 3x10⁶ vs. C. sinensis PBS 
INJ 
-1 -1.849 to -0.1509 ** 0.0039 
C. sinensis FF 3x10⁶ vs. Both NT -1 -1.849 to -0.1509 ** 0.0039 
C. sinensis FF 3x10⁶ vs. Both PBS FF -1 -1.849 to -0.1509 ** 0.0039 
C. sinensis FF 3x10⁶ vs. Both FF 3x10⁶ 1.067 0.2175 to 1.916 ** 0.0011 
C. sinensis FF 3x10⁶ vs. Both PBS INJ -1 -1.849 to -0.1509 ** 0.0039 
C. sinensis PBS INJ vs. C. sinensis INJ 
3x10⁶ 
1.267 0.4175 to 2.116 **** <0.0001 
C. sinensis PBS INJ vs. Both FF 1x10⁶ 1.233 0.3842 to 2.082 **** <0.0001 
C. sinensis PBS INJ vs. Both FF 3x10⁶ 2.067 1.218 to 2.916 **** <0.0001 
C. sinensis PBS INJ vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
C. sinensis PBS INJ vs. Both INJ 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
C. sinensis INJ 1x10⁶ vs. Both FF 3x10⁶ 1.467 0.6175 to 2.316 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both NT -1.267 -2.116 to -0.4175 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS FF -1.267 -2.116 to -0.4175 **** <0.0001 
C. sinensis INJ 3x10⁶ vs. Both PBS INJ -1.267 -2.116 to -0.4175 **** <0.0001 
Both NT vs. Both FF 1x10⁶ 1.233 0.3842 to 2.082 **** <0.0001 
Both NT vs. Both FF 3x10⁶ 2.067 1.218 to 2.916 **** <0.0001 
Both NT vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Both NT vs. Both INJ 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
Both PBS FF vs. Both FF 1x10⁶ 1.233 0.3842 to 2.082 **** <0.0001 
Both PBS FF vs. Both FF 3x10⁶ 2.067 1.218 to 2.916 **** <0.0001 
Both PBS FF vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 
Both PBS FF vs. Both INJ 3x10⁶ 1.4 0.5509 to 2.249 **** <0.0001 
Both FF 1x10⁶ vs. Both PBS INJ -1.233 -2.082 to -0.3842 **** <0.0001 
Both FF 3x10⁶ vs. Both PBS INJ -2.067 -2.916 to -1.218 **** <0.0001 
Both FF 3x10⁶ vs. Both INJ 1x10⁶ -0.9667 -1.816 to -0.1175 ** 0.0072 
Both PBS INJ vs. Both INJ 1x10⁶ 1.1 0.2509 to 1.949 *** 0.0005 






Table C1. Average weight of faeces from G. mellonella larvae after force feeding 














4 0.23 0.21 0.17 0.20 0.18 
24 0.78 0.76 0.77 0.27 0.41 















4 0.18 0.17 0.17 0.13 0.16 
24 0.85 0.76 0.44 0.74 0.53 















4 0.26 0.13 0.09 0.10 0.05 
24 0.79 0.40 0.16 0.04 0.17 






  PBS + 2% 
Ethanol  
Untreated 
4 0.15 0.86 
24 0.75 1.22 






Table C2. Statistical significance of faeces weight from G. mellonella larvae after 
force feeding AZA 1, 2 or 3. 
Time elapsed (hours) 
    
24 Mean 
Diff. 
95.00% CI of diff. Summary Adjusted 
P Value 
AZA1 5 ng/larva vs. AZA3 100 
ng/larva 
0.6233 0.01684 to 1.230 * 0.0374 
AZA1 5 ng/larva vs. AZA3 150 
ng/larva 
0.74 0.1335 to 1.346 ** 0.0039 
AZA1 5 ng/larva vs. AZA3 300 
ng/larva 
0.6133 0.006839 to 1.220 * 0.0445 
AZA1 12.5 ng/larva vs. AZA3 
150 ng/larva 
0.7167 0.1102 to 1.323 ** 0.0063 
AZA1 25 ng/larva vs. AZA3 
100 ng/larva 
0.61 0.003505 to 1.216 * 0.0471 
AZA1 25 ng/larva vs. AZA3 
150 ng/larva 
0.7267 0.1202 to 1.333 ** 0.0051 
AZA1 37.5 ng/larva vs. 
Untreated 
-0.75 -1.356 to -0.1435 ** 0.0031 
AZA1 50 ng/larva vs. Untreated -0.61 -1.216 to -0.003505 * 0.0471 
AZA2 5 ng/larva vs. AZA3 100 
ng/larva 
0.69 0.08351 to 1.296 * 0.0108 
AZA2 5 ng/larva vs. AZA3 150 
ng/larva 
0.8067 0.2002 to 1.413 *** 0.0009 
AZA2 5 ng/larva vs. AZA3 300 
ng/larva 
0.68 0.07351 to 1.286 * 0.0131 
AZA2 12.5 ng/larva vs. AZA3 
150 ng/larva 
0.7133 0.1068 to 1.320 ** 0.0067 
AZA2 37.5 ng/larva vs. AZA3 
150 ng/larva 
0.6967 0.09017 to 1.303 ** 0.0094 
AZA3 20 ng/larva vs. AZA3 
100 ng/larva 
0.63 0.02351 to 1.236 * 0.0332 
AZA3 20 ng/larva vs. AZA3 
150 ng/larva 
0.7467 0.1402 to 1.353 ** 0.0034 
AZA3 20 ng/larva vs. AZA3 
300 ng/larva 
0.62 0.01351 to 1.226 * 0.0396 
AZA3 50 ng/larva vs. Untreated -0.62 -1.226 to -0.01351 * 0.0396 
AZA3 100 ng/larva vs. 
Untreated 
-0.86 -1.466 to -0.2535 *** 0.0003 
AZA3 150 ng/larva vs. PBS -0.71 -1.316 to -0.1035 ** 0.0072 
AZA3 150 ng/larva vs. 
Untreated 
-0.9767 -1.583 to -0.3702 **** <0.0001 
AZA3 300 ng/larva vs. 
Untreated 
-0.85 -1.456 to -0.2435 *** 0.0003 
48  
    
AZA1 5 ng/larva vs. AZA1 150 
ng/larva 
0.7733 0.1668 to 1.380 ** 0.0019 
AZA1 5 ng/larva vs. AZA1 300 
ng/larva 
0.62 0.01351 to 1.226 * 0.0396 
AZA1 5 ng/larva vs. AZA3 150 
ng/larva 
0.9333 0.3268 to 1.540 **** <0.0001 
206 
 
AZA1 5 ng/larva vs. AZA3 300 
ng/larva 
0.8233 0.2168 to 1.430 *** 0.0006 
AZA1 12.5 ng/larva vs. AZA3 
150 ng/larva 
0.75 0.1435 to 1.356 ** 0.0031 
AZA1 12.5 ng/larva vs. AZA3 
300 ng/larva 
0.64 0.03351 to 1.246 * 0.0278 
AZA1 25 ng/larva vs. AZA1 
150 ng/larva 
0.7 0.09351 to 1.306 ** 0.0088 
AZA1 25 ng/larva vs. AZA3 
150 ng/larva 
0.86 0.2535 to 1.466 *** 0.0003 
AZA1 25 ng/larva vs. AZA3 
300 ng/larva 
0.75 0.1435 to 1.356 ** 0.0031 
AZA1 25 ng/larva vs. AZA2 
21.5 ng/larva 
-0.6933 -1.300 to -0.08684 * 0.0101 
AZA1 37.5 ng/larva vs. AZA2 
37.5 ng/larva 
-0.6533 -1.260 to -0.04684 * 0.0217 
AZA1 37.5 ng/larva vs. AZA3 
20 ng/larva 
-0.6667 -1.273 to -0.06017 * 0.0169 
AZA1 37.5 ng/larva vs. PBS -0.73 -1.336 to -0.1235 ** 0.0048 
AZA1 37.5 ng/larva vs. 
Untreated 
-0.9433 -1.550 to -0.3368 **** <0.0001 
AZA1 50 ng/larva vs. AZA2 5 
ng/larva 
-0.68 -1.286 to -0.07351 * 0.0131 
AZA1 50 ng/larva vs. Untreated -0.79 -1.396 to -0.1835 ** 0.0013 
AZA2 5 ng/larva vs. AZA3 150 
ng/larva 
0.9933 0.3868 to 1.600 **** <0.0001 
AZA2 5 ng/larva vs. AZA3 300 
ng/larva 
0.8833 0.2768 to 1.490 *** 0.0001 
AZA2 12.5 vs. AZA3 150 
ng/larva 
0.8533 0.2468 to 1.460 *** 0.0003 
AZA2 12.5 ng/larva vs. AZA3 
300 ng/larva 
0.7433 0.1368 to 1.350 ** 0.0036 
AZA2 25 ng/larva vs. AZA3 
150 ng/larva 
0.7567 0.1502 to 1.363 ** 0.0027 
AZA2 25 ng/larva vs. AZA3 
300 ng/larva 
0.6467 0.04017 to 1.253 * 0.0246 
AZA2 37.5 ng/larva vs. AZA3 
150 ng/larva 
0.8133 0.2068 to 1.420 *** 0.0008 
AZA2 37.5 ng/larva vs. AZA3 
300 ng/larva 
0.7033 0.09684 to 1.310 ** 0.0082 
AZA3 20 ng/larva vs. AZA3 
150 ng/larva 
0.8267 0.2202 to 1.433 *** 0.0006 
AZA3 20 ng/larva vs. AZA3 
300 ng/larva 
0.7167 0.1102 to 1.323 ** 0.0063 
AZA3 100 ng/larva vs. 
Untreated 
-0.6933 -1.300 to -0.08684 * 0.0101 
AZA3 150 ng/larva vs. PBS -0.89 -1.496 to -0.2835 *** 0.0001 
AZA3 150 ng/larva vs. 
Untreated 
-1.103 -1.710 to -0.4968 **** <0.0001 
AZA3 300 ng/larva vs. PBS -0.78 -1.386 to -0.1735 ** 0.0016 
AZA3 300 ng/larva vs. 
Untreated 





Figure C1. Dispersion plot of the merged timepoint of Untreated (U) vs AZA1, OA, 
and PBS.  
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Risk assessments, a full list provided as a PDF.  
 
   BH1 
 
 
RISK ASSESSMENT OF AN ACTIVITY INVOLVING DELIBERATE WORK WITH 
MICROORGANISMS 
 
This risk assessment form should be used to assist in the assessment of risks from an activity involving 
deliberate work with an infectious of harmful biological agent. The aim of the assessment is to identify 
those at risk from infection or other harm and the measures required to eliminate or control the risks to 
human health and the environment to an acceptable level.  
 
SECTION 1: PROJECT INFORMATION 
1.1 Principal Investigator/Academic Supervisor 
Name College 
Dr Christopher Coates Science, Department of Biosciences 
 1.2 Person undertaking this risk assessment (if different from above) 
Name College  
Helena Emery (PGR) Science, Department of Biosciences 
1.3 Project title 
Using the insect model, Galleria mellonella, for gut-related pathobiology 
 
1.4 Brief overview of the work (in layman’s terms ) 
Challenging insect larvae (Galleria mellonella) with bacteria known to cause, or associated with, gastric 
damage. Using these insect larvae provides a well-established, ethical alternative to rodent testing.  
 
 The aim is to induce damage using bacteria (Mycobacterium avium (subspecies) paratuberculosis, 
Campylobacter jejuni) via two inoculation methods (intrahaemocoelic injection, gavage). Experimental 
larvae will then be monitored for survivorship and gut restitution, and ‘treated’ with colostrum, mushroom 
extract (Cordyceps sinensis) and common anti-ulcer drugs. In this instance, we are using the insect as a 
screening tool by following well-established protocols in our lab and the published literature (e.g., Coates et 




Coates, C. J., Lim, J., Harman, K., Rowley, A. F., Griffiths, D. J., Emery, H., & Layton, W. (2018). The insect, Galleria mellonella, is a compatible 
model for evaluating the toxicology of okadaic acid. Cell Biology and Toxicology, 1-14. 
 
Lim, J., Coates, C. J., Seoane, P. I., Garelnabi, M., Taylor-Smith, L. M., Monteith, P., ... & May, R. C. (2018). Characterizing the Mechanisms of 
Nonopsonic Uptake of Cryptococci by Macrophages. The Journal of Immunology, ji1700790. 
 
Senior, N. J., Bagnall, M. C., Champion, O. L., Reynolds, S. E., La Ragione, R. M., Woodward, M. J., ... & Titball, R. W. (2011). Galleria mellonella as 









SECTION 2: IDENTIFICATION OF BIOLOGICAL HAZARDS  
2.1 List microorganisms deliberately used  
Name of microorganism Mycobacterium 
avium (subspecies) 
paratuberculosis 
Campylobacter jejuni Clostridium difficile 
Identified as human pathogen 
on ACDP list1 
Yes Yes Yes 
If yes please state hazard group 2 2 2 
If not on ACDP list, is there any 
evidence to support the 
microorganism may present a 
risk to human health 
Click or tap here to 
enter text. 
Click or tap here to 
enter text. 
Click or tap here to 
enter text. 
Normal routes of human 
infection 
☐ Inhalation 
  Oral/ingestion 
☐ Mucocutaneous 
☐ Percutaneous 




  Oral/ingestion 
☐ Mucocutaneous 
☐ Percutaneous 




  Oral/ingestion 
☐ Mucocutaneous 
☐ Percutaneous 
☐ Via vector (e.g. 
insect) 
 Allergen 
Multiplicity of infection if 
known (i.e. number of 
organisms required to establish 
an infection) 
N/A N/A N/A 
Consequence of infection to 
humans 
Suspected cause of 
Johne’s disease in 
ruminants and 
linked to Crohn’s 




antibiotics may be 
required in severe 
infection or those 
immunocompromised. 
In some cases, 
infection can result in 
irritable bowel 
syndrome.   




antibiotics may be 
required. Serious 
infection can damage 
the bowel requiring 
surgery.  
Is the microorganism a 
specified animal pathogen 
(SAPO2) 
No No No 
If yes please state SAPO hazard 
group 
Choose an item. Choose an item. Choose an item. 
Detail of any other harm the 
microorganism may pose to the 




SECTION 3: EXPERIMENTAL PROCEDURES  
3.1 Description of experimental procedures:  
(Brief details, also indicate any non-standard laboratory operations and any procedures that might require 
specific control measures e.g. use of sharps, generation of aerosols, in vivo work) 
>All experimental work will be carried out in the recently refurbished CAT2 facility, Wallace 044.  
>A standardised inoculum of each bacterium will be prepared (exponential phase) in sterile phosphate 
buffered saline (PBS). 
>Each insect larvae is weighed, inspected for visual signs of infection/damage (i.e., melanisation) and 
placed in a petri dish (n =  10 per replicate) lined with Whatman filter paper and wood shavings (provided 
by commercial supplier)  
>Larvae are chilled on ice for 2-5 minutes (immobilises insects) prior to the administration of bacteria 
using a 26/27 gauge needle. The larvae can be held with sterile forceps to reduce the risk of accidental 
puncture of skin. Insects can be inoculated by intrahaemocoelic injection, or by force feeding (gavage).    
>Each insect receives 10-20 μL inoculum. Negative controls are given PBS. Sharps will be disposed of in 
the appropriate containers.  
>Experimental G. mellonella are incubated between 30 and 37 °C for up to 10 days in the dark 
(depending on the experiment).   
>At 4, 24, 48 and 72 hours post-treatment, survivorship, pupation and melanisation are monitored by 
following a well-established ‘health index’ for this insect (Loh et al., 2013) 
>In some instances, insects will be co-treated with an anti-inflammatory (anti-ulcer) drug, colostrum or 
extracts from the medicinal fungus, Cordyceps sinensis, in attempts to gauge putative repair and 
restitution properties 
>Additionally, some insects will be sacrificed by fixation (for wax histology) or dissected on ice to remove 
the midgut for nucleic and amino acid (DNA, RNA, protein) extractions.  
>Any contaminated tissues will be bagged and frozen, autoclaved and disposed of following university 
guidelines and procedures.  
 





3.2 Quantities used and frequency of use:  
This information will enable you to determine the likelihood of exposure and therefore the risks from this 
particular activity. Please indicate maximum culture volumes at any time shown as multiples of flask 
volumes to give an idea of scale. 
Max. volume per 
culture/sample 
Culture <50 ml 
Sample ~20 µl 
Max. volume per experiment:  <1 ml on each 
occasion 
Frequency of experiments  10 Galleria for each bacterium, per replicate 
 
Survivorship: 
40x Galleria for M. avium paratuberculosis  (ATCC 
BAA-968) 
40x Galleria for C. jejuni (ATCC BAA-224) 
40x Galleria for C. difficile (ATCC 51695) 
40x Galleria for PBS (negative control)  
 
Gut dissections/wax histology: 
30x Galleria for M. avium paratuberculosis  
30x Galleria for C. jejuni  
30x Galleria for C. difficile   
30x Galleria for PBS (negative control)  






SECTION 4: MEASURES TO PREVENT OR CONTROL EXPOSURE  
Preventing exposure  
4.1 Could a less hazardous substance (or form of the substance) be used instead?  
(If it can, then it should be used or justification be given here why it is not being used.  COSHH requires 
substitution with less hazardous materials wherever possible, but there may be good reasons for not using 
them.) 
Only known hazardous substance will be the bacterial inocula required for infection. Recent evidence 
suggests that substituting pathogenic gut bacteria with ‘symbiotic’ bacteria (e.g., Bacteroides vulgatus; 
Lange et al., 2018) leads to differential innate immune responses of the insect host, therefore less 
hazardous alternatives are not suitable here.  
 
Lange, A., Schäfer, A., Bender, A., Steimle, A., Beier, S., Parusel, R., & Frick, J. S. (2018). Galleria mellonella: a novel invertebrate model to distinguish 
intestinal symbionts from pathobionts. Frontiers in immunology, 9. 
Controlling exposure  
4.2 Containment Level - what containment level is required for this work with regard to COSHH/SAPO?   
 1  2  3 
CL3 only – application for derogation from the following controls (list if relevant and justify) 
Click or tap here to enter text. 
Premises where this work will be carried out  




Will the work be segregated from others not involved in the work and if not, how will they be informed of 





Work will be segregated. Bacterial cultures and infected insects will be stored separately from other 
work. Two dedicated incubators (30/37oC) will be used exclusively for this. Appropriate warning signs 
are in place on entrance to the lab, and signage will be placed on incubators whilst experiments are 
running.  
 
One (of two) microbiological safety cabinets will be used to work with the gut-related pathogens (a 
sign to reflect this will be on display).  
 
 
4.3 Engineering Controls (Containment & Ventilation) 
a) Is a microbial safety cabinet (or isolator for in vivo work) required? These must be used for activities 
generating potentially infectious aerosols or splashes.   
 YES    NO    Class:   I     II    III 
 
If required, what processes require its use? Preparation of bacterial inocula for in vivo work 
Specify other local ventilation control measures considered appropriate (e.g. downdraft table, isolator): 
N/A 
b) Will centrifugation be used? 
   YES     NO    
If yes, will buckets and rotors be sealed?    YES     NO    
If yes, where will buckets or rotors be opened? Click or tap here to enter text. 
If yes, how will spillages in the centrifuge be 
dealt with? 
Click or tap here to enter text. 
c) Will incubators be used? 
   YES     NO    
If yes, what type (e.g. shaking)? Static 
If yes, how will spillages in the incubator be 
dealt with? 
Whole larvae will be secured in a petri dish in a dedicated 
incubator. Liquid cultures will be cleared using absorbent 
material and ethanol/disinfectant spray. Contaminated 
absorbent material will be autoclaved.   
d) Will sharps be used:  
   YES     NO    
If yes, list and justify their use: 27 gauge needle will be used to inoculate Galleria 
mellonella larvae. This instrument is necessary for 
administration of accurate dosages.  
Control measures  Appropriate PPE will be used throughout including 
gloves. Larvae will be chilled on ice to reduce movement 
and held with forceps during inoculation to reduce risk of 
sharps injury (following standardised procedures).   
e) Will animals be deliberately infected with these biological agents? 






If yes, describe the procedure, control measures  
and whether shedding of infectious agents by 
animals is expected? 
Galleria mellonella are considered a non-animal 
technology (NAT) in the context of UK animal use 
regulations (ASPA) where procedures on this species are 
not regulated. However, insects will be deliberately 
infected and shedding of infectious material may occur via 
faces in larvae force-fed bacteria. In this instance, the 
faeces and contaminated larvae, petri dish and filter 
paper will be collected when the experiment is 
completed, bagged and stored frozen (-20oC to -80oC) 
until autoclaving following the university procedures. 
Infected insects will be stored separately in a dedicated 
static incubator.  
 
 
4.4 Personal Protective Equipment (PPE):  
Lab coat Gloves Eye or face (specify if yes) Other (specify) 
 YES    YES     NO       YES     NO    Click or tap here to enter text. 
Details: Details: Details: 




4.5 Transportation  
a) How will viable material be transported within the laboratory ? 
Bacterial cultures will be prepared in Corning (vented screw-cap) conical flasks.  
Infected insects will be transported in petri dishes secured with tape.   
 
b) How will viable material be transported locally outside the laboratory ?  
No reagent or living organism will leave the laboratory during experimentation. 
In some instances, fixed insects will be transported in 70% ethanol to the histology suite for wax 
embedding (023, Wallace) 
 
c) Will viable material be shipped anywhere (off  campus)?    YES     NO    
If yes, what will be shipped? Click or tap here to enter text. 
If yes, how will this be shipped (e.g. Category 
A, Category B, Exempt, Non-hazardous)? 
Click or tap here to enter text. 
 
 
4.6 Waste disposal procedures:  
(Disinfectants, concentrations, exposure times, autoclaving procedures, incinerator procedures, include any 
animal related wastes.) 
Waste Decontamination method (include details on efficacy) 
Disposal route 
e.g. drain/incineration/landfill 
Liquid waste Bacterial cultures will be inactivated on site using a 
disinfectant (bleach, Virkon S 2% solution for 1 hour) 
prior to autoclaving 
Drain, once deactivated 
 
Solid waste All Galleria mellonella larvae will be frozen prior to 
autoclaving  
Following University procedures 
Incineration once deactivated 
Sharp waste Decontaminated with bleach/Virkon 2% solution for 1 
hour and into sharps bin.  




* Virkon™ S is the breakthrough disinfectant formulation that defines on farm biosecurity. A 2% solution has 
been powerful, proven performance against over 500 strains of viruses, bacteria and fungi including Foot and 
Mouth Disease (FMD), Avian Influenza, Salmonella and Campylobacter, Virkon™ S is selected by governments 
worldwide for Emergency Disease Control. 
Alternatively, a 2% Biocleanse solution can be used too.  
Biocleanse (Teknon®) has powerful bactericidal and virucidal properties. Biocleanse concentrate is free from 
sodium hypochlorite, phosphates and enzymes and effectively removes blood, fat, proteins, grease and other 
organic and non-organic contaminants whilst simultaneously disinfecting the treated surface. It is safe to use on 
ferrous and non-ferrous metals, ceramics, glassware and plastics. Biocleanse kills E. coli, Salmonella, Listeria, 
Candida and Penicillium at 1% dilution and MRSA at 2% dilution. Efficacy against C. difficile, Avian Flu, HIV and 
HBV is proven at 5% dilution. In addition, under COSHH Regulations, the product does not require a maximum 
exposure limit and when diluted to normal use concentrations, is not irritating to skin. 
 
4.7 Emergency procedures 
 (spillages – if not covered by local rules/standard operating procedure) Remember to take into account 
route of exposure 
Inside primary containment (if relevant e.g. MSC, isolator) 
2% Virkon, followed by 70% alcohol 
Outside primary containment but within the laboratory (secondary containment) 
2% Virkon, followed by 70% alcohol 
Outside secondary containment (if relevant): 
Click or tap here to enter text. 
Other procedures (e.g. following any kind of accidental exposure, needlestick etc.):  
Click or tap here to enter text. 
 
 
SECTION 5: PERSONNEL AND HEALTH ISSUES 
5.1 Vaccination  
For ACDP 2 or above human pathogens - to be completed by Occupational Health 
Is an effective vaccination available for any of the pathogens associated with this work?   
No 
 
5.2 Is health surveillance/health clearance required? 
Staff and postgraduate research students    YES     NO    
Taught students (undergrad and MSc)    YES     NO   (initial Health clearance only) 
5.3 Identify any particular groups of workers who may be at increased risk from this material: (for 
example pregnant workers, young persons under 18, disabled workers, those with pre-existing disease that 
increases susceptibility.) 
Immuno-compromised (antibiotic regime, HIV+) 
 
Anyone who might have compromised resistance to disease for any reason should seek advice from 
the University Occupational Health Service regarding the need for additional precautions. 
5.4  Information, instruction and training  
Describe the training that will be given to all those affected (directly or indirectly) by the work activity.  
044 Laboratory training and inductions will be provided Dr Christopher Coates and/or Dr Almudena Ortiz-
Urquiza. If concerns are raised regarding pre-existing conditions, advice will be sought from University 













SECTION 6: DECLARATIONS AND APPROVAL 
Principal Investigator: 
I the undersigned: 
• Confirm that all information contained in this assessment is correct and up to date 
• Will ensure that suitable and sufficient instruction, information and supervision is provided to all 
individuals working on the activity 
• Will ensure that no work will be carried out until this assessment has been completed and 
approved and that all necessary control measures are in place 
• Will ensure that all information contained in this assessment will remain correct and up to date 
and re-submit for approval if any significant changes occur 
• Work will only be undertaken in appropriate facilities 
Name Signature  Date  




Approval on behalf of the College (Head of College approval required for ACDP HG3/4, SAPO 2-4 and 
organisms listed on Schedule 5 process) – College BSO and University BSA)  
(The person supporting this proposal must not be involved in the project being proposed.) 
Name Signature  Date  
Click or tap here to enter text. 
There is no BSO for CoS 
 




Click or tap to enter a date. 
Approval on behalf of the University (for ACDP HG2-4, SAPO2-4 and organisms listed on Schedule 5 
process) – College BSO and University BSA 
Name Signature  Date  
Click or tap here to enter text. 
 
Click or tap here to enter text. 
 
 
Click or tap to enter a date. 
 
Additional information: 
Laboratory 044 has restricted access at the discretion of Dr Christopher Coates and Dr Almudena Ortiz. 
This lab is equipped with a Salto electronic lock.  
A designated autoclave is located in the Wallace Building room 001. This autoclave is regularly validated 
using a 12-point thermocouple technique. Staff technicians keep records of the validation.  Once 
autoclaved the waste will be place in tiger bags and disposed into the autoclave skip situated in the car 
park between Margam and ILS1.  
There is a designated lidded bin to store and transport double-bagged waste from lab 044 to the autoclave. 
Autoclave facilities are in the same building. 
SECTION 7: LIST OF WORKERS UNDER THIS PROJECT 
Full Name ( Worker type Signature and date  
Staff Postgrad - 
Research 
Postgrad 
- taught  
UG Other  
Dr Christopher Coates           
Details 
Click or tap here to enter 
text. 
Helena Emery           
Details 
H Emery 15/01/2019 
Dr Christopher 
Cunningham 
          
Details 
Click or tap here to enter 
text. 
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